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SUM M ARY
Specific, sensitive and direct RIAs for the measurement of melatonin and its 
major urinary m etabolite, aM T6s have been developed and applied to investigations 
of the effects of depression, anorexia nervosa and antidepressant drug treatm ent
upon m e la ton in  secretion.
A normal range of melatonin levels was defined from 24-hour plasma 
melatonin profiles collected from 81 healthy volunteers. In c lin ic a l studies 
controlled for the variables known to a ffe c t melatonin secretion, ne ithe r the 
amplitude nor tim in g  o f the melatonin rhy thm  was altered in endogenous (un ipo lar) 
depressed patients, whereas patients with seasonal a ffective  disorder displayed 
elevated morning m e la ton in  levels and greater interindividual variation in the 
tim in g  and duration of m ela ton in  secre tion . Only in pa tien ts  w ith  anorexia nervosa 
were changes in am plitude  o f the m ela ton in  rhy thm  observed. Increased nocturnal 
plasma m e la ton in  and urinary aM T6s excretion were found in anorectics compared 
to  hea lthy women o f either norm al or low body w e ight.
The noradrenerg ic control of m ela ton in  secretion in man was demonstrated 
by an acute s tim u la tio n  o f evening m elaton in  and aM T6s production in normal 
vo lunteers following treatm ent w ith  specific noradrenaline uptake inhibitors, DM1 
and o xap ro tilin e . Furthermore, the adm in is tra tion  o f rolipram, a phosphodiesterase 
inhibitor, increased n ig h t-tim e  urinary aM T6s excretion in normal subjects, 
suggesting tha t cyc lic  AMP may influence the production o f m elaton in  in man.
The role o f the pineal as an index o f B-adrenergic fun c tio n  was investiga ted. 
C hronic (3 weeks) DMI tre a tm e n t stimulated nocturnal m ela ton in  secretion in 
depressed patien ts  although m ela ton in  levels in norm al subjects were no d iffe re n t 
fro m  pretreatm ent values. In add ition , repeated DM I in jec tions (22 days) increased 
day- and n ig h t-tim e  ra t pineal m elaton in  concentrations in conjunction w ith  a 
decrease in p ineal and c o rt ic a l 6-adrenoceptor density. C on tra ry  to some popular 
theories o f antidepressant drug action  our findings do not provide evidence fo r
i l l
reduced noradrenergic neurotransm ission during DM I therapy.
Plasma m e la ton in  and urinary aM T6s provide unique markers in psychiatric 
studies fo r rhythm  disturbances and the effects of antidepressant drugs. I t  appears 
from the present studies th a t m e la ton in  production, a t least in the ra t, is not a 
good index o f antidepressant-induced changes in B-adrenergic recepto rs . M elaton in  
production probably reflects the functional status of the noradrenergic synapse in 
the pineal gland. W hether i t  has any re levance to central noradrenergic a c tiv ity  is 
open to question.
i v
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ABBREVIATIONS
A C TH  adren o co rtico tro p h ic  hormone
aHT N -ace ty lse ro ton in
aMT m e la ton in
aM T6G 6-hydroxy m e la ton in  g lucuronide
aM T6H 6-hydroxy m ela ton in
aM T6s 6-su lphatoxy m ela ton in
b.i.d . tw ic e  daily
B density of specific binding sites
cAM P c y c lic  3',5'-adenosine monophosphate
cGMP cyclic 3',5'-guanosine monophosphate
CMS ce n tra l nervous system
CSF cerebrosp inal fluid
CV c o e ff ic ie n t o f va ria tion
DAS donkey anti-sheep
DCC d icyc lohexy lca rbod iim ide
DHA d ihydroa lp reno lo l
DMF d im e thy lfo rm am ide
DMI desm ethy lim ipram ine
DSM D iagnostic and S ta tis tic a l Manual
EDTA ethylenediam inetetraacetic acid
FSH fo ll ic le  s tim u la tin g  hormone
GABA ^-am inobutyric acid
GC-MS gas chrom atography-m ass spectroscopy
GH grow th  hormone
H A  5-hydroxyindole  ace tic  acid
HIOM T hydroxy in d o le -O -m e th y ltra ns f erase
HE 5 -hydroxy tryp topho l
v i l
HPLC high pressure liqu id  chrom atography
HT seroton in
HW 5-hydroxytryp tophan
IC YP iodocyanopindolo l
i.d. in tra de rm a l
ÏHYP iodohydroxybenzylp indo lo l
i.p. in tra p e rito n e a l
i.v . intravenous
K o apparent d issociation  constant
1-dopa 1-dihydroxyphenylalanine
LH lu te in iz in g  hormone
MA 5-methoxyindole ace tic  acid
ML 5-m e thoxy tryp topho l
NADPH 6-nicotinamide adenine d inuc leo tide  phosphate
PCPA parachlorophenyla lan ine
PFP pen ta fluo rop rop ion ic
POPOP l,4 -d i-2 -(5 -pheny loxazo iy l)-benzene
PPO 2,5-d iphenyloxazole
PVN p a rave n tr icu la r nuclei
REM rap id  eye m ovem ent
RDC Research D iagnostic C r ite r ia
RIA radioim m unoassay
SAD seasonal a ffe c tiv e  disorder
SAM S-adenosy 1-methionine
s.c. subcutaneous
SCG superior cervical ganglia
SCN suprach iasm atic  nucleus
SD standard dev ia tion
SEM standard error o f mean
V l l l
SNAT seroton in  N -ace ty ltrans fe rase
TCA tricyclic  antidepressant
TLC thin layer chromatography
VIP vasoactive intestinal polypeptide
W tryptophan
a / 6-receptor a / 6-adrenergic receptor
o /6 -agonist/antagonist a / 6-adrenergic agonist/antagonist
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CHAPTER 1
LITER A TU R E REVIEW
11.1. IN TR O D U C TIO N
Studies over the las t tw o  decades have shown th a t the pineal gland plays an 
essentia l re g u la to ry  ro le  in animals where the seasonal cycle of breeding depends 
upon the annual change in daylength (photoperiod). The p ineal, through its  
secretion of the methoxyindole melatonin, enables seasonal breeders to perceive 
changes in photoperiod length . The secretion of m e la ton in  shows a m arked 24-hour 
rhythm being high at night and suppressed during the day. Changes in the 
env ironm enta l photoperiod acting via the nervous system a lte r the p a tte rn  o f 
melatonin secre tion . These changes in m e la ton in  production  act as signals fo r the 
precise tim in g  o f pho toperiod ic  a c t iv ity  (rev iew ; A rend t, 1986a). In th is  sense the 
pineal may be considered to  act as a photoneuroendocrine transducer o f 
env ironm enta l in fo rm a tio n  (Axelrod, 1974). In some birds and lower vertebra tes 
the pineal also serves as a c ircad ian  time-keeping system (rev iew ; Rusak, 1982).
In many photoperiodic species (R e ite r, 1980; Tam arkin  et al, 1985) 
p inea lectom y e ffe c t iv e ly  prevents the rep roductive  response (as determ ined by 
gonad size or endocrine param eters) to  artific ia lly  imposed daylengths. There is 
evidence however th a t in the absence of the pineal in sheep (B ittm a n  et al, 1983) 
and fe rre ts  (H e rbe rt, 1981) rep roductive  cycles persist but run out o f phase w ith  
the annual cyc le . I t  is possible th a t environm enta l fac to rs  o ther than lig h t may 
regu la te  the tim in g  o f seasonal breeding in some species in the absence o f the 
p ineal.
D ay-n igh t rhythm s in m e la ton in  have been found in v ir tu a lly  a ll species 
studied so far, inlcuding man (review; Waldhauser and Wurtman, 1983). Melatonin
appears to be secreted d ire c tly  in to  the periphera l circulation (Rollag et al, 1978) 
and w h ils t i t  is not the only ac tive  pineal compound i t  rem ains the best periphera l 
index o f pineal a c tiv ity .  Studies in a number o f species have shown tha t the 
duration of melatonin synthesis and/or m ela ton in  secre tion  re f le c t  the length of 
na tu ra l lig h t (A rend t, 1979, Illne rova  and Vanecek, 1980).
The adm in is tra tio n  o f m e la ton in  to, fo r example, pinealectom ised or in ta c t
ham sters, sheep, m ink, and deer (rev iew ; A rend t, 1986a) w il l  induce rep roductive  
changes corresponding to a given photoperiod. These experiments have shown that 
the duration of melatonin secretion is important for its effects on photoperiodic 
responses.
The precise location of target sites for melatonin action in the control of 
seasonal breeding is unclear. Specific melatonin binding sites have recently been 
located in the suprachiasmatic nuclei of the hypothalamus and the median 
eminence areas of rat brain (Vanecek et al, 1987).
In add ition  to  its  seasonal effects, melatonin w ill entrain the circadian 
rest/ac tiv ity  rhythm in rats (Redman et al, 1983) and when suitably timed, may
m od ify  its  own endogenous rhy thm  and c ircad ian  rhythm s in co rtiso l secre tion  and 
fatigue/alertness in man (A rend t et al, 1987).
Humans are not considered to  be a pho toperiod ic species although recent 
evidence (Rosenthal et al, 1984; Broadway et al, 1987) ind ica tes th a t both norm al 
subjects and psych ia tric  pa tien ts  are sensitive to  daylength change.
The pineal may have a fun c tio n  in humans com parable to  th a t in other 
mammals, however to  date its  ro le  s t i l l  aw aits d e fin it io n . Due to  its  consistent 24- 
hour variation and high amplitude, the measurement of melatonin has provided a 
particularly stable rhythm for circadian studies in man.
1.2. THE M A M M A LIA N  P INEAL
1.2.1. In trod u c tion
The m am m alian pineal consists o f p inea locytes evolved from  the 
pho torecep tor and g lia l ce lls found in low er ve rteb ra tes. In birds and reptiles i t  has 
a m ixed photoreceptor (th ird  eye) and secre to ry  fun c tio n  but in mammals the gland 
is e n tire ly  secre to ry .
The pineals o f d if fe re n t mammals vary in shape, size and position  (V o llra th ,
1981). In the rat the pineal is situated immediately beneath the skull, weighs 
around 1 mg and receives one o f the riches t blood supplies o f any organ.
In the course o f evolution the mammalian pineal has retained a fun c tio na l 
association with the light-dark cycle (shown by the circadian rhythm of melatonin 
production) but has lost the intrinsic oscillatory properties of the lower vertebrate  
pineal. Sympathetic innervation is necessary for mammalian pineal melatoninergic 
fu n c tio n  and although the pineal conta ins a large number of indoles and peptides 
melatonin, since its in itia l isolation by Lerner and colleagues, (1960), still remains 
the pineal 'hormone' of interest.
1.2.2. Synthesis and m etabo lism  o f melatonin
(a) Synthesis
M e la ton in  is synthesised from c irc u la tin g  tryptophan alm ost exclus ive ly 
w ith in  the pineal cell (reviews; A xe lrod , 1974; K le in , 1979) as shown in F ig . 1.1. 
T ryptophan is hydroxy la ted  to  5-hydroxy tryp tophan  which is then decarboxylated to 
form serotonin. Some o f the seroton in  is m etabolised by monoamine oxidase, some 
leaves the ce ll and is taken up by the sym pathe tic  nerve te rm in a l fo r storage w ith  
noradrenaline and the remaining portion is acetylated by the enzyme serotonin N- 
ace ty ltrans fe rase  (SNAT) to  form the melatonin precursor N -ace ty lsero ton in . 
M e la ton in  is synthesised from N -ace ty lse ro ton in  by the enzyme hydroxy indole-O- 
m ethyltransf erase (H IOM T); S-adenosy 1-m ethionine (SAM) is a co-factor.
Mammalian HIOMT is h igh ly loca lised in the pineal gland but is also found in 
the  re tin a  and H arderian gland (C ard ina l! and W urtm an, 1972). The pineal 
a dd itio n a lly  synthesises a large number o f o ther hydroxy- and methoxyindoles from  
sero ton in  (described by Sm ith, 1983).
(b) P ineal c ircad ian  rhythm s
The f ir s t  circadian rhy thm  discovered in the pineal was tha t o f serotonin 
(Quay, 1963). The concentration o f seroton in  in the pineal is higher than any region
TRYPTOPHAN
C H 2C H N H 2C O O H  
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^Tryptophan hydroxylase 
CH2CHNH2COOH
5-HYDROXYTRYPTOPHAN
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Fig. 1.1 Synthesis of melatonin from tryptophan in the pineal gland.
in the brain and its levels are highest during the day (light phase) and lowest during 
the night (dark phase). In the rat pineal^ the highest levels of melatonin occur at 
night (Lynch, 1971) in phase with peaks in SNAT (Klein and W eller, 1970) and a 
slightly raised HIOMT activity (Axelrod et al, 1965): all are 180° out of phase with  
the serotonin rhythm. The relationship between the day- night rhythm s is shown in 
Fig. 1.2. A circadian rhythm in the content of rat pineal SAM has been reported  
with a 5-fold increase during the day (Chabannes et al, 1984). In contrast to plasma 
levels, the concentration of tryptophan is highest in the pineal a t the end o f the 
lig h t period and fa lls  w ith  the onset o f darkness (Sugden, 1979). Pineal tryp tophan 
is used m a in ly  at n igh t and i t  is the enzym ic a c tiv ity  (not the uptake of tryptophan) 
th a t is ra te  l im it in g  in the synthesis o f sero ton in . I t  has been assumed th a t SNAT 
a c t iv ity  is the rate l im it in g  step fo r m e la ton in  synthesis in the ra t since with the 
onset o f darkness, a 15-60 fo ld  increase is observed compared to  a 2-3 fo ld  increase 
in HIOMT a c tiv ity .  Reports o f daytim e m e la ton in  s tim u la tio n  in the ra t following 
adm in is tra tio n  o f seroton in  precursors has however im p lied  mass-action e ffe c ts  in 
m e la ton in  production (N am boodiri et al, 1983).
Various methods have been used to  measure the fem tom o le  amounts of 
m e la ton in  in b io log ica l tissues (Section 1.6.1.). The pineal day- n ight rhy thm  in 
m e la ton in  leve ls is re fle c te d  in serum, urine  and cerebrospinal f lu id  (CSF) o f many 
animals inc lud ing  rats, hamsters, sheep, cows, monkeys and man (review, 
Waldhauser and Wurtman, 1983). C ircu la tin g  m ela ton in  has been shown to  be a 
good index o f p ineal m e la ton in  in the ra t (Wilkinson et al, 1977) however, th is  may 
not necessarily be the case fo r o ther species.
(c) Metabolism
M ela ton in  has a h a lf- l ife  o f between 10 and 40 m inutes In  ra ts and m ore than 
90% is c leared in a single pass through the liver. Reports have shown tha t 
rad io labe lled  m e la ton in  adm inistered to  m ice and ra ts  is rap id ly  metabolised by the 
liv e r  microsomal system  in to  6-hyd roxym ela ton in  which is excreted in to  the urine
600
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Fig . 1.2 C ircad ian  rhythm s in indole m etabolism  in the ra t pineal gland 
(K le in , 1979).
The shaded area represents the dark period of the lig h ting  
cycle .
7as the sulphate conjugate (55-80% ) and glucuronide conjugate (5-30%) (Kveder and 
M clsaac, 1961; Kopin  et al, 1961). Less than 1% o f m e la ton in  is excre ted  
unchanged, however it is possible that some (up to 12%) is excreted as the non- 
indolic m etabolite, N-acetyl-5-m ethoxy-kynurenam ine (see Fig. 1.3.). The pattern  
of metabolism in man has been shown to be similar (Jones et al, 1969) and is 
described in Section 1.3.1. However 6-sulphatoxymelatonin (aM T6s) does not 
appear to be the major m etabolite in sheep (English et al, 1987).
A th ird  metabolic pathway o f dém éthy la tion  has been proposed in tw o  reports  
from the same laboratory (Leone and Silman, 1984; Young et al, 1985). Using a gas
chrom atography-m ass spectrometry m ethod these authors found tha t in the rat and 
in man, exogenous m e la ton in  is metabolised to  N -ace ty lse ro ton in  in add ition  to  6- 
hydroxym ela ton in . They suggested tha t previous th in  laye r chromatography 
methodology was inadequate fo r detection o f conjugated N-acetylserotonin 
compounds in urine. R ecently  Vakkuri and colleagues, (1987) id e n tif ie d  a cyclic 
isom er o f 2-hydroxy m e la ton in  in human and rat urine a fte r  administraton o f 
syn th e tic  m e la ton in . This novel m etabo lite  accounted fo r  about 5% o f the u rinary  
metabolites o f m e la ton in  in the ra t. The m etabo lic  pathways are represented in 
Fig. 1.3.
1.2.3. C ircad ian  control of SNAT and melatonin rhythm s
(a) N eural pathway
The da ily  rhythm s in pineal SNAT a c tiv ity  and melatonin concen tra tion  are 
tru ly  circadian as they persist in the absence o f the entraining light-dark cyc le  ie 
continuous darkness (Ralph et al, 1971). The endogenous b io log ica l clock driv ing  
these rhythm s in the ra t, appears to  be located in the suprachiasmatic nuclei (SCN) 
o f the hypothalam us, since lesions between the SCN and the pineal (Moore and 
K le in , 1974) and lesioning of the  SCN (K le in  and Moore, 1979) abolish the rhythm. 
The SCN is connected to  the pineal gland by a neural c irc u it  tha t includes both 
ce n tra l and periphera l structures (rev iew ; K le in , 1979). L ig h t controls the
z—o— CJ
o
~o
2 X
O O
-o g
O r oO r u
O
"1
8
o
\
S
(D CUu u ro CO
la VO CO
CD
*C
'c
o
D
o
D
c cn
c
c o c
c c
o o
"5
(0
E
CD
CD >x CD
E X E
>s 2 >>X CO Xo
u
TD i
o
t-.
x>
> , 3 > \
JZ to n
VO vÔ VO
rH  rvi rA  < r
o
CD
(U
2
CT
iZ
9production of melatonin throughout this neural pathway which includes the retina, 
the retinohypothalamic projection, the SCN, the paraventricular nuclei (PVN), the 
superior cervical ganglia (SCG) and sympathetic innervation (Fig. 1.4.). 
Disconnection of the SCN from the retina leads to a free running melatonin 
rhythm, and the effects of light on the melatonin rhythm-generating system are 
most probably effects upon the oscillator situated in the SCN. This oscillator 
apparently drives a number of other biological rhythms (eg. growth hormone, rest- 
activity):how ever evidence is accumulating to suggest that other oscillators exist 
and these may interact to drive circadian rhythms (Folkard et al, 1984).
Pineal activ ity  may not be exclusively under autonomic co n tro l since 
morphological and electrophysiological experiments have indicated the presence of 
central neural input to the pineal of many m am m alian species (Mé Her and K o rf, 
1983).
(b) A drenerg ic  regu la tion
The transm itter regulating pineal melatonin production in the ra t is 
noradrenaline, which is released at n igh t in response to  s tim u la ting  signals 
o rig in a tin g  in the SCN (B row nste in  and A xe lrod , 1974). N oradrenaline (a mixed a 
and 6-agonist) acts on postsynaptic 6 . -adrenoceptors to stimulate adenylate 
cyclase and to  increase cyc lic  AMP synthesis which m ediates the induction  and 
activation of SNAT (Klein, 1979) and HIOM T (Sugden and Klein, 1983). An 
add itiona l e ffe c t o f noradrenaline is the rapid s tim u la tion  o f p inea locyte  cyclic 
GMR However the role of this nucleotide in the pineal is not known (Klein et al, 
1981).
The rhythmic neural input is coupled to  variable 6-rece p to r se n s itiv ity . 
Rom ero and A xe lrod , (1974) found the responsiveness of the pineal 6-adrenoceptor 
was around 10 tim es g rea te r a t the end o f the lig h t period (0600 to  1800 h) than at 
the  end of the dark period (1800 to  0600 h). These authors suggested th a t 
supersensitivity o f the receptor was the resu lt of decreased noradrenaline release
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11
during day-tim e, and subsensitivity of increased release at night. Romero and 
colleagues, (1975) also reported a diurnal variation in the number of specific 6- 
adrenergic binding sites in the rat pineal gland. The number of binding sites was
low est a fte r  12 hours of darkness and co rre la ted  w ith  changes in pineal cyclic AMP 
stimulation.
The long-held b e lie f tha t melatonin synthesis is co n tro lle d  exc lus ive ly  by 
postsynaptic 6-recep to rs  was challenged by the observation th a t postsynaptic ot,- 
adrenoceptors p o te n tia te  the 6-adrenerg ic stimulation of pineal SNAT (K le in  e t al, 
1983a). Noradrenaline was also shown to regulate pinealocyte cyclic AMP and 
c y c lic  GMP through th is  synerg is tic  mechanism invo lv ing  both and 6, -  
adrenoceptors (Vanecek et al, 1985). A c tiv a t io n  o f a.-adrenoceptors alone 
however had no apparent e ffe c t on c y c lic  nucleotide or SNAT activity levels 
in d ica ting  th a t 6-ad renerg ic  s tim u la tion  is an absolute requ irem ent fo r pineal 
function. A drenerg ic  s tim u la tio n  o f cyclic AMP apparently requires a C a^^- 
phospholip id-dependent p ro te in  kinase (p ro te in  kinase C) (Sugden et al, 1985) but 
the mechanism fo r cyclic GMP stimulation is unknown. K le in  and colleagues, 
(1981) found th a t adrenerg ic stimulation by denervation  or chron ic lig h t exposure 
enhanced the c y c lic  AMP response but dim inished the c y c lic  GMP response in ra t 
pineals. This phenomenon, te rm ed see-saw signal processing, has recently been 
shown to  invo lve rec ip ro ca l changes in the a,-adrenerg ic component of the cyc lic  
GMP response and the 6 . -adrenergic component o f the c y c lic  AMP response 
(Vanecek e t al, 1986). I t  has been postulated tha t th is  mechanism form s the basis 
o f p inea locyte  changes which occur as a result o f changes in environm enta l 
lig h tin g .
Furtherm ore^ in co n tra s t to  p ineal 6^-adrenoceptors, pineal a.-adrenoceptors
do not show a c ircad ian  rhy thm  in density or dow n-regu la te  a fte r  acute or chronic 
a dm in is tra tio n  o f adrenerg ic agonists (Sugden and K le in , 1985).
P rostaglandins (sp e c ifica lly  PGEG have been implicated in the noradrenaline- 
c o n tro lle d  m e la ton in  synthesis (C ard ina li and R it ta ,  1983). S pecific  recepto r sites
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fo r  prostaglandins have been found in p ineal membranes. The ac tion  of 
noradrenaline upon pineal a^-adrenoceptors apparently increases pinealocyte PGE^ 
levels which seems to regulate adenylate cyclase activ ity  and in turn increase 
SNAT activ ity  and melatonin production. This interm ediate role of prostaglandins 
has been found by Cardinali and colleagues to be complementary rather than 
necessary fo r p ineal function.
Presynaptic a - and B -adrenoceptors are present on the noradrenerg ic nerve 
endings of the rat pineal gland and these receptors have been shown to regulate 
feedback mechanisms for the co n tro l o f noradrenaline release (Pelayo et al, 1977).
(c) A dd itio n a l transmitters and receptors
The s tim u la tion  of adrenerg ic receptors is apparently  not the only mechanism 
fo r SNAT induction . I t  has now been shown tha t vasoactive in te s tin a l po lypeptide 
(VIP) is also present in the gland (Uddman et al, 1980) and th a t spec ific  binding 
s ites fo r VIP have been observed in  ra t p ineal ce lls (Kaku et al, 1983). Fu rthe rm ore  
VIP has been found to  be a potent stimulator of rat pineal adenylate cyclase and 
SNAT a c tiv ity  through in te ra c tio n  w ith  spec ific  VIP receptors (Kaneko et a l, 1980; 
Y u w ile r, 1983). I t  was proposed th a t th is  mechanism is independent and probably 
additive to  the B-adrenoceptor pathway in rat p inealocytes. Yuw iler, (1987) has 
re ce n tly  shown th a t a -adrene rg ic  agonists m arkedly enhance the VIP-induced 
s tim u la tio n  o f ra t pineal SNAT. This augm entation can be blocked by a . -  but not 
« 2" antagonists and the re p o rt suggests th a t protein kinase C is invo lved in the 
augm enta tion. I t  has become apparent tha t the VIP and B.-adrenoceptor systems 
are linked in th e ir  a b ility  to  in te ra c t with the a.-adrenergic system. This find ing  
is o f in te res t because i t  explains the mechanism through which the p inea locyte  
could in teg ra te  peptide and noradrenaline s tim u la tion , which may occur as the 
re su lt o f both ce n tra l and periphera l s tim u la tio n  (see F ig . 1.5).
The com p lex ity  o f p ineal m e la ton in  regu la tion  has been underlined by the 
find ing  o f numerous other neu ro transm itte rs  and corresponding binding sites in
13
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Fig. 1.5 Diagram summarising the neural and synaptic mechanisms controlling 
the synthesis of melatonin and other pineal indoles/modified from Cardinali et al, 
1984.")
Abbreviations of pineal indoles according to Smith, 1982 : W, tryptophan; HW, 5- 
hydroxytryptophan; HT, 5-hydroxytryptamine; aHT, N-acetyl-5-hydroxytryptam ine; 
HA, 5-hydroxyindole acetic acid; HL, 5-hydroxytryptophol; MA, 5-methoxyindole 
acetic acid; ML, 5-methoxytryptophol.
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mammalian pineal glands (review; Ebadi and Govitrapong, 1986). It  has been
proposed th a t a v a rie ty  o f p ineal n eu ro tra nsm itte rs  orchestrate the functions o f a 
cascading group o f recep to r sites. M uscarin ic  cholinergic receptors have been 
found in the rat and sheep pineal, whereas GABA, Substance P-ergic, D 2" 
dopaminergic, S^-serotoninergic, and glutamatergic sites have been detected  in 
bovine pineals. The molecular complex comprising GABA, benzodiazepine and 
barbiturate binding sites has been found in both human and bovine pineal 
membranes (Low enste in  et al, 1984b). The precise function o f many of these pineal 
receptors is at present unknown.
Hormones have been shown to  act on p inealocytes themselves or at the leve l 
o f pinealopetal neural pathways and the mechanisms of these actions are the 
subject o f a review (C a rd ina li, 1984).
1.2.4. E ffe c ts  o f lig h t upon m ela ton in  production
(a) Suppressive effects
Under conditions of constant lig h t, rhythms in SNAT activ ity  and melatonin
concen tra tion  are abolished in the ra t and monkey (K le in  and W eller, 1970; Perlow 
e t al, 1981). Moreover^ sudden lig h t exposure at n igh t, even o f jus t one m inute  in 
dura tion , suppresses elevated SNAT and m e la ton in  leve ls in experim en ta l animals 
(rev iew ; Illne rova  and Vanecek, 1985; R e ite r, 1985). Suppression of SNAT occurs 
im m ed ia te ly  w ith  the decline in m e la ton in  leve l corresponding to its  h a lf-life  in 
plasma or CSF. Interspecies d iffe rences in pineal se n s itiv ity  to  lig h t trea tm en ts  of 
varying  in te n s ity , duration and wavelength are w e ll documented (R e ite r, 1985). 
Fo r instance^very low  in ten s ity  lig h t o f only 0.2 lux is required fo r  p ineal SNAT 
suppression in rats whereas around 300 lux is requ ired  to  reduce n ig h t-tim e  plasma 
m e la ton in  leve ls in man (see Section 1.3.4.). I t  has been proposed by R e ite r and 
colleagues, (1983) th a t these differences may be due to the interspecies differences 
in env ironm enta l lig h tin g  h is to ry . In the Syrian hamster^ lig h t in the blue-green 
range o f the spectrum  was found to  be the most e ffe c t iv e  suppressant^whereas red
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l ig h t is in e ffe c t iv e . The ac tion  spectrum  for lig h t suppression of m ela ton in  
p roduction  corresponded to  th a t o f rhodopsin (B ra inard  et al, 1984).
A fte r a one minute light pulse, SNAT activ ity  in the ra t, was reported to 
decline at the same rate obtained following 6-blocker administration (Vanecek and 
Illne rova , 1979). Furthermore^infusion of the 6-agonist isoprenaline prevented the  
suppressive effects of brief light pulses (Illnerova and Vanecek, 1979) suggesting 
tha t night-tim e lig h t treatm ent inh ib its  the release o f noradrenaline from  pineal 
sympathetic nerve endings presumably via the retinohypothalamic pathway.
The ability of the melatonin generating system(at least in the rat) to restore 
night-tim e melatonin levels after brief light exposure depends upon the time of 
treatm ent.
(b) E n tra in ing  effects of lig h t
Besides suppression o f pineal rhythms, l ig h t can in te ra c t with the endogenous 
pacemaker (the SCN) as a zeitgeber (tim e-giver) and entrain the rhythmic 
production of m ela ton in  with environm enta l lig h tin g . In the rat, studies o f 
Illnerova and Vanecek (rev iew ; 1985) have indicated that b rie f lig h t pulses of only 
one m inute  dura tion  may ac t as entraining signals. C ritica lly  tim ed  light pulses 
applied before midnight were found to phase delay the pineal SNAT rhythm  
whereas pulses a fte r midnight phase advanced the rhythm in SNAT activ ity . These 
authors found th a t the evening rise and the morning decline in SNAT a c tiv ity  did 
not always respond to  lig h t pulses w ith  pa ra lle l phase sh ifts . The in te ra c tio n  o f 
lig h t w ith  the pacemaker may be predicted by phase response curves (Illnerova and 
Vanecek, 1985; Lew y 1983b) which indicate how the phase s h ift depends on the 
phase at which the stim u lus is applied. Illnerova and Vanecek, (1982) proposed dual 
oscillatory control of m ela ton in  secre tion ; an evening o sc illa to r (E) con tro ls  the 
SNAT rise and a morning oscillator (M) controls the SNAT decline. E may be 
coupled to  dusk and M to  dawn but both oscillators may in te ra c t w ith  each o ther. 
These resu lts have ind ica ted  th a t in ra ts a t least, the m e la ton in  rhythm  is driven by
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a complex pacemaker.
1.2.5. E ffe c t o f drugs on m e la ton in  p roduction
A variety of drugs have been shown to act upon pineal receptors and enzymes 
(reviews; Minneman and Wurtman, 1976; Smith, 1981b). Emphasis has been placed 
upon drugs which a ffec t sympathetic neurotransmission and hence act upon 
pinealocyte adrenoceptors. In addition^increasing evidence of central neural input 
to the pineal has led to studies of central nervous system (CNS) 
depressan t/s tim u lan t drug effects on m elaton in  secretion. Reports o f in vivo drug 
effects upon mammalian melatonin synthesis are briefly reviewed.
The directly acting 6-adrenoceptor agonist isoprenaline w il l  s tim u la te  
daytime m ela ton in  production in ra ts  (K le in , 1979) and mares (Sharp et al, 1980). 
Moreover  ^ a dm in is tra tio n  of the a -agon is t phenylephrine po ten tia tes  the 
isoprenaline-induced rise in rat pineal melatonin (Klein et al, 1983a), whereas 
adrenergic agonists have previously fa ile d  to  s tim u la te  m e la ton in  in the Syrian 
hamster (Lipton et al, 1982) and man (see Section 1.3.5.). Recent reports however, 
have shown th a t isoprenaline s tim u la tio n  o f m elaton in  in the Syrian hamster is 
restricted to the la t te r  ha lf o f the da ily  dark period only (Reiter et al, 1987). This 
group also found tha t the ham ster pineal gland is sensitive to  noradrenaline 
stimulation (in combination with a noradrenaline uptake inhibitor, 
desm ethy lim ip ram ine ) only in the second ha lf o f the dark period. R e ite r and co­
authors, have proposed th a t darkness is required fo r the developm ent o f m axim al 
s e n s itiv ity  o f the pinealocyte receptors in the hamster. In man (see Section
1.3.2.2.) i t  has proved d ifficu lt to  s tim u la te  m ela ton in  p roduction  w ith  adrenergic 
agonists.
W hether the find ings in  Syrian hamsters are applicab le  to  the lack o f response 
in man rem ains to  be determ ined. Interspecies d iffe rences are also h igh ligh ted by 
a re p o rt tha t a -b u t not 6 -recep to r antagonists may be e ffe c tiv e  in suppressing 
m e la ton in  production in sheep (Klein e t al, 1983b). H o w e v e r, English et al.
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(unpublished) and Morgan et al, (1987) have been unable to  reproduce th is  
suppression in sheep using the ot,-antagonist prazosin. The lack of e ffec t with
adrenerg ic antagonists may be dose re la ted .
In the ra t, administration of dopamine (Deguchi and Axelrod, 1972) or the 
noradrenaline precursor 1-dopa (Lynch et al, 1973) causes a rapid increase in pineal
SNAT a c t iv ity  and m e la ton in  con ten t in vivo . The mechanism may invo lve  release 
o f noradrenaline from  sym pathe tic  nerve te rm ina ls  or possibly the d ire c t ac tion  of 
dopamine upon the p inea locyte . These e ffe c ts  have not been re p lica te d  in o ther 
species.
Increased a v a ila b ility  o f serotonin may be more important fo r  m ela ton in  
synthesis than had previously been thought since adm in is tra tion  o f the serotonin 
p recursor, 5-hydroxy tryptophan will increase daytim e m e la ton in  in sheep 
(N am bood iri e t al, 1983). The a rom a tic  amino acid decarboxylase inh ib ito rs , 
benserazide (A rend t et al, 1981) and carbidopa (Oxenkrug et al, 1984) w ill decrease 
ra t p ineal m e la ton in  content^ presum ably by decreasing the a v a ila b ility  o f the 
precursor seroton in  and o f noradrenaline. D ep le tion  of serotonin by p- 
ch lo rophenyla lan ine (PCPA) tre a tm e n t also reduces ra t pineal m e la ton in  levels 
(N iles e t al, 1984).
CNS depressants such as phénobarbital, morphine and diazepam have been 
found to rapidly reduce nocturnal SNAT activity in the rat (Zatz and Brownstein 
, 1979). A d m in is tra tio n  of des-tyrosine-y-endorphin and haloperidol to ra ts 
elicited an increase in pineal melatonin content (Gaffori et al, 1983). Lowenstein 
and co-workers, (1984a) have demonstrated a suppression o f night-tim e m ela ton in  
production in naloxone treated rats. These authors suggested that opioids and 
op io id  antagonists a ffe c t m e la ton in  p roduction  by actions at cen tra l opioid 
synapses (Lowenste in et al, 1984a).
A ntidepressant drugs, p a rtic u la r ly  noradrenaline or serotonin-uptake 
b lockers, and monoamine oxidase inh ib ito rs , have been shown to  increase m ela ton in
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production. Acute daytime administration (50 mg/kg) of clomipramine, 
imipramine, desmethylimipramine (DM I), m aprotiline and pargyline all induced an 
acute increase in both pineal and plasma melatonin in rats (W irz-Justice et al, 
1980c). The monoamine oxidase inhibitor pargyline, had the most marked elevation 
presumably due to the net e ffec t of increased neurotransmitter levels combined 
with increased precursor levels. Some antidepressant drugs slow certain circadian 
rhythms in rats (discussed in Section 1.5.3.). The e ffect of chronic antidepressant 
treatm ent upon melatonin secretion in the rat is discussed in Section 1.5.4.
1.3. THE H U M A N  PINEA L
1.3.1. Introduction
The human pineal gland is situated in the centre of the brain attached to  the 
posterior wall of the third ventricle by a th in  stalk (F ig 1.6). Large varia tions  have 
been reported in  size and w e ight (around 170 mg, mean) and in the ex ten t o f human 
pineal gland c a lc if ic a t io n , however^ melatonin synthesis seems to occur even in the 
presence of heavy c a lc if ic a tio n  (W etterberg, 1979). There is apparently no 
co rre la tio n  between plasma m ela ton in  levels and the ex ten t o f p ineal c a lc if ic a tio n  
in norm al adults (Bojkowski, 1988).
The measurement of m ela ton in  in human tissues and body fluids under various 
conditions has provided observations comparable with those from animal studies. 
In it ia l reports  o f a day-n igh t rhythm  o f m ela ton in  in human blood (Pelham et al,
1973) and urine (Lynch et al, 1975) have been confirmed by all investigators to 
da te . M e la ton in , SNAT and HIOMT have been identified in human pineals and 
m e la ton in  has been found in CSF and discrete brain areas (review; Vaughan, 1984). 
I t  has been shown th a t the pineal is the main source o f circulating m ela ton in  in 
man (see Section 1.3.5.(f)). I t  is unclear, however, w hether pineal m ela ton in  is 
directly secreted in to  CSF and w hether its  presence in CSF has b io log ica l 
s ign ificance . The find ings o f m e la ton in  and also spec ific  binding sites for
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m ela ton in  (see Vaughan, 1984) in human bra in have been in te rp re te d  as an 
ind ica tion  o f ce n tra l ta rg e t areas fo r  m e la ton in  action .
The fa te  o f plasma melatonin in humans (Jones et al, 1969) is s im ila r to  th a t 
in rats (Kveder and Mclsaac, 1961) since radiolabelled melatonin, administered to 
volunteers appeared in the urine as alviT6s (60-70%) and 6-hydroxymelatonin 
glucuronide (20-30%) with a trace of unchanged melatonin. Metabolic studies have 
shown that melatonin is prim arily metabolised in the liver (Wurtman et al, 1968). 
Furthermore patients with cirrhosis demonstrated lower clearance rates (Iguchi et 
al, 1982a; Lane and Moss, 1985). Plasma and u rinary aM T6s levels in man display a 
marked circadian rhythm (Arendt et al, 1985) and provide a good index of 
m e la ton in  secretion, as shown in F ig . 1.7. M e la ton in  administered in 
pharmacological doses has been shown to have an e lim ina tio n  h alf-life  o f around 
30-50 minutes, in norm al vo lunteers (Waldhauser et al, 1985; Aldhous et al, 1985).
1.3.2. C on tro l o f human m e la ton in  secre tion
It appears tha t the sympathetic neural pathway m ed ia ting  the cen tra l control 
o f pineal fun c tio n  is s im ila r in humans and ra ts  since patien ts  w ith  sym pathe tic  
neuro log ica l lesions show consistent abolition of the circadian m elaton in  rhythm  
(Section 1.3.4.(b)). Vaughan, (1984) found normal melatonin levels in stressed 
volunteers and patien ts  su ffe ring  from  severe burns^ suggesting tha t m ela ton in  
secre tion  is not an ind ica tion  o f general sym pathe tic  a c t iv ity .
The effects of light and o f sympathetic m anipu la ting  drug trea tm en ts  have 
constituted much of the research into the mechanisms controlling human
m ela ton in  p roduction.
1.3.2.1. Human m e la ton in  secre tion  and lig h t
(a) E n tra inm en t
Until recently i t  was believed tha t lig h t was un im portan t fo r the entra inm ent
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Fig . 1.7 A. Mean + SEM plasma levels o f m ela ton in  and aMT6s in 10 subjects 
(8 M, 2 F) sampled hourly for 24 hours.
B. Mean + SEM urinary aMT6s excre tion  during 6 hourly in terva ls  
fo r  24 hours in the same individuals.
(from  A rendt et al, 1985)
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of circadian rhythms in humans (Czeisler et al, 1981). However, i t  is now known 
that, as in other species, there are two different effects of light upon melatonin 
secretion in man : an entrainment e ffec t and an acute suppressant e ffec t (Lewy, 
1983b).
Human m e la ton in  secretion is endogenous since i t  persists under cond itions o f 
continuous darkness, dim light or all night waking. Furthermore daytime melatonin 
secretion is una ffec ted  by a period o f darkness and/or sleep during the day (review; 
Vaughan, 1984). Desynchronisation of the melatonin rhythm from the day-night 
cycle in blind subjects (Lewy and Newsome, 1983) has implicated the light/dark  
cyc le  as the entra in ing  fa c to r in m a in ta in ing  a consis ten tly  tim ed noctu rna l rise in 
norm al subjects. A fte r  an imposed s h if t  in the lig h t/d a rk  (12-hour phase delay). 
Lynch and colleagues, (1978b) reported  th a t in norm al subjects the usual nocturna l 
m e la ton in  peak adjusted to  the new 'dark position ' within 7-12 days.
Recently^ th ree  separate studies dem onstrated the phase sh iftin g  e ffe c ts  o f 
b rig h t lig h t in man. C ze is le r and colleages, (1986) showed tha t exposure to  b righ t 
lig h t in the evening phase delayed the body tem pera tu re  and co rtiso l rhythm s in 
one subject. A rend t and Broadway, (1986) and Broadway et al, (1987) provided the 
f irs t  demonstration th a t b rig h t but not d im  lig h t tre a tm e n t, during the A n ta rc t ic  
winter, phase sh ifte d  the m e la ton in  rhy thm  in norm al subjects to  a phase position 
s im ila r to  th a t found in summer. This study also reported th a t humans unlike 
anim al species^ respond to  changes in photoperiod by phase shifting the m ela ton in  
rhy thm  ra th e r than by a lte ring  the dura tion  o f secretion. Lewy and co-workers 
(1987)  ^also dem onstrated a phase s h if t  (advance) in the onset o f n ig h t-tim e  
m ela ton in  production  in 8 pa tien ts  fo llo w in g  7 days exposure to  b rig h t morning 
light. A cu te  exposure to  b rig h t evening lig h t has been shown to  phase delay the 
rhy thm  o f u rinary  6 -su lpha toxym ela ton in  exc re tion  in 6 norm al subjects (Kennaway 
et a l, 1987).
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(b) Suppression
Early work had shown that a rtific ia l light at night did not a ffect melatonin 
secretion (Jimerson et al, 1977; Arendt et al, 1978). However Lewy et al, (1980) 
clearly demonstrated that if the light was of sufficient intensity (2500 lux) night­
tim e melatonin secretion was suppressed, returning to normal levels with lights off. 
Ordinary room light (500 lux) was ineffective, whereas 1500 lux had interm ediate  
effectiveness. The human species was clearly more insensitive to light treatm ent 
compared to other animal species. However^ a later report from Lewy's group 
(Lewy et al, 1985a) indicated tha t a wide range existed in the m e la ton in  repense o f 
normal volunteers to  dim lig h t (500 lux). F u rthe rm ore , we have re ce n tly  shown 
th a t dim  lig h t o f only 300 lux significantly suppressed plasma m ela ton in  and aMT6s 
levels in 4 out o f 5 male volunteers (Bojkowski e t al, 1987a). The discrepancy 
between the la tte r study and the in it ia l study o f Lew y et al, (1980) may have been 
due to  in te r in d iv id u a l v a ria tio n  in se n s itiv ity  to  lig h t or to  d iffe rences in the tim in g  
o f lig h t tre a tm e n ts  and standardisation o f the amount o f lig h t received by each 
subject. I t  is s t i l l  not known w hether a d iu rna l v a ria tio n  exists in the se n s itiv ity  to  
light fo r  m e la ton in  suppression.
Rebound increases o f nocturnal serum m ela ton in  leve ls have been found in 
normal subjects, following evening suppression with bright light (Beck-Friis et al, 
1985c). This group has also shown a lack o f the rebound phenomenon in depressed 
patients (Beck-Friis et al, 1986) and this has been proposed as a test for the
eva lua tion  of noradrenergic recep to r fun c tio n  in man. We have been unable to  
confirm these find ings in norm al vo lunteers (Bojkowski et al, 1987a).
B ra inard and co-workers, (1985) have shown th a t the wavelength o f lig h t 
(m axim um  around 509 nm) is im p o rta n t fo r  m ela ton in  suppression. I t  is not known 
w hether in humans as in animals there  is a rec ip roca l intensity-duration  
re la tionsh ip  between lig h t and m ela ton in  suppression. However^ i t  is evident th a t 
norm al subjects are m ore sensitive to  d im  lig h t than previously thought.
Ind iv idua ls liv in g  and working predominantly indoors w ith  low  in ten s ity
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lighting have entrained melatonin rhythms (G riffiths et ai, 1986). It is possible
however tha t e n tra inm en t in the absence o f b rig h t lig h t is due to o ther tim e  cues.
Lewy and colleagues, (1985c) advanced dusk by sampling volunteers in the 
evening under dim light for a period of one week. The onset in melatonin secretion 
was advanced over an 8 day period by more than 2 hours in response to  the 
imposed earlier dusk. They proposed a 'clock-gate' model to explain the late onset 
and early  o ffse t o f m ela ton in  production in the summer compared to  w in te r. The 
model assumes that both dawn and dusk entrain the pacemaker for human 
melatonin secre tion .
The relationship between the human melatonin rhythm and light has provided
good evidence fo r the existence o f a neural pathway co n tro llin g  m e la ton in  
secretion s im ila r to  tha t o f experim en ta l animals.
1.3.2.2. M an ipu la tion  w ith  drugs affecting the sym pa the tic  nervous system
(a) Suppression
As described above, lig h t o f s u ffic ie n t in ten s ity  can suppress nocturna l 
m e la ton in  secre tion . 6-Adrenergic blockade in humans has also successfu lly 
prevented the normal rise  o f plasma or u rinary  melatonin e ithe r by a dm in is tra tion  
of propranolol (Vaughan et al, 1976; Hanssen et al, 1977; Moore et al, 1979) or the 
pe riphe ra lly  ac ting  6-adrenoceptor blocker, atenolol (Cowen e t al, 1983a; A rend t 
e t al, 1985). This e ffe c t o f a teno lo l provided evidence th a t the human pineal is 
outside the pharm aco log ica l blood bra in ba rrie r. Furthermore, Cowen and co- 
authors, (1985a) reported that chronic treatm ent with 6-adrenoceptor blockers in 
hype ractive  patients caused a persistent reduction  in plasma m ela ton in .
In add ition  to the 6-adrenergic effects^ the re  is some evidence tha t a -  
adrenoceptors may in fluence  human m ela ton in  secre tion . Infusions o f clonidine, an 
oc^-sdrenoceptor agonist, have been shown to reduce (Lewy et al, 1986) or not to 
a ffe c t (Grasby and Cowen, 1987b) noctu rna l plasma melatonin in normal subjects. 
Lewy's group reported  a h igh ly linea r dose-response relationship between the
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amount of clonidine administered and the observed suppression. We have shown 
that oral administration of prazosin, an Og^-antagonist, reduced evening plasma 
melatonin in male volunteers (described in Section 1.4.2.).
Reports by Beck-Friis et al, (1983) and Demisch et al, (1987a) have 
demonstrated a reduction in serum melatonin by acute oral administration of 
dexamethasone. Beck-Friis and co-workers have hypothesised that cortisol may 
influence melatonin levels by mediating a change in pineal 6-adrenoceptor 
sensitivity.
(b) S tim u la tion
A tte m p ts  to s tim u la te  human circulating m ela ton in  by administration o f 6- 
agonists such as isoprenaline and orciprenaline in doses sufficient to  e lic it  
cardiovascular responses have been in e ffe c tiv e  during the daytime, evening or 
night-tim e (Vaughan et al, 1976; Moore et al, 1979; Lewy 1983a; Palazidou, Franey, 
A rend t and C heckley, unpublished observations, 1986). Ritodrine, a 62- 
adrenoceptor agonist has been shown to  acute ly  s tim u la te  daytim e plasma 
m e la ton in  in women (D esir e t al, 1983) but these findings have been unconfirmed 
(Krautgasser-Gasperotti et al, 1983). We have also been unable to  repeat the 
find ings o f D esir and colleagues, (1983) using infusions o f sa lbutam ol, a spec ific  62- 
adrenoceptor agonist, during the daytim e or la te  evening upon plasma m ela ton in  
levels in male volunteers (Palazidou, Franey, A rendt and Checkley, unpublished 
observations, 1986). Since 6 -agonists s tim u la te  m e la ton in  secretion in 
expe rim en ta l anim als i t  is possible tha t h igher doses are required fo r  the same 
effects in man.
To e lim ina te  inconvenient night-tim e sampling i t  would clearly be desirable
to develop a tes t o f p ineal func tion  applicab le  during the daytime. A number o f 
studies have shown an apparent stimulation of daytim e human m ela ton in  secretion 
by various means such as adm in is tra tion  o f destyrosyl-^ -endorphin (C laustra t et 
al, 1981), th y ro id  s tim u la ting  hormone and danazol (B irau, 1981), heavy exercise
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(Carr et al, 1981), the met-enkephalin analogue FK33-824 (Lissoni et al, 1986a), 
tetrahydrocannabinol (Lissoni et al, 1986b), 8-methoxypsoralen (Birau, 1981; Grota  
et al, 1985) and 5-methoxypsoralen (Souetre et al, 1987). In most of these studie^ 
the mechanism, significance and reproducibility of results is not known, however 
reports of psoralen effects seem to be in agreement and deserve further 
investigation.
In contrast with animal studies^administration of the catecholamine precursor 
1-dopa has been ineffective in stimulating melatonin production in man (Arendt, 
1978; Wetterberg, 1978; Moore et al, 1979). Dopamine agonists have been tried  
with no significant e ffect (review; Vaughan, 1984). 5-Hydroxytryptophan 
administration to  children and adults produced no appreciable daytim e increase in 
m e la ton in  (C ava llo  e t al, 1987) despite reports o f stimulation in sheep (N am boodiri 
et al, 1983). Chlorpromazine (a -ad renerg ic  and dopamine blocker) raised day and 
n ig h t-t im e  plasma m e la ton in  leve ls in a dose response manner (Sm ith et al, 1979). 
However^ the authors concluded tha t the drug blocked hepatic m etabolism  and th is 
contributed to the observed increase in melatonin.
N oradrena line  uptake in h ib ito rs  such as the antidepressant drug DM1, have 
acu te ly  increased evening levels o f m e la ton in  in norm al volunteers (Cowen et al, 
1985b; Franey et al, 1986) but not daytim e leve ls (discussed in Section 1.4.1.). 
M oreover, increased daytim e plasma m ela ton in  in norm al volunteers and depressed 
pa tien ts  has been found fo llow ing  adm in is tra tio n  o f monoamine oxidase in h ib ito r 
antidepressants such as clorgyline (Type A) (Murphy et al, 1986) and 
tra ny lcyp rom ine  (mixed) (Oxenkrug et al, 1986). Demisch and co-workers, (1987b) 
were unable to reproduce these results^ but found significantly higher morning 
leve ls o f m ela ton in  a fte r tre a tm e n t the n ight before w ith  the serotonin uptake 
in h ib ito r fluvoxam ine . We have described (see Section 4.2.) elevated n ig h t-tim e  
aMT6s e xc re tion  in norm al vo lunteers fo llo w in g  administration of ro lip ra m , a 
phosphodiesterase in h ib ito r (Checkley et al, 1987). This study ind icates a role fo r 
cyclic AM P in human m e la ton in  p roduction.
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I t  is possible that the increases observed following antidepressant 
administration are the resu lts o f phase changes in the m e la ton in  rhythm (M urphy e t 
al, 1986; Franey et al, 1986; Demisch et al, 1987b). The effects of chronic 
tricyclic  antidepressant administration are discussed in Section 1.5.
Adrenergic control of human melatonin secretion is only partially defined 
since the lack of e ffect of 6-agonists, 5-hydroxytryptophan and 1-dopa remains 
unexplained.
1.3.3. Physio log ica l Variations
Reports o f norm al values fo r blood m e la ton in  in populations of hea lthy adults 
have, in recent years, been in good agreem ent (Table 1.1) despite the sm all 
numbers of subjects studied. Mean peak values are situated around 40-60 pg /m l 
and daytim e levels are usually below the l im it  o f detection of radioimmunoassay 
(R IA ; 5-10 pg/m l) and gas chrom atography-m ass spectroscopy (GC-MS; 2-10 pg /m l) 
techniques. There is however^ large in te r in d iv id u a l va ria tion  in the levels o f 
overnight melatonin reported  ^ whereas in tra in d iv id u a l m elaton in  secre tion  
dem onstrates rem arkable  s ta b il ity  in the am ount secreted and the duration  and 
shape o f the m e la ton in  secretion p ro file  (Lynch et al, 1975; Arendt, 1979; A ra to  et 
al, 1984). Reports of day and night-tim e melatonin levels substantially higher than 
those shown in Table 1.1 are lik e ly  to  be an overes tim a tion  due to less spec ific  
methods o f m easurem ent. Melatonin levels are s im ila r in plasma and serum 
(W etterberg, 1978) and there is a good co rre la tio n  between blood and urinary values 
(Lynch et al, 1978a; Lang et al, 1981). The establishment of CSF values in normal 
subjects is d i f f ic u l t  since studies have been few . However levels are apparently 
low er than found in plasma (A rendt et al, 1977a; Brown et al, 1979). N ig h t-tim e  
plasma aMT6s leve ls are approx im ate ly  tw ic e  those o f m elatonin and mean urine 
aMT6s levels are around 5-15 pg/24 h compared to  40-80 ng/24 h fo r m ela ton in  in 
urine (A rend t e t al, 1985; Bojkowski et al, 1987b).
E arly  studies dem onstrated pu lsa tile  m e la ton in  secre tion  superimposed on the
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Method D aytim e  N ig h t-tim e  No. o f Subjects R eference
GC-MS 1.5-5 19-43 Lewy and Markey, 1978
RIA 10 + 1.5 31 + 5.1 12 F e rr ie r et a l., 1982
7 + 1.0 83 + 20 Iguchi e t a l., 1982b
<10 65 + 10.5 11 A ra to  et a l., 1984
47 33 B eck -F riis  et a l., 1984
7 + 1.0 60 + 7 Vakkuri e t al., 1984a
9 + 1.5 49 + 4.0 31 Waldhauser et a l., 1984
60 + 7 22 W etterberg  e t a l., 1984
<10 45 + 10 11 Arendt, 1985
Table 1.1 Blood m e la ton in  values in hea lthy adults (x + SEM; pg/m l)
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day-night secretory rhythm (Vaughan et al, 1978; Weitzman et ai, 1978). The 
frequency o f pulses was suggested to be hourly (Weinberg et al, 1979) or around ten 
minutes (Vaughan et al, 1979). However, Arendt et al, (1982) measuring serum 
levels every sixty minutes and Bojkowski et al, (1987b) measuring night-tim e  
plasma melatonin and alviT6s every th irty  seconds did not find evidence of 
significant pulsatile secretion. Episodic secretion with two or more peaks in the 
night-tim e melatonin profile has been observed in a number of subjects (Arendt, 
1985). Nocturnal melatonin levels (Arendt et al, 1982) and peak values (Arato et 
al, 1984) have been shown to  correlate w e ll w ith  overnight melatonin secretion.
The role o f melatonin in the regulation o f the hypo tha lam ic - p itu ita ry  - 
gonadal axis in animals has prompted studies of variations in melatonin secretion 
related to  reproductive fun c tio n . Beck-Friis and co-workers, (1984) reported 
higher m ela ton in  levels in females than males, however the difference disappeared 
when results were adjusted for body height and no d iffe re n ce  was found between 
pre- and postmenopausal women. Serum m ela ton in  changes during the menstrual 
cyc le  were reported in early studies using one sample tim e  po in t every two-three  
days of the cycle  (W etterberg  et al, 1976; Arendt, 1978). M ela ton in  secretion was 
found to  be low est at the tim e  o f ovu la tion . Higher than norm al levels were 
measured in th is  study and were probably due to less spec ific  R IA  m ethodology at 
the tim e  (Arendt, 1978). Fe llenberg et al, (1982) fa ile d  to  de tect changes in 
u rinary  6-hydroxymelatonin during the m enstrual cyc le . More re ce n tly  however, 
Webley and co-workers, (1985) measured m e la ton in  throughout a 24-hour period and 
found s ig n ific a n tly  h igher levels during the lu tea l phase and a nadir a t the tim e  of 
ovu la tion . These authors have suggested a positive  re la tionsh ip  between melatonin 
and progesterone since in fou r con tracep tive  p ill users and in la te  pregnancy, 
noctu rna l m e la ton in  concentra tions were significantly higher than in a group of 
norm a lly  cycling women. To date the number o f subjects involved in m enstrua l 
cyc le  studies has been sm all.
Many investiga tions invo lv ing  measurements at iso lated tim es o f the 24-hour
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cyc le  have shown no conclusive re la tionsh ip  between endogenous plasma m e la ton in  
and puberty. High day- and n ig h t-t im e  leve ls in p repuberta l ch ild ren  have been 
reported in a number of separate studies (Silman et al, 1979; Das Gupta et al, 1983; 
Waldhauser et al, 1984) with many other groups reporting no apparent difference. 
(Lenko et al, 1981a; Ehrenkranz et al, 1982). The situation at present is 
unresolved, however if plasma levels are high in prepuberty^ this may be due to 
gross changes in body size during puberty^ since total urinary 24-hour excretion of 
melatonin (Lem aitre et al, 1981; Lenko et al, 1981b) and aM T6s (Bojkowski, 1988) 
has indicated sim ilarity between the sexes pre and post-pubertally.
Blood melatonin levels (Waldhauser and Steger, 1986) and urinary aM T6s 
levels (Bojkowski, 1988) remain relatively constant during adolescence and young-
m iddle adulthood^but in e lderly  subjects there is a c lear decline in the am plitude  of 
the  melatonin rhy thm  in blood (W etterberg, 1979; Iguchi e t al, 1982b) and in the 
u rina ry  excretion o f conjugated 6 -hydroxym e la ton in  (Sack et al, 1986).
The relationship o f m ela ton in  p roduction  to body size remains unclear and is 
probably o f l i t t le  importance. C orre la tions  in plasma have been reported  to  be 
positive (Arendt et al, 1982; Ferrier et al, 1982) or in a larger study, negative 
(Beck-Friis et al, 1984). Bojkowski, (1988) found no correlation between urinary 
aM T6s excretion and body weight in normal adults. Beck-Friis et al, (1984) 
observed a significant negative correlation between plasma m ela ton in  and height^ 
whereas Sack et al, (1986) found a positive relationship between total daily 6- 
hydroxym ela ton in  excre tion  and height.
A seasonal rhy thm  in human plasma melatonin was reported in an early  study 
using single time point sampling throughout one year (Arendt et al, 1977b). Low 
values in spring and autumn and high values in w in te r and summer were 
contradicted in a la te r  repo rt suggesting a peak in spring (To itou et al, 1981). The 
m easurem ent o f m ela ton in  throughout 24 hours has ind icated no seasonal 
differences in peak plasma m ela ton in  levels (Beck-Friis et al, 1984; A rend t 1985) 
but evidence o f a s h if t  in the m e la ton in  rhy thm  towards a phase advance in summer
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is convincing (Illnerova et al, 1985; Bojkowski and Arendt, 1988; Broadway et al, 
1987). Unlike seasonally active animals^it is possible that man responds to changes 
in the photoperiod by phase shifting the melatonin rhythm instead of changing the 
duration of secretion.
1.3.4. P a tho log ica l Variations
The role of the pineal has been investigated in a multitude of diseases with an 
endocrine/neuroendocrine basis and in particular diseases with associated rhythm  
abnormalities. Only in the investigation of affective disorders have the m ajority of 
studies (described in Section 1.4.) indicated abnormal production of melatonin.
(a) Blindness
The effect of reduced lig h t perception upon melatonin secretion in man has 
been investigated in a sm all number o f b lind subjects with re tin a l dysfunction . 
Sm ith et al, (1981a) reported  high daytim e and lower n ig h t-tim e  plasma melatonin 
levels in the blind however a fu l l analysis o f the rh y th m ic  ch a rac te ris tics  o f 
secretion was not a ttem p ted . Vaughan et al, (1982) have shown tha t the tim in g  o f 
the nocturnal melatonin peak, in four subjects, was outside the range for sighted 
con tro ls  but tha t the phase re la tio n  between m e la ton in  and co rtiso l was 
m ain ta ined. Lewy and Newsome, (1983) have reported a phase delay o f the 
m ela ton in  secre to ry  rhy thm  in one b lind  ind iv idua l and a free  running rhythm  in 
another. These authors suggested th a t the lig h t-d a rk  cyc le  is important fo r the 
en tra inm en t o f m e la ton in  secre tion  in man however o ther tim e  cues may be 
invo lved.
(b) CNS lesions
Kneisley et al, (1978) found no melatonin excre tion  rhy thm  in the urine o f six 
quadrip leg ic patien ts w ith  periphera l sym pathe tic  dysfunction. Patien ts w ith  the 
Shy-Drager syndrome (m u ltip le  system atrophy) and w ith  id io pa th ic  o rtho s ta tic
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hypotension (defect in post ganglionic nerves) displayed low or absent nocturnal 
elevations of urinary 6-hydroxym e la ton in  (Tetsuo et al, 1981). M oreover, in 
advanced diabetic autonomic neuropathy (O'Brien et al, 1984) the plasma melatonin 
rhythm was abolished. Six patients with Parkinsons disease (basal ganglion 
degeneration) were found to have normal melatonin rhythms (Vaughan et al, 1981) 
demonstrating specificity in the location of lesions that interupt the melatonin 
pathway in man.
(c) Insomnia
I t  has been proposed tha t endogenous m ela ton in  in man is invo lved in 
circadian cycles of sleep and sleepiness (Anton-Tay et al, 1971; Cramer et al,
1974). S ynthe tic  m e la ton in  administered chronically can entrain the daily a c tiv ity  
rhythms o f ra ts  (Redman et al, 1983) and low  doses o f m e la ton in  (2 m g/day) 
adm in istered in the afternoonhavebeen shown to  increase evening fa tigue  in norm al 
volunteers (Arendt et al, 1984). However, few  reports have described plasma 
m e la ton in  and d isturbed sleep. W etterberg, (1978) reported high melatonin levels 
in the plasma and urine of one chron ic insom niac. We have observed undetectable 
plasma melatonin leve ls in one vo lun teer who com plained o f poor sleep (sub- 
c lin ic a l) . M e la ton in  was adm inistered (5 m g/day) at 2300 h fo r one month in a 
double b lind  cross-over study but no e ffe c t o f m elaton in  was observed upon se lf- 
ra ted  la tency  to  sleep or q ua lity  o f sleep in th is  ind iv idua l (Franey and A rend t, 
unpublished results).
(d) Endocrinopathies
D isturbances o f endocrine func tion  have been linked w ith  abnormal m elaton in  
secretion (W etterberg, 1978; B irau, 1981; Das Gupta et al, 1983),However to date^ 
most reports  are not consistent and are d if f ic u l t  to  in te rp re t. W erner et al, (1981) 
described a norm al noctu rna l rise o f serum m ela ton in  in fo r ty - f iv e  patien ts  w ith  
grow th  hormone and p ro la c tin  secreting adenomas w ith  no re la tionsh ip  between
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m ela ton in  and serum grow th  hormone or p ro la c tin . H ow ever, these authors noted 
an absence o f a noctu rna l m ela ton in  rise in pa tien ts  w ith  large p itu ita ry  tum ours 
and reduced or absent serum melatonin in six out of ten patients with Cushings 
disease (excess A CTH ). It has been proposed that melatonin secretion in man is 
independent of p ituitary abnormalities unless there is an accompanying disturbance 
o f the hypothalam us (Vaughan, 1984). Low to  absent levels of m ela ton in  have been 
reported in males with the frag ile-X  syndrome (O'Hare et al, 1986). It has been 
proposed tha t melatonin deficiency may be responsible fo r features o f 
hypergonadism associated with this disorder.
(e) Cancer
The effects of the pineal gland and m e la ton in  upon tum our grow th  have been 
reviewed by Lapin, (1979), Tapp, (1982) and Blask, (1984). Melatonin  
a dm in is tra tio n , no tab ly  in the la te  a fte rnoon, has in several cases dim inished the 
g row th  o f tum ours and th e ir  métastasés in anim al models, p a r tic u la r ly  those 
invo lv ing  m am m ary carcinogenesis. Bartsch et al, (1981) reported a trend  tow ards 
low  nocturnal m ela ton in  among breast cancer patien ts . This was con firm ed  by 
Tamarkin et al, (1982) but only in pa tien ts  w ith  estrogen recep to r pos itive  tum ours. 
Tapp, (1982) observed particularly large pineal glands in patients dying with 
carcinoma of the breast. Bojkowski, unpublished resu lts, (1988) has observed no 
difference in u rinary  aMT6s excretion in pa tien ts  w ith  breast cancer compared to 
contro ls .
(f) P ineal tum ours
M ela ton in  may be absent, normal, unusually high or arrhythm ic^ in patien ts  
w ith  pineal tum ours (for rev iew ; Vaughan, 1984). We have observed very low  to  
normal 24-hour plasma m ela ton in  in five  young untreated patien ts w ith  pinealom a 
who, fo llo w in g  rad io the rapy tre a tm e n t, displayed undetectable  or unchanged leve ls 
(Roberts, F raney, A rend t, unpublished resu lts). N euw elt and Lew y, (1983) reported
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in one patient a normal 24-hour rhythm of plasma melatonin which was abolished 
a fte r surgical removal of a pineal tumour which histologically was an astrocytoma 
with some pinealoblastoma cells. This publication provided good evidence for the 
pineal origin of human circulating melatonin. Classification of pineal tumour cell 
types in relation to melatonin secretion profiles may provide an explanation for the 
variety of secretory patterns observed in the small number of patients studied so 
fa r. Pinealomas have been diagnosed in a few young women presenting symptoms 
o f anorexia nervosa (G a rfin ke l and Garner, 1982).
(g) Anorexia nervosa
The influence of m ela ton in  upon rep roductive  hormones and its  possible 
re la tionsh ip  w ith  body w e igh t has prom pted investiga tions o f m ela ton in  in anorexia 
nervosa in view  of reported  abnormalities in LH  and p ro la c tin  rhythm s (G arfinke l 
and G arner, 1982). R eports o f 24-hour melatonin in anorexia nervosa are 
c o n flic tin g . G a rfin ke l and Garner, (1982) c ite d  an apparently unpublished repo rt by 
Brown and colleagues: five  em aciated subjects w ith  p rim a ry  anorexia nervosa a ll 
showed the expected noctu rna l rise in m ela ton in  whereas th ree  o f the subjects 
showed fla tte n e d  noctu rna l p ro la c tin  levels and a ll f iv e  displayed an im m atu re  
circadian LH  p a tte rn . C o n tro l subjects were not reported . A norm al function  of 
the pineal in anorexia nervosa was also suggested by Dalery and co-workers, (1985) 
and Baronowska and associates, (1986). In the e a rlie r o f the tw o  studies, e ight non- 
depressed patients displayed 24-hour plasma melatonin and plasma 
m e la to n in /co rtiso l ra tios  w ith in  a norm al range. The con tro l groups however, were 
unmatched men and women. Baronowska and colleagues studied e igh t women with 
anorexia nervosa and the resu lts  were compared w ith  those from  a con tro l group o f 
seven healthy women m atched fo r age and investiga ted  during the la te  fo llic u la r  
phase of the m enstrua l cycle. One anorectic women w ith  55% w eight loss 
dem onstrated an inve rted  m e la ton in  rhy thm , otherwise m ela ton in  secre tion  was 
norm al in the pa tien ts . Low  serum m ela ton in  in anorexia nervosa was observed by
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Birau et al, (1984) who studied ten women with anorexia nervosa in relapse and 
compared results with ten healthy, regularly cycling women within the same age 
range. The decrease in nocturnal melatonin was interpreted by the authors as 
evidence for hormonal im m aturity. Conversely in a recent study^ melatonin 
secretion was reported to be significantly enhanced in fourteen anorectic patients 
compared to a group of nine female controls sampled in the follicular phase 
(Ferrari et al., 1987). Melatonin secretion has not been investigated to date in 
healthy women o f low body w e ight.
(h) K leine-Levin Syndrome
Comparisons have been drawn between anorexia nervosa in which sleep 
du ra tion  and food in take  are decreased and the K le ine -L e v in  Syndrome, a relatively  
rare contrasting disorder o f periodic sleepiness and excessive appe tite  
predominantly occurring in adolescent males. We have reported persistence of 
normal m ela ton in  and cortisol rhythm s during a period of hypersomnia in one 
p a tie n t (Thompson e t al, 1985a) and norm al m e la ton in  but abnormal cortisol 
rhythms in the recovered s ta te . A no ther pa tien t displayed undetectable  plasma 
m e la ton in  on three sam pling occasions whereas the cortisol rhy thm  was normal 
(Palazidou, Franey; unpublished results). Although episodes o f hypersomnia are not 
accompanied by changes in the melatonin rhythm^it is possible that a disturbance 
o f b io log ica l rhythm s m ight predispose patients to  develop the syndrome.
(i) Schizophrenia
Investigations in to  the pineal and psychiatry have in general been centered 
around the a ffe c t iv e  disorders (Section 1.4.). However, suggestions o f possible 
p ineal invo lvem ent in schizophrenia (H orrob in , 1979) and find ings of low am plitude 
m e la ton in  in unspecified psychiatric patien ts (Sm ith e t al, 1979) and schizophrenic 
pa tien ts  (F e rr ie r et al, 1982) requ ire  fu r th e r investiga tion  for m eaningfu l analysis.
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1.4. MELATONIN AND AFFECTIVE DISORDERS
1.4.1. Introduction
Historically the pineal gland has been associated with brain function. Its 
location in the centre of the human brain has suggested a behavioural role to some 
authors. In the early 17th centur)/ Descartes proposed the pineal as both the seat 
of rational thought and the union of body and soul: from thereon physicians studied 
the pineal in the hope of find ing  a relationship w ith  m enta l disorder (review; M ullen 
and Silman, 1977).
Melatonin i ts e lf  has been proposed as an antidepressant (Papavasiliou et al, 
1972). The idea was based upon in itial reports showing increased levels of cerebral 
serotonin in response to  m ela ton in  administration in rats (A n ton-Tay et al, 1968). 
This group reported  euphoria in normal volunteers following m ela ton in  
administration (A n ton-Tay et al, 1971). However, when m ela ton in  was 
administered in large amounts, during the day to depressed patients .it apparently 
produced an exacerbation  o f the depressive symptom s (Carm an et al, 1976).
The developm ent o f RIAs fo r m e la ton in  (Section 1.6.1.) opened new areas o f 
investigation for neurobiologists and psychiatrists and the vast m a jo r ity  o f 
pathological studies have focused upon affective  disorders and antidepressant 
treatm ent (review; Grasby and Cowen, 1987a). Melatonin secretion may be seen 
as a marker providing information about adrenergic function, the endogenous 
c ircad ian  pacemaker and the effects o f lig h t in depressive illness.
1.4.2. A ffe c t iv e  disorders - a b r ie f descrip tion
A ffe c t iv e  d isorder is a te rm  defin ing  m enta l disorders, the cen tra l fea tu re  o f 
which is a change in mood. This includes d is tin c t pa tho log ica l states o f mood 
e la tion  in the case o f mania and mood low ering  in depression. R ecurrent bouts of 
illness are seen genera lly  interspersed w ith  com plete recovery (rev iew ; Hamilton, 
1979). Research on the biochemical changes associated w ith  mania and depression
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suggests th a t many o f them  cannot be regarded as secondary consequences o f the 
developm ent o f illness but are p rim a ry . This idea has been reinforced by reports of 
genetic factors in a ffective  disorder and by the success of chemical prophylactic 
treatm ents such as lithium in manic depressive illness.
The most important distinction between the d ifferent types of depression is 
that between unipolar depression and bipolar manic-depressive illness. Depression 
has been described a heterogeneous disorder (Hollister, 1986) and a number of 
methods of classification are available. Spitzer et al, (1978) developed the widely 
used Research Diagnostic C riteria  (RDC) based on the presence or absence of 
mania as well as the severity of depression. RDC were developed into the current 
classification of the Diagnostic and Statistical Manual (DSM -III) which is now used 
as the offic ia l system in the USA.
Response to treatm ent depends upon the type o f depression. L ith iu m  is more 
effective  in lengthening the in te rva l between a ttacks  and shortening the period of 
illness w ith  bipolar than with unipolar illness. W ith in  the group o f depressions, a 
number o f drugs are used with varying success in treatm ent. 'F irs t-g en e ra tio n ' 
antidepressants such as t r ic y c lic  antidepressants and monoamine oxidase inh ib ito rs  
are e ffective  in about 60-65% of depressed patients but have numerous side 
e ffe c ts . The newer 'second-generation' antidepressants have more to le rab le  side- 
effects and possibly a more rapid onset of action (Hollister, 1986).
The e ffe c ts  o f tricylic  antidepressants upon pineal gland and brain receptor 
func tion  are discussed in Section 1.5.
1.4.3. C ircad ian  rhythm s in depression
Ind iv idua ls w ith  mood disorders frequen tly  display temporal re g u la rity  in the 
onset of depressive or manic episodes, in the daily fluctuations of symptom 
seve rity  and in sleep disturbance. C ircad ian  phenomena such as rapid eye 
movement (REM) sleep, ccrtisol and prolactin secretion and body temperature 
rhythms have been reported to be altered during depression (Goodwin et al, 1982;
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Kripke, 1983; Wehr et ai, 1983). Moreover, some cases of recurrent a ffective  
disorder appear to follow menstrual, or seasonal rhythms. Depression appears to be 
commonest in spring and autumn (Eastwood and Peacocke, 1976) and mania has 
been reported to be most frequent in the summer (Symonds and Williams, 1976). 
Rosenthal and associates, (1984) have described an atypical form of depression that 
occurs regularly in the winter months (Section 1.4.) and more recentlv this group 
described the reverse syndrome with an opposite pattern, namely depressions in the 
summer and remission periods in the autum n/winter (Rosenthal et al, 1986). 
Biochemical factors that may be related to depressive illness (eg tryptophan, 5-HT) 
have been shown to vary s ig n ific a n tly  in depressed patien ts  according to  the season 
(Swade and Coppen, 1980), although this is also true of normal populations (W irz- 
Justice  e t al, 1977).
The ex ten t to  which circadian or seasonal symptom s occur in depression is 
unclear a lthough a variety of hypotheses of circadian rhythm dysfunction have been 
proposed (review; Healy, 1987). Halberg, (1968) postulated tha t c ircad ian  rhythms 
in manic-depressives were no longer synchronised with the environmental light- 
dark cyc le  but were 'free -runn ing '. Other investiga to rs  have proposed loss o f 
amplitude (Schulz and Lund, 1985), phase advance (Papousek, 1975; Goodwin et al, 
1982) and dysregulation (Siever and Davis, 1985). These hypotheses have a ll 
suggested that the organisation of rhythm icity is impaired in depression. 
Furthermore, Jauhar and W eller, (1982) demonstrated tha t the ex te rna l and 
internal desynchronising e ffe c ts  o f 'jet-lag ', fo llo w in g  f lig h ts  over several tim e  
zones, acted as a precipitant o f a ffe c tiv e  illness in predisposed individuals: east- 
west flights induced depression whereas west-east flight precipitated hypomania.
H
The m a jo rity  o f recent studies have been in favour o f a phase advance 
hypothesis (Wehr et al, 1980; Goodwin et al, 1982). This hypothesis m igh t explain 
period ic  fea tu res such as early  morning awakening and d iurnal va ria tion  of mood. 
I t  has been suggested however th a t depressed patien ts  may be subgrouped in to  
those with phase advance or those w ith  phase delay syndromes (K ripke , 1983; Lewy
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et al, 1985b). Lewy and co-w orkers, (1985b) have shown tha t b rig h t lig h t exposure 
in the morning advances c ircad ian  rhythms and th a t bright l ig h t exposure in the 
evening delays them. They have suggested that the circadian rhythms of patients 
with 'w inter depression' (Section 1.4.5.) are abnormally phase delayed and that 
depressive sym ptom s may be a lle v ia te d  by m orning light treatm ent (Lewy et al, 
1987).
I t  has been speculated by some authors th a t antidepressant drug tre a tm e n ts  
v/ork by correcting the circadian rhythm disruption (Section 1.5.3.).
The im portance  o f considering c ircad ian  rhythm s in depression is h igh ligh ted  
by consistent reports  o f abnormalities in the 24-hour patte rns o f hormone secre tion  
where none had been apparent on sampling at single t im e  points only (Healy, 1987). 
M e la ton in  has been o f p a rtic u la r in te re s t as a chronobiological m arker o f a ffe c tiv e  
illness (Section 1.4.4.). In th is  respect j  the m ela ton in  rhy thm  may provide 
in fo rm a tio n  about both changes in am plitude  and phase sh ifts  in depression.
1.4.4. M e la ton in  in depressive disorders
An early  study by Jim erson and co-workers, (1977) described u rinary 
melatonin levels (using a tadpole bioassay) in six patients with primary affective  
d isorder and in six contro ls . They were unable to  dem onstrate a d iffe rence  
between the tw o groups. L a te r, W irz -Jus tice  and A rend t, (1979) reported  low early 
m orning m e la ton in  leve ls (using single tim e  po in t sampling) in unipo lar depressives. 
W etterbe rg  and colleagues, (1979; 1984) proposed a lin k  between reduced m ela ton in  
secretion and raised night-time co rtiso l levels, measured in depressed patien ts. 
M endlew icz e t al, (1979) also found low ered am plitude  o f the nocturna l rise in 
m e la ton in  in three out o f four pa tien ts  and again a fte r recovery. However, the 
high daytim e  leve ls measured in th is  study raise doubts about the specificity o f 
m easurem ent. Branchey et al, (1982) reported  tha t in three patien ts^ co rtiso l 
became norm al a fte r  recovery from  depression, w h ils t m ela ton in  rem ained low .
The use o f m e la ton in  as a t r a i t  m arker and the in te ra c tio n  between m ela ton in
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and cortisol secretion have been discussed extensively by Wetterberg's group 
(W etterberg et al, 1982; Wetterberg et al, 1984; Beck-Friis et al, 1985a; 1985b). A 
series of studies by this group have described lower night-tim e serum melatonin in 
depressed patients who were non-suppressors to dexamethasone as compared to 
controls or to depressives with a normal cortisol response to dexamethasone. 
Similar results were reported by Claustrat et al (1984^who found low amplitude of 
nocturnal melatonin in combination with hypercortisolaemia in depressed patients. 
Low m e la ton in  was maintained in both acute depressive patien ts  during rem ission 
and in chronic bipolar and unipolar patients during their euthymie phase 
(W etterberg et al, 1984). These authors also related the 'low melatonin syndrome' 
to patients w ith  a fam ily history of a ffe c t iv e  disorder, thereby suggesting that low 
melatonin may be a tra it marker for depression. Brown et al (1985a; 1985b^have 
also found reduced concentrations of melatonin in severely depressed patients; 
however^ these researchers found no association between m ela ton in  and cortisol in
these patients. 6 -Sulphatoxymelatonin was measured (using GC-MSy in the urine of 
e ight melancholic patien ts  (Boyce, 1985). Although three patien ts  did not show 
nocturnal e leva tion  o f the metabolite^ there was no relationship between the 
patients response to dexamethasone and the aM T6s measured. A trend towards a 
phase advance of melatonin in patients showing hypercortisolaemia (W etterberg et 
al, 1984) was not observed by Claustrat and colleagues (1984).
Lewy et al (1979)^ in a group of four rapid cycling bipolar depressed patients 
and fou r unmatched normal controls^found raised m ela ton in  secretion during mania 
compared with the depressed phase in patients, and compared to the normal group. 
Lewy, (1983b) and Nair et al, (1984) have reported that melatonin secretion is 
phase advanced in depression. This result tends to support the theory th a t some 
depressions are accompanied by a phase advance of the circadian system. In 
contrast. Van Cauter and colleagues (1985)^ showed a clear phase delay in the 
tim in g  o f the noctu rna l acrophase in thirteen out o f sixteen untreated patien ts  
compared to e igh t age m atched controls. It should be noted tha t these la tte r
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studies were performed a fte r four days of habituation to an a rtific ia l 16:8 light- 
dark cycle,
D ie tze l et al, (1986a) classified a group of depressed patients according to 
the season of sampling and found high summer and low winter values (opposite to 
their control group) with no evidence of a 'low melatonin syndrome'. Jarre tt et al, 
(1985) examined the pattern of nocturnal melatonin secretion in a group of 16 
depressed women and found no difference in values compared with data from eight 
hea lthy women studied under identical conditions.
I t  is c lear that no real consensus exists concerning the production of 
m e la ton in  in depression. Further investigation . under c a re fu lly  controlled 
conditionals required.
1.4.5. Seasonal affective disorder, the pineal gland and lig h t tre a tm e n t
The importance of the pineal gland in modulating seasonal rhythms in animals 
led to speculation tha t i t  may have a ro le  in the regu la tion  o f the marked seasonal 
changes in mood, sleep, appetite and w e ight seen in patien ts  w ith  seasonal 
affective disorder (SAD). The d isorder is characterised (Rosenthal e t al, 1984) by 
recurring cycles of autumn-winter depression predom inantly  in women who report 
amongst the typical symptom s of depression, atypical carbohydra te  craving, 
hypersomnia and weight gain.
The connection w ith  the pineal was strengthened by the find ing  o f Lew y et al, 
(1980) that bright full spectrum light is required to suppress human melatonin 
secre tion . This group successfully tre a te d  a patient w ith  regu la rly  occurring 
w in te r depressions by extending the photoperiod w ith  six hours o f bright light 
(Lewy et al, 1982). Several controlled studies followed, based on the theory tha t 
the e ff ic a c y  o f phototherapy depended on its  m o d ifica tio n  o f m e la ton in  secretion 
and/or on its  a b ility  to  correct abnorm ally tim ed  circadian rhythm s. Rosenthal's 
group found, in a series o f experiments, th a t extending the short w in te r 
photoperiod m orning and evening by 5-6 hours w ith  b rig h t light (>2500 lux.
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V ita lig h t, D u ro -te s t C orpora tion ) induced rem ission in tw enty-seven out o f th ir ty -  
one pa tien ts  w ith in  2-4 days. Relapse occurred 2-4 days a fte r  w ith d raw l 
(Rosenthal et al, 1984; 1985; 1986). Light of ordinary domestic intensity (dim light) 
had lit t le  or no e ffec t. Other groups also confirmed that phototherapy was an 
effective  treatm ent for SAD (Lewy et al, 1985b; W irz-Justice et al, 1986a; 
Hellekson et al, 1986). There was unfortunately lit t le  published data on the 
melatonin secretion profiles of SAD patients. Mean early evening melatonin levels 
in four SAD patients appeared to be higher than two control subjects. (Rosenthal 
et al, 1986) although interindividual variation in such small samples was extremely 
large.
The superiority of bright light over dim light was compatible with the 
melatonin hypothesis th a t d im  lig h t does not suppress m ela ton in  and would be 
ineffective. However, W irz-Jus tice  and colleagues (1986a)^found bright and dim  
lig h t to be equally effective  antidepressants .with remission las ting  longer a fter 
b rig h t lig h t treatm ent. Moreover, the most effective tim es for l ig h t tre a tm e n t 
were suggested to be early morning (Lewy et al, 1982; 1987) evening (James et al, 
1985) or at any tim e  during the day (Hellekson et al, 1986). F u rthe r studies showed 
the e ff ic a c y  o f lig h t treatm ent to be duration dependent (Term an et al, 1986; W irz- 
Justice et al, 1986b) rather than photoperiod dependent (Checkley et al, 1986a; 
Thompson et al, 1986). Following these reports the role of melatonin in SAD was 
questioned. Wehr et al, (1986) demonstrated tha t b rig h t lig h t applied as a summer 
or as a w in te r photoperiod was equally effective w ith  no measurable e ffe c ts  o f 
treatm ent upon melatonin secretion (in three subjects). Checkley e t al (1986a) 
showed that long duration of light rather than the applied photoperiod was 
im p o rta n t fo r an antidepressant e ffe c t o f lig h t and th a t there was no relationship 
between c lin ic a l response and changes in m ela ton in  secre tion .
Rosenthal et al, (1987) investiga ted  the role of m e la ton in  in several ways. 
They administered m elaton in  to pa tien ts  in an a tte m p t to  antagonise the e ffe c ts  o f 
lig h t tre a tm e n t and gave a tenolo l (Rosenthal et al, 1988) to  suppress m ela ton in  and
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mimic the antidepressant e ffec t of phototherapy. There was no significant e ffec t 
of these treatm ents. C learly the mechanism of action of phototherapy requires 
more investigation. Rosenthal (1986)yhas shown that the antidepressant effects of 
light are mediated via the eye, not the skin, and may have direct effects upon the 
neuroendocrine/immune system. It  is unlikely that phototherapy treatm ent is due 
to a placebo e ffec t since patients who have responded to bright light treatm ent 
only, expected dim red control lights to be the active treatm ent (Kripke et al, 
1983; Checkley et al, 1986a).
Several investigators have described successful bright light treatments of 
patients with non-seasonal major depression (Kripke et al, 1983; D ie tze l et al, 
1986b). W irz-Justice and colleagues (1986a) have suggested that even normal 
individuals may benefit from phototherapy. However, Yerevanian et al (1986)^ 
found that bright l ig h t tre a tm e n t was significantly effective amongst SAD pa tien ts  
only, compared to nonseasonal depressives matched for age and sex. F urthe rm ore , 
Broadway and colleagues (1987)^found no mood change in norm al subjects following 
phototherapy.
I t  is possible tha t visual sensitivity is im pa ired  or enhanced in d iffe re n t 
p a tien t subgroups. Lewy et al, (1981) observed th a t noctu rna l m elaton in  in manic- 
depressive patien ts  was suppressed by a low er intensity l ig h t than normals. 
F u rthe rm ore  th is  research group has shown th a t b rig h t lig h t exposure in the 
m orning advances c ircad ian  rhythms and that b rig h t lig h t exposure in the evening 
delays them  (Lewy e t al, 1985b). They hypothesised th a t the c ircad ian rhythm s o f 
most pa tien ts  w ith  winter depression are abnorm ally phase-delayed and they have 
reported a superior response to m orning lig h t tre a tm e n t only (Lewy et al, 1987). In 
this study the tim e  o f plasma m e la ton in  onset in SAD pa tien ts  pretreatm ent was 
s ig n ific a n tly  delayed compared to con tro ls . Lew y and co-w orkers, (1985b) have 
fu rth e r hypothesised th a t non-seasonal depressives are phase-advanced and would 
b ene fit fro m  evening lig h t tre a tm e n t.
A carefully co n tro lle d  study of m ela ton in  secre tion  in larger numbers of SAD
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pa tien ts  would be o f in te res t, but i t  appears at present that the pineal gland does 
not play a m ajor ro le  in the mechanism o f tre a tm e n t for SAD.
1.5. ANTIDEPRESSANT DRUG TREATMENT: THE PINEAL GLAND
A MODEL FOR ADR EN ER G IC  FU N C TIO N
1.5.1. In trod u c tion
T ric y c lic  antidepressant drugs (TCAs) in h ib it serotonin and noradrenaline
eg
uptake in nerve terminals (^ersen and Mackay, 1979) and until recently it was 
assumed that antidepressant drugs act by enhancing neurotransmission at 
monoaminergic synapses (Schildkraut, 1965; Bunney and Davis, 1965). However, 
this e ffe c t on monoamines occurs w ith in  m inutes or hours a fte r  acute 
administration o f TCAs and does not expla in  the observation that days or weeks o f 
continuous antidepressant therapy are normally required before c lin ic a l 
im provem ents are observed. It has been shown th a t chronic adm in is tra tion  (1-3 
weeks) to  ra ts  o f many d iffe re n t trea tm en ts  including TCAs and monoamine 
oxidase inhibitors produces a reduction in the number o f postsynaptic 3-adrenergic 
receptors in fo reb ra in  regions (Banerjee e t al, 1977; S e llinger-B arne tte  et al, 1980). 
This find ing  o f a common mechanism of action  led to the hypothesis that the 
therapeutic e ffe c ts  o f antidepressant tre a tm e n t m ight be due to a s low ly occurring 
reduction in neurotransmission through 3-adrenergic synapses (Sulser e t al, 1978; 
Sulser, 1979; Charney et al, 1981).
The TC A  desm ethy lim ipram ine  (DMI) is a relatively se lective  inhibitor of 
noradrenaline uptake. The most deta iled  studies o f antidepressant action  in 
experimental anim als and in depressed patien ts  have been conducted using chronic 
DM I tre a tm e n t. However i t  is s t i l l  not c lea r w hether the net e ffe c t o f chronic DMI 
a dm in is tra tio n  is to increase or decrease noradrenergic neurotransm ission. 
Moreover no c lin ic a l measure o f the responsiveness o f cen tra l 3-adrenoceptors is 
ava ilab le . The pineal gland provides a convenient model to assess the e ffe c t o f
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chron ic  antidepressant treatm ent upon noradrenerg ic transm ission (Checkley e t al, 
1986b; Lew y, 1984). M e la ton in  secre tion  in the ra t is dependent upon p re - 
junctional a^-adrenergic receptors and postsynaptic and a ,-adrenergic
receptors (Section 1.2.). Measurement of melatonin secretion following activation  
of the noradrenaline-dependent pinealocyte adenylate cyclase system provides a 
marker of pineal adrenergic activ ity  in humans and other species and an assessment 
of the net effect o f D M I-induced receptor changes upon th is  system.
1.5.2. A ctions o f DMI upon ce n tra l adrenergic receptors
It is widely known that antidepressants especially TCAs act upon a variety of 
receptors. This has been shown by behavioural, electrophysiological and more 
re ce n tly  radioligand binding studies (rev iew ; Snyder and Peroutka, 1984). DMI has 
fewer sedative and anti-cholinergic actions than most other TCAs and although 
DM I is considered a re la tiv e ly  sp ec ific  noradrenaline uptake inhibitor i t  is possible 
th a t a t the rapeu tic  concentrations^ i t  inh ib its  5-HT uptake in normal volunteers 
(Cowen et al, 1986). The most consistent observations fo llow ing  long te rm  DMI 
tre a tm e n t have been changes in central adrenergic receptors,' these are b r ie fly  
rev iew ed here and summarised in F ig . 1.8.
1.5.2.1. E ffe c ts  o f DMI upon 3-adrenerqic receptors
(a) R eceptor number
N oradrenaline reuptake in h ib itio n  by DM I m igh t be expected to down regulate 
3-adrenoceptors since i t  is w e ll known tha t chron ic tre a tm e n t in ra ts w ith  d ire c tly  
ac ting  3-agonists reduces the binding o f rad io labe lled  3-adrenergic antagonists 
(Wang and U 'P richard , 1980).
Banerjee and co-workers, (1977) published the f ir s t  repo rt o f the development
S u b
o f 3-adrenerg ic recep to r .sens itiv ity  in ra ts fo llo w in g  da ily  injections o f DMI
r 3 1
(10 m g/kg, i.p ., fo r  6 weeks). S pecific  binding of the rad io ligand Hi -
d ihydroa lp reno lo l (D H A) to  bra in microsomal fra c tion s  was s ig n ific a n tly  reduced
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Fig. 1.8 Sites of action of DM I at the noradrenergic synapse
1.
2.
3.
4.
5.
6.
7.
Binding to SCN
Reduced cyclic AMP responsiveness (chronic treatm ent) 
Blockade of postsynaptic a.-adrenoceptors  
Increase in sensitivity? (chronic treatm ent)
Decrease in postsynaptic 8-adrenoceptor density 
(chronic treatm ent)
Inhibition of noradrenaline uptake
Decrease in presynaptic a 2-8drenoceptor responsiveness 
(chronic treatm ent)
Blockade of presynaptic histamine and muscarinic receptors,
functional significance not knov/n 
Inhibition of 5-H T uptake?
NE, noradrenaline: H2, histamine-2; M, muscarinic
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following DMI treatm ent although the dissociation constant (K ^ ) was unaltered. 
Results from this study are shown in Table 1.2. Sara! and colleagues, (1978) 
demonstrated that a single injection of DM I (10 mg/kg, i.p.) did not produce a 
change in 8-adrenoreceptor number, although as few as two injections of DMI 
resulted in a significant decrease in 8-receptor binding with maximum reduction in 
binding of about 35% ^occurring a fte r five injections. Using the radioligand
1 25
I_ -iodohydroxybenzylpindolol, (IH YP) to label 8-adrenergic receptors, Wolfe
and colleagues, (1978) also reported a 35 to 40% decrease in the density of 8-
adrenoceptors in the rat cerebral cortex following chronic DM I treatm ent
(10 mg/kg, i.p., b.i.d.). This effect was maximal a fte r  five to seven days of
treatm ent and persisted for twenty-one days. When DMI administration was
I 125
discontinued, the amount of _ I .  -IH YP  binding recovered to normal levels 
within a week.
Burki and co-workers, (1981) also showed a significant reduction in 8- 
adrenoceptor density a fte r daily DMI injections (6 mg/kg, i.p., 6 days). A summary 
o f the results o f Scatchard analyses perfo rm ed by these authors is presented in 
Table 1.2.
Cortical 8-adrenergic receptors (compared to sub-cortical areas) appear to 
be most sensitive to these antidepressant effects (Bergstrom and Kellar, 1979).
3 1Three groups have concluded that the observed reduction in _ HJ -DH A binding 
produced by chronic DMI administration was not related to the physical presence of 
the drug (Sarai et al, 1978; Wolfe et al, 1978; Bergstrom and K ellar, 1979). 
M inneman e t al, (1979) demonstrated th a t chronic DMI treatm ent significantly
reduced the number o f 8^-receptors but not the 82-recep to rs in the rat cerebral 
cortex.
S cott and Crews, (1983) reported  tha t blockade of a 2-adrenerg ic receptors
w ith  phenoxybenzamine (3.75 m g/kg, i.p., b.i.d.) in com bination with DMI (3.75
! 3
mg/kg, i.p., b.i.d .) accelerated the decrease in  ^ H j -DHA binding whereas 
combined administration o f DMI and the a , -antagonist prazosin had no e ffe c t on
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-D H A  binding. The authors com m ented tha t antagonism of presynaptic  
inhibition of noradrenaline release by phenoxybenzamine, further increased 
synaptic noradrenaline levels with an accompanying potentiation of 8-adrenergic 
receptor down-regulation.
To date all clinically e ffective  antidepressant drugs and electroconvulsive
5hcx:l<5
therapy share the ability to decrease the number of cortical 8-adrenergic 
recepto rs. The effec t of antidepressant drugs upon c ircad ian  rhythm s in 8- 
receptor numbers is described in Section 1.5.3.
(b) Noradrenergic cyclic AMP generating system
Wolfe and co-workers (Wolfe et al, 1978) reported that the decreased density 
o f 8-adrenergic receptors fo llow ing  chronic DM I treatm ent was correlated w ith  the 
decreased a b ility  o f noradrenaline to  s tim u la te  cyclic AM P production . Treatm ent 
with D M I (10 mg/kg i.p.) for 7 to 21 days resulted in a 35-40% decrease in the 
cyclic AMP response to isoprenaline in rat cortical slices. This loss of 
responsiveness was accompanied by a 35 to  40% decrease in the number o f 8- 
adrenerg ic recepto rs. The ra t lim b ic  forebrain has also been used as a fun c tio na l 
model o f chron ic DM I action w ith  the same resu lts  (Vetu lan i et al, 1976). However 
basal cyclic AMP levels (unstimulated) remained unchanged in brain tissue 
fo llo w in g  repeated DM I tre a tm e n t. W olfe and co-workers, (1978) found tha t the 
antidepressant-induced reduction  in rat brain 8-adrenoceptor responsiveness, was 
not evident in heart tissue, suggesting tissue s p e c ific ity  for the adrenergic e ffe c ts  
o f antidepressant drugs.
1.5.2.2. E ffe c ts  o f DM I upon q p-adrenerq ic receptors
(a) A n im a l studies
3The effec t o f chronic DM I a dm in is tra tion  upon the binding of H -
parf ioL
clonidine - a highly selective ot2l 89onist, to rat brain presynaptic ct2-adrenoceptors
has produced some conflicting resu lts. However, using b iochem ica l and
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physio log ica l methods, th ree  weeks o f DM I tre a tm e n t in experim en ta l anim als has 
resu lted  in a c lea r reduction  in the status o f central a ^-re ce p to rs  (Crews and 
Smith, 1978; Sugrue, 1982). The observations that long term  treatm ent was 
required for these effect^ im plies  that ci2"^'^^Gnergic receptors are relevant to the 
mechanism of action of DMI.
One of the effects of clonidine is release of growth hormone (OH) and this 
effec t is thought to depend upon the stimulation of centrai ct2-3drenoceptors, 
(mainly postsynaptic). In experimental animals^ chronic treatm ent with DMI 
inhibits the GH response to clonidine (Van Spanning and Van Zwieten, 1973). This 
endocrine test has provided a suitable tool fo r  studies in humans (review; Siever et 
al, 1987).
(b) C linical studies
A num ber o f investigations by Checkley and associates have shown that acute 
DMI tre a tm e n t (1 week) to norm al volunteers and to depressed patients^ enhanced 
the GH response to  c lon id ine  whereas th ree  weeks o f tre a tm e n t a ttenua ted  the 
response in both groups of subjects (Checkley et al, 1986b; Glass et al, 1982; Corn 
et al, 1984). Patient groups displayed a lower than normal response to clonidine 
before tre a tm e n t, suggesting th a t ag-ad renerg ic  recep to r func tion  is a lte red  in 
depression but responds norm a lly  during TCA treatm ent. The in it ia l increase 
observed afte r acute DMI tre a tm e n t was in te rp re te d  as an e ffe c t o f noradrenaline 
uptake blockade and the secondary decrease was suggested to  be due to adaptive 
dow n-regu la tion  o f a 2-adrenoceptors (Corn et ai, 1984). These findings are 
com parable to  anim al studies showing increased noradrenaline turnover w ith  long 
te rm  DM I tre a tm e n t and decreased tu rnove r w ith  acute adm in is tra tion  (Charney et 
al, 1981).
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1.5.2.3. E ffe c ts  o f DMI upon a . -adrenergic recepto rs
(a) Animal studies
TCAs themselves bind to ra t brain a .-receptors  (U'Prichard et al, 1978) and 
therefore interfere with ligand binding methods. However, DM I has been shown to 
bind w ith  low  a f f in ity  to  a,-receptors  (U 'P richard  et al, 1978), being one o f the 
least sedating TCAs, and therefore causes less interference. H j-W B4101 and
3 !
H -prazosin have been used to selectively label a .-adrenerg ic  receptors.
Peroutka and Snyder, (1980) reported no significant e # c t  upon a .-adrenergic
re ce p to r binding in ra t ce rebra l co rtex  following th ree  weeks of DM I (10 m g/kg 
i.p .) tre a tm e n t. This find ing  was replicated by Mogilnicka et al, (1987) who showed 
a decrease in the density o f 8-adrenergic receptors a fte r  ch ron ic DMI tre a tm e n t
3 1
which was not accompanied by changes in the density o f binding sites fo r  _ H i - 
prazosin. However this group did observe enhanced a .-rec e p to r m ediated 
behaviour, fo llo w in g  administration o f the a.-agonist phenylephrine, in animals 
receiving long te rm  DM I tre a tm e n t.
(b) C lin ic a l studies
A num ber o f behavioural and physio log ica l anim al studies have ind ica ted  a , - 
supersensitivity a fte r chronic DMI treatment^ but at present^there is no clinical 
measure o f the responsiveness o f ce n tra l a.-adrenergic receptors in humans. Shur 
and Checkley, (1982) have used the human pupil as a periphera l model fo r these 
investiga tions. In man, phenylephrine produces a dose-related d ila tio n  o f the pup il: 
a.-adrenerg ic  receptors m ediate dilation whereas muscarinic receptors m ediate  
constriction o f the pupil. These authors have shown tha t one and th ree  weeks of 
DM I tre a tm e n t reduced the responsiveness o f the human pup il to phenylephrine in 
both pa tien ts  and co n tro l subjects (Shur and Checkley, 1982; Thompson et al, 
1985b). Furthermore^ DMI i ts e lf  increased pupil d iam ete r probably due to its  
a f f in ity  fo r  a.-receptors . These studies however produced no evidence fo r 
supe rsens itiv ity  o f a.-adrenergic recepto rs and the authors have cautioned tha t
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this peripheral model may not be indicative of central a .-rec e p to r responsiveness.
1.5.3. Antidepressant tre a tm e n t and receptor rhythm s
The assumption that the observed changes in receptor numbers following 
ch ron ic  antidepressant tre a tm e n t m igh t account fo r the la tency in clinical onset o f 
antidepressant action has been questioned (H ealy, 1987). In it ia l dem onstra tions o f 
d iu rna l changes in p ineal adrenoceptor func tion  (A xe lrod , 1974) were followed by 
studies showing th a t the process o f desensitisation o f hypersensitive  receptors is a 
relatively  rapid event taking 12-24 hours (Schwartz et al, 1979). Campbell and 
colleagues, (1985) have further suggested that CNS neurotransmitter receptors 
show c ircad ian  rhythm s and tha t ch ron ic tre a tm e n t w ith  antidepressant drugs 
changes the tem pora l ch a rac te ris tics  (wave form, am plitude and phase) o f these 
receptor rhythm s in experim en ta l anim als (W irz -Jus tice  and C am pbell, 1982).
Rhythm s in a . - and 8-adrenergic, cholinergic, dopam inergic and opiate  
receptors were phase delayed fo llo w in g  chron ic  imipramine a dm in is tra tio n  in the 
ra t. fu rthe rm o re  the free  running period o f the rest a c t iv ity  cycle  was lengthened 
(W irz -Jus tice  e t al, 1980a; 1980b).
Wirz-Justice and co-workers, (1983) have reported  binding o f antidepressant 
drugs to the circadian clock (SCN) and when TCAs were applied chronically to the 
SCN, circadian tim e  keeping was a lte red  in labo ra to ry  anim als (Groos and Mason, 
1982). It has been proposed th a t antidepressant drugs act by lengthening (delaying) 
c ircad ian  rhythm s (W irz -Jus tice  e t al, 1980b). This supports the hypothesis o f a 
phase advance in some rhythm s in depression (Goodwin e t al, 1982).
1.5.4. E ffe c ts  o f ch ron ic  TCA adm in is tra tio n  on m e la ton in
and pineal gland func tion
The e ffe c ts  o f acute antidepressant drug a dm in is tra tion  upon ra t p ineal 
indole leve ls and human m e la ton in  leve ls are reviewed in Sections 1.2.5. and
1.3.2.2. respec tive ly . The long-term e ffe c ts  on pineal func tion  o f o ther
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antidepressant drugs such as lith iu m  and monoamine oxidase inh ib ito rs  have been 
reviewed by Murphy et al, (1986) and Seggie et al, (1987) and will not be included 
here.
1.5.4.1. TCAs and ra t p ineal func tion
(a) Effects of TCAs upon the pineal 8-adrenoceptor/adenylate 
cyclase system
The lo n g -te rm  adm in is tra tio n  o f antidepressants has been shown to reduce 
the number of 8-adrenoceptor binding sites in rat brain tissue (Section 1.5.3.). 
Researchers have used -D H A  binding methods to measure pineal 8-
adrenoceptor density following chronic DMI treatm ent and a summary of results is 
given in Table 1.3.
Reduced pineal 8-adrenoceptor numbers following repeated da ily  DM I 
injections to rats was in itially  demonstrated by Moyer et al, (1979). This group 
showed tha t acute administration o f DM I had no e ffe c t upon 8-adrenoceptor 
density. The ro le  o f DMI in blockade o f presynaptic noradrenaline uptake was 
illu s tra te d  by Moyer and colleagues, (1981) since its  e ffe c ts  were prevented in 
anim als whose pineal glands had been denervated by superior ce rv ica l 
ganglionectom y. Heydorn and co-workers, (1982) also showed tha t repeated DM I
administration reduced _ ^H J -D H A  binding to pineals 3 hours and 24 hours but not 
48 or more hours a fte r  the f in a l DMI in je c tion . The reduction  was o f s im ila r 
m agnitude w hether animals (housed in env ironm enta l chambers, reversed lighting) 
were killed a fte r 6 hours of light or after 6 hours of dark. Cowen et al, (1983b) in
r 3 1
con tras t found th a t daytim e  pineal [ HJ -D H A  binding although showing a trend 
tow ards a D M I-induced reduction , was not s ig n ific a n tly  d if fe re n t between control 
and DM I (10 mg/kg; 10 days) tre a te d  animals.
I t  is apparent from  the re p o rt o f Skene, (1985) th a t TCAs w ith  higher 
s e le c tiv ity  fo r blockade o f noradrenaline uptake, as compared to  seroton in  (see 
Table 1.4.) have a g rea te r potency to  dow n-regula te  8-adrenoceptors. C hronic DMI
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Co.)
S Y N A P TO S O M A L  
U P T A K E  I N H I B I T I O N
( u M )
D M I 0 . 0 0 1 5
P r o t r i p t y l i n e 0 . 0 0 3
N o r t r i p t y l i n e 0 . 0 1 1
I m i p r a m i n e 0 . 0 2
A m i t r i p t y l i n e 0 . 0 2
C h l o r I m i p r a m i n e 0 . 0 4 4
T r i m i p r a m i n e 1 . 0
B u t r i p t y l i n e 1 .  7
(b)
SY NA PTO SO M A L  
U P T A K E  I N H I B I T I O N
I C ^  ( p M )
C h l o r i m i p r a m i n e 0 . 0 1 5
A m i t r i p t y l i n e -
I m i p r a m i n e 0 .  2C,
N o r t r i p t y l i n e 0 . 4 2
P r o t r i p t y l i n e 1 . 6 2
D M I 2 . 0
T r i m i p r a m i n e 8.2
B u t r i p t y l i n e 1 0 . 0
R e f e r e n c e R a n d r u p  a n d  
B r a e s t r u p ,  1 9 7 7 .
I C j o , d r u g  c o n c e n t r a t i o n  r e q u i r e d  t o  p r o d u c e  50%  
i n h i b i t i o n  o f  n o r a d r e n a l i n e  r e u p t a k e .
Table 1.4 R e la tive  potencies o f the TCAs as inh ib ito rs  o f (a) noradrenaline 
uptake (b) serotonin uptake.
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was c le a rly  m ore po ten t than o the r TCAs tested^ in producing a reduction in p ineal 
6 -adrenoceptor density.
In the work of Moyer et al, (1979; 1981), repeated but not acute 
administration of DMT reduced the ability of isoprenaline and noradrenaline
adm in is tra tio n  e ith e r in v itro  or in vivo^ to  e levate  concentra tions o f adenylate 
cyclase and cyclic AMP. However, basal (unstimulated) levels of adenylate 
cyclase, c y c lic  AMP and c y c lic  AMP phosphodiesterase were not a lte red  by chronic 
DM I administration. Skene, (1985) showed that the reduction in cyclic AMP
responsivesness to  in vivo or in v itro  isoprenaline was induced by chronic DMI 
tre a tm e n t only and not by o the r TCAs tested.
M oyer and co-workers, (1986) have re ce n tly  reported  tha t both acute and 
repeated DMI tre a tm e n t produced decreases in c y c lic  AMP responsiveness w hich 
were not correlated e ith e r temporally or q u a n tita tiv e ly  w ith  a lte ra tions  in 6- 
adrenoceptors. These authors suggested th a t antidepressant-induced increases in 
noradrenerg ic s e n s itiv ity  may be regula ted at m u ltip le  sites. In th is  study^Moyer et 
al, (1986) showed th a t both acute (a fte r 24 hours) and chronic (5 days) DMI 
tre a tm e n t produced a reduction  in ra t pineal cyc lic  AMP-dependent pro te in  kinase 
a c t iv ity .  I t  was proposed th a t a negative feedback system may operate w ith in  24 
hours to reduce the concen tra tion  o f th is enzyme in response to the higher 
intrasynaptic leve ls o f noradrenaline fo llow ing  DMI administration.
(b) TCA effects upon pineal SNAT and indole levels
Studies o f the e ffe c ts  o f chron ic TCA adm in is tra tion  upon rat pineal indole 
leve ls (p a rtic u la r ly  m e la ton in ) have produced c o n flic tin g  results. A summary o f 
these resu lts is presented in Table 1.5.
W irz-Justice  and co-workers, (1980c) found tha t chronic a dm in is tra tion  o f the 
TC A ch lo rim ip ram ine  caused a s ig n ifica n t reduction  o f elevated pineal m e la ton in  
following an acute in je c tio n  o f ch lo rim ip ram ine  2 hours prior to  sa c rifice . C hronic 
DMI tre a tm e n t was also shown to reduce ra t pineal and serum elevated m elaton in
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levels during the dark phase but not during the light phase (Heydorn et al, 1982). 
These authors reported a 50% reduction in isoprenaline stimulated melatonin levels
in vivo fo llow ing  repeated DM I in jec tions. In agreem ent w ith  the find ings o f 
Heydorn and colleagues, (1982), Cowen et al, (1983b) showed that repeated DM I 
administration reduced the isoprenaline-induced increase in pineal melatonin 
content. However in constrast to the previous study, these authors found no 
significant e ffect of DM I upon the usual nocturnal rise in pineal melatonin. Cowen 
and co-workers, (1983b) suggested that down-regulation of 8-adrenoceptors may be 
an adaptive response to  m a in ta in  normal pineal function. C hronic imipramine 
treatm ent was later shown to induce significant decreases in both the dark phase 
m e la ton in  and the N-acetylserotonin content o f rat pineals compared to controls 
(Friedman et al, 1984). The findings of Burns and Brown, (1984) supported the 
hypothesis o f Cowen's group (Cowen et ai, 1983b), since their study dem onstrated 
no effec t o f chronic DMI tre a tm e n t upon the night-tim e rise in p ineal and serum 
m e la ton in  levels. Furthermore, although pineal N -ace ty lse ro ton in  was s ig n ifica n tly  
low ered a fte r  2 weeks o f DM I, 3 weeks o f tre a tm e n t had no e ffe c t. These findings 
ind ica ted  tha t the e ffe c t o f repeated DMI in jections upon pineal func tion  may be 
trans ien t and th e re fo re  investiga tions should exam ine antidepressant e ffe c ts  over 
much longer periods o f tim e .
Only one group has assessed the effects of chron ic DM I upon ra t p ineal SNAT 
activ ity . Bronstein and colleagues, (1984) found that following incubation with
isoprenaline, pineal SNAT a c tiv ity  was s ig n ifica n tly  low er in ra ts rece iv ing  
repeated DM I injections compared to those receiving saline. Basal p ineal SNAT 
a c t iv ity  (in the absence of isoprenaline) was however shown to  be higher in animals 
trea ted  w ith  DMI, most probably due to high daytim e levels o f DM I-induced 
synaptic  noradrenaline.
The e ffe c t o f repeated DM I in jec tions in vivo upon unstim ula ted  in v itro  
r 3 1
metabolism o f [ H j  -serotonin by rat pineal organ cu ltures has produced results in
m arked con tras t to  previous studies (P illay  and P o tg ie te r, 1984; Skene, 1985). A
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num ber o f TCAs were tested for 20 day periods and a il antidepressant treatm ents  
increased the levels of N-acetylserotonin and melatonin secreted over 24 hours into 
culture medium, compared to controls. Chlorimipramine, a selective serotonin 
uptake inhibitor was the least e ffective  and DM I was the most e ffective  in 
producing the observed increase. 5-Hydroxytryptophol and 5-hydroxyindole acetic 
acid were also increased with corresponding decreases in 5-methoxytrytophol and 
5 -m ethoxy indo le  ace tic  acid concentrations. Subsensitiv ity  o f the 6- 
adrenoceptor/adenylate cyclase system clearly did not result in reduced 
noradrenerg ic activ ity  but was associated w ith  s ig n ific a n tly  increased 
noradrenerg ic function.
The effec t of long term DM I treatm ent and associated 6-adrenoceptor
subsens itiv ity  upon m ela ton in  production  and secre tion  in the ra t pineal gland is 
unclear. Differences in dose, dura tion  o f treatm ent, tim e  o f sa c rifice , lig h tin g  
conditions and s tim u li used to challenge pineal noradrenergic responsiveness may 
have con tribu ted  to  discrepant results.
Only one group has investiga ted  the e ffe c t o f repeated DM I adm in is tra tio n  (5 
m g/kg da ily  fo r 14 days) upon the c ircad ian  rhythm  in pineal m ela ton in  
concentration (Ross et al, 1983). DM I treatm ent caused a significant shift of the 
whole curve to the le f t  giving a higher m e la ton in  peak value 2 hours p rio r to 
con tro ls . In contrast to  find ings from brain recep to r studies (Section 1.5.3), a 
phase advance in m elaton in  secre tion  not a phase delay was induced by chronic DMI 
treatm ent.
Single tim e  po in t studies can provide m isleading in fo rm a tion  about various 
p ineal param eters and the re fo re  a su itab le  circadian experim enta l design is 
required  fo r m eaningfu l analyses o f the e ffe c ts  o f antidepressant drugs.
1.5.4.2. Antidepressant therapy and human m ela ton in  secretion
W hether or not dow n-regu la tion  o f p ineal 6-adrenoceptors occurs in humans 
during chron ic TC A tre a tm e n t has been questioned. 24-Hour plasma m elaton in
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changes during TC A drug treatm ent in hea lthy vo lunteers and depressed pa tien ts  
have provided usefu l in fo rm a tion .
In normal subjects acute DM I administration elevates nocturnal plasma
of
melatonin (Section 1.3.2.). A fte r 3 weeks,continuous DM l trea tm ent, 24-hourL ^
m ela ton in  leve ls have re turned  to baseline (p re tre a tm e n t) leve ls (Thompson et al, 
1985b; Cowen et al, 1985b). Cowen and co-workers, (1985b) observed elevated 
midnight melatonin levels for at least 7 days of DM l treatm ent whereas we found 
no d iffe re n ce  between p re -tre a tm e n t m ela ton in  levels compared to levels on day 7 
o f tre a tm e n t. Cowen's group reported  an acute increase in plasma m ela ton in  levels 
fo r 24 hours a fte r  DMI withdrawal and both studies ind ica ted  th a t by day 7 post­
withdrawal, m ela ton in  secretion was no d if fe re n t to pre-treatm ent levels. These 
workers suggested that removal of DM I caused a transient rebound increase in 
noradrenergic activ ity . They postu lated tha t reduced f ir in g  o f b ra in  p re junctiona l 
noradrenergic neurones may be invo lved in the adaptive changes observed during long 
te rm  DM I adm in is tra tio n .
In depressed patien ts  the e ffe c ts  o f antidepressant therapy upon m elaton in  
secre tion  have yielded in te res ting  data. Halbreich e t al, (1981) found e levated 
daytim e m ela ton in  levels in patients trea ted  with DM I fo r  6 weeks although the 
enorm ously high levels reported  in th is study (100-500 pg /m l) may w e ll ind ica te  
m ethodolog ica l problems.
Thompson et al (1983; 1985b) have shown tha t n ig h t-tim e  plasma m ela ton in  
levels were s ig n ific a n tly  elevated above p re tre a tm e n t levels in depressed patien ts  
during both 1 and 3 weeks o f DMI therapy. Subsequent investiga tions by Sack and 
Lew y, (1986) have supported these findings^ since th is  group also found a pers is ten t 
increase in u rinary  6-hydroxy melatonin fo llow ing  1, 2 and 3 weeks o f DMI 
tre a tm e n t. I t  appears fro m  these studies th a t the pineal response to antidepressant 
tre a tm e n t may be d ifferent/a ltered  in depressed patients compared to contro ls.
In contrasty o ther investiga to rs  have reported  no difference between
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p re tre a tm e n t plasma m e la ton in  leve ls and leve ls a fte r  4 weeks or more o f 
treatm ent (W irz-Justice and Arendt, 1980; Mendlewicz et al, 1980; Brown et al, 
1985b).
Chronic (3 weeks) treatm ent with monoamine oxidase type A inhibitors, 
known to reduce 6-adrenoceptor density in rat brain tissue, was shown by Murphy 
et al, (1986) to elevate early morning plasma melatonin levels in depressed 
patients.
If  plasma melatonin measurements provide a suitable marker of adrenergic 
function, these studies raise a number of questions and provide possible answers 
concerning adrenergic function in depression and antidepressant treatm ent and will 
be discussed in greater detail in Chapters 5 and 6.
1.6. M ETHODOLOGY
1.6.1. Measurement of melatonin
The measurement of picogram  levels o f melatonin in b io log ica l flu ids has 
required the development o f sensitive assay m ethodology applicable to the routine
analysis o f la rge numbers o f samples generated by c ircad ian  and seasonal studies.
The f irs t  q u a n tita tiv e  de te rm ina tion  o f m e la ton in  u tilised  its  effects on the 
dermal meianophores of tadpoles (Mori and Lerner, 1960). Although it is possible
to de te rm ine  p ineal gland m elaton in  w ith  g reat s p e c ific ity  using the tadpole 
bioassay o f Ralph and Lynch (1970) the m ethod is insensitive (> 100 pg) fo r the 
quantitation o f m e la ton in  in sm all samples o f plasma, urine or CSF.
E s tim a tion  o f m ela ton in  by flu o r im e try  (Maickel and M iller, 1968) has poor 
s e n s itiv ity  (> 10 ng) and s p e c ific ity  fo r sample analysis. However, the use o f 
f lu o r im e tr ic  de te c tion  in com bination  w ith  reverse phase HPLC (Anderson et al, 
1982) is s u ff ic ie n t fo r  the measurement o f p ineal gland m e la ton in  (> 100 pg).
The in tro d u c tio n  o f GC-MS assays w ith  e lec tron  capture de tec tion  (Pelham et
62
al, 1972; Smith et al, 1976) and negative chemical-lonization mass spectrometry 
(Lewy and Markey, 1978) provided important qualitative and quantitative  
information on pineal indole content. Lewy and Markey's method permits 
measurement of melatonin in human plasma at concentrations as low as 1 pg/ml. 
Beck and co-workers, (1981) developed an extraction procedure capable of 
separating 5-m ethoxytryptam ine, 5-methoxytryptophol, 5-methoxyindole and 
melatonin from  each other. This assay has been used to measure these 
methoxyindoles in pineal glands from sheep, pigs, rats and humans. More recently^ 
the extraction and derivatising procedures of Lewy and Markey, (1978) have been 
simplified by Skene and colleagues, (1983) to fac ilita te  the practical measurement 
o f la rger numbers o f samples. Fellenberg et al, (1980) measured aMT6s in the urine 
o f hea lthy vo lunteers using GC-MS to  detect conjugated 6-hydroxymelatonin. The 
se n s itiv ity  o f th is method was around 50 ng aMT6s/10 m l urine. The s p e c ific ity  o f 
GC-MS renders the technique inva luable  fo r the va lida tion  o f ex is ting  and fu tu re  
assay methods but the high cost and tim e  consuming prepara tion  o f samples makes 
GC-MS at present im p ra c tica l fo r assays on a large scale.
For the vast m a jo rity  o f researchers^R IA  has been the method o f choice, 
p e rm itt in g  the es tim a tion  o f m ela ton in  in sm all volumes o f plasma and single 
p ineals in a number o f species. The o rig ina l pub lica tions o f m e la ton in  R IA  (A rendt 
et al, 1975; Levine and Riceberg, 1975) were followed by a variety of other RIA  
methods dem onstra ting  se n s itiv ity , s p e c ific ity  and precision ( fo r reviews see 
Arendt, 1978, 1986b; Rollag, 1981).
RIA perform ance depends upon sample preparation, the p u r ity  and spec ific  
a c t iv ity  o f the rad io labe l and the a f f in ity  and specificity o f the antiserum . A 
num ber o f methods have been used to  produce a n ti-m e la ton in  antisera fo r RIA. As 
the m e la ton in  m olecule  is not its e lf  antigenic, i t  (or one o f its  analogues) must f irs t  
be coupled to  an immunogenic c a rr ie r p ro te in . High a f f in ity  spec ific  antisera have 
been produced in animals (m ain ly rabb its) using m ela ton in  its e lf  as hapten 
(W urzburger et al, 1976; Pang et al, 1977), N -a ce ty l-5 -m e th o xy tryp tophan  (A rendt
63
et al, 1975), indomethacin (Levine and Riceberg, 1975), N-acetyl-serotonin  
(Kennaway et al, 1977), l-(para-carboxybenzyl)-m elatonin (Grota et al, 1981) and 
N-succinyl-5-m ethoxytryptam ine (Rollag and Niswender, 1976). O f the original 
RIA's all but one used a commercially available tritia ted  melatonin tracer (26-40 
Ci/m m ol). Rollag and Niswender (1976), radioiodinated the melatonin analogue N- 
3-(4-hydroxyphenyl)-propionyl-5-methoxytryptamine for use as a tracer resulting in 
high sensitivity (2-3 pg/tube) of the standard curve. This method however has 
generated large inter-laboratory variations in melatonin levels obtained in human 
plasma: some researchers have reported daytime levels as high as 100 pg/ml 
compared to < 5 pg/ml by GC-MS measurement.
A ll the original methods required p rio r extraction o f m e la ton in , sometimes 
w ith  fu r th e r purification using chromatographic techniques^ depending upon the 
specificity o f the antiserum. Am m onium  sulphate or double antibody p re c ip ita tio n  
have been equally e ffe c t iv e  in the separation o f bound and free hormone.
More re ce n tly  w ith  the use o f h ighly spec ific  antibodies^ i t  has been possible 
to dete rm ine  melatonin d ire c tly  in human plasma without p rio r e x tra c tio n  (Fraser 
et al, 1983a). The s im p lic ity  o f the m ethod enables a higher sample throughput and 
due to the availability of high specific activity tritia ted  melatonin (80-90 Ci/mmol)^ 
assay sensitivity is at least 5 pg/ml plasma. The method has been adapted for a 
number of species e.g. sheep (English et al, 1986); penguin (Cochran, unpublished); 
ra t (Webley et al, 1985); goat (Deveson and Arendt, unpublished) and marsupial 
(Loudon et al, 1985) plasma and human saliva (Miles et al, 1985).
Other RIA improvements have resulted from simplified techniques for the 
production of high specific activ ity  iodinated labels. Vakkuri et al, (1984a) have 
iodinated melatonin directly using Jodogen and the assay has been validated to 
measure m elaton in  extracted from  human serum, saliva and urine (Vakkuri et al, 
1985). A sm all percentage o f m elaton in  is excre ted unchanged but urinary 
measurem ents provide only a crude p ic tu re  o f m elaton in  secre tion . The major 
m etabolite aMT6s may now be measured in both human plasma and urine by direct
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RIA with a tritia ted  tracer (Arendt et al, 1985) and with a radioiodinated tracer 
(Aldhous and Arendt, 1988). This non-invasive method has obvious advantages for 
circadian and seasonal studies and is described in detail in Section 2.1.5.
Reported levels of melatonin have decreased over the years, and appear to 
have reached a nadir, implying that methods are now more specific. Despite 
reasonable agreement between most laboratories for day and night-tim e melatonin 
values[,the importance of rigorous validation procedures has been stressed not only 
for new assay methods but for adaptation o f methods for different species (Arendt, 
1981).
Recently immunoassays incorporating enzymes (Ferrua and Masseyeff, 1985)
and lum inescent labels (Gupta e t al, 1985) instead of radioactive tracers have been 
developed for m ela ton in  assay, but samples to  be measured have required prior 
e x tra c tio n .
1.6.2. B -Adrenerq ic receptor binding methods in membrane 
preparations from rat brain and p ineal glands
Traditionally, 6-adrenergic recepto rs  o f a va rie ty  o f non-neural tissues have
been characterised in d ire c tly  by measurem ent o f a lte red  adenylate cyclase a c tiv ity
or of intracellular cyclic AMP in response to 6-adrenergic agonists and antagonists.
Due to  the d if f ic u l ty  o f measuring physio log ica l responses o f 6-adrenergic
recepto rs  in the CNS, the developm ent o f d ire c t rad io ligand binding methods has
allowed investiga tors  to  localise, characterise and investiga te  the regu la tion  o f 6-
adrenerg ic receptors in the bra in.
In itia lly  radioligands were not o f s u ff ic ie n tly  high specific a c tiv ity  and
s p e c ific ity  to id e n tify  the sm all number o f 6-adrenoceptors present in various
tissues studied. However, in 1974 th ree  groups independently developed methods
fo r the direct id e n tif ic a tio n  o f 6-adrenoceptors using the rad io labe lled  6-
adrenerg ic antagonists [ H J-p ro p ran o lo l (L e v itz k i e t al, 1974), H J-
1 75 1
d ihydroa lp reno lo l (DH A) (Lefkowitz et al, 1974) and L IJ -
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iodohydroxybenzylpindoloi (IHYP) (Aurbach et al, 1974). Since then^ a number of
other suitable radioligands have become commercially available (for review see
Burgisser and Lefkow itz, 1984) including _ j -iodocyanopindolol (IC YP) which
I ?
combines high affin ity  with high specific radioactivity and_ H j-C G P -12177  which 
reportedly binds exclusively to receptors on the outside surface of the cell 
membrane. A number of 6-agonist radioligands are commercially available but all 
possess significantly lower affin ities than do their antagonist counterparts.
The most widely used radioligand has been _ H j -D H A . In itia l studies using 
this ligand were described with membranes from frog erythrocytes (Mukherjee et
3
al, 1975): H J-D H A  was extensively characterised, chemically and
pharmacologically as an active potent antagonist of isoprenaline-stimulated 
adenylate cyclase activ ity . A t the same time the ligand was used to investigate 
binding sites in brain and pineal gland homogenates. 6-Adrenergic receptors were 
characterised in the cerebral cortex o f the rat (Alexander et al, 1975) and of rat
3 1
and monkey (Bylund and Snyder, 1976): ce n tra l binding sites labelled with _ H j -
DHA were shown to have similar properties to the 6 . -receptors in the periphery.
3 I
These authors also found _ H i -D H A  binding to be greatest in the subcellular
fra c tion s  conta in ing  high concentrations o f synaptic membranes and synaptosomes 
3 I
indicating that H J -D H A  binds predominantly to synaptic receptor sites. The 
radioligand binding sites were reported in pineal gland homogenates (Zatz et al, 
1976) and the binding demonstrated in h ib itio n  o f 6-adrenergic receptor regulated 
adenylate cyclase a c tiv ity  (Kebabian et al, 1975). The pineal 6-receptors were of 
high density (Greenberg and Weiss, 1978) and shown to be of the 6n-subtype 
(P a rfitt et al, 1976).
The majority of researchers to date, investiga ting  6-adrenergic recep to r 
status in bra in  or p ineal tissue, have used modifications o f the methods described 
above. The binding studies were generally performed by incubating a membrane 
preparation w ith  the rad io ligand u n til a steady s ta te  leve l o f binding was a tta ined . 
The rad io ligand bound to  membrane sites was iso lated by e ith e r c e n tr ifu g a tio n  or
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wi+h
vacuum f i l t r a t io n  through glass fib re  filters, fo llow ed  by a wash o f ice -co ld  b u ffe r. 
Analysis of radioligand binding data has been derived from the mass action law and 
plotted by the Scatchard method (Scatchard, 1949) or classic Michaelis-Menten  
enzyme kinetics.
The values reported fo r  K „  (the apparent d issocia tion  constant) and Bu  '  ^ max
(density of specific binding sites) have shown large interlaboratory variations. 
Details of the original and modified j -D H A  binding methods are reviewed in 
Table 1.6. (cortex) and Table 1.7. (pineal). In general, K^'s reported for i. ^ H j -  
DHA binding in cortex preparations (0.8 - 1.5 nM) have been within the range (0.5 - 
2 nM) found in the periphery (Burgisser and Lefkow itz, 1984) but, Kj^'s obtained 
from  binding studies in p ineal homogenates have been higher ( 3 - 5  nM). The 
published B ^  values have ind icated a density o f binding sites 3-4 fo ld  h igher in 
the p ineal than in the cortex.
' 125 'The re la tiv e ly  new ligand L I J -IC Y P  has been used fo r cha rac te risa tion  
of 6-adrenergic receptors in rat brain (Petrovic et al, 1983) and in rat and hamster 
pineal homogenates (C ra ft et al, 1985) resu lting  in K^'s o f 35-50 pM and the re fo re  
h igher a f f in ity  binding. The binding o f l  ^H j -CGP-12177 to  6-adrenergic 
recep to r sites in ra t co rtex  and pineal glands from  rat, ham ster and mouse has been 
characterised and qua n tified  (W ilkinson and Wilkinson, 1985) using a new sim ple and 
rapid assay m ethod. C ortex  slices and single whole pineals m ainta ined in a 
balanced oxygenated medium are incubated with the radioligand (CGP) reported to 
bind to  ce ll surface receptor sites. The method dispenses with tim e  consuming 
ce n trifu g a tio n  o f tissue homogenates and provides a system fo r the fu tu re  
exam ination  o f recepto rs in intact fresh tissue.
1.7. THE THESIS
The developm ent o f d ire c t, sensitive and spec ific  RIAs fo r the de te rm ina tion  
o f m elaton in  and aMT6s are described in th is  thesis. These methods were applied 
to c a re fu lly  co n tro lle d  studies o f m ela ton in  secre tion  in man.
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The RIAs were va lida ted  fo r the de te rm ina tio n  o f m ela ton in  in ra t serum and 
pineal samples. Existing radioligand binding methods were modified for the
m easurem ent o f 6-adrenoceptors in ra t p ineal and co rtex  tissues.
Melatonin secretion in a ffective  disorders and the effects of antidepressant 
drug treatm ents are reported.
CHAPTER 2
IVIETHODOLOGY
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2.1. RADIOIMMUNOASSAY OF MELATONIN AND 6-SÜLPHATOXYMELATONIN
2.1.1. CHEMICALS REAGENTS AND EQUIPMENT
A. B u ffe r components and other chem icals
T ric ine
Tween 20 (Polyoxyethylenesorbitan)
Charcoal, activated, untreated powder
(100-400 mesh)
RPM I-1640 culture medium 
Ovalbumin
lodo-Gen (l,3 ,4,6-tetrachloro-3,6-diphenylglycouril) 
Dicyclohexylcarbodiimide (DCC)
NADPH  
Niacinamide 
G lu ta th ione  
L-ascorbic acid
G elatine
Glucose
Am m onium  sulphate 
Sodium chloride 
Potassium hydroxide 
Potassium chloride 
Sulphuric acid 
G lac ia l a ce tic  acid
D extran  T -70
B. Drugs
Phénobarb ita l 
Benserazide hydroch loride
C. Indoles and analogues 
Melatonin
6-hydroxym e la ton in
N -a ce ty ltryp to p ha n
N -ace ty lse ro ton in
T ryp topho l
Tryptophan
Tryp tam ine
5-methoxytryptamine
5-m ethoxy tryp top h o l
5-hydroxy tryp ta m in e
5-hydroxyindo le  acetic acid
N-acetyltryptam ine
N -a ce ty l-5 -m e tho xy  tryp tophan
Suppliers
SIGMA Chemical Co. 
Ltd., Fancy Road, 
Poole, Dorset.
BDH Chem icals L td ., 
Poole, D orset.
Pharmacia (Great Britain) 
Ltd., Pharmacia House, 
Midsummer Boulevard, 
Milton Keynes, Bucks.
SIGMA Chemical Co. Ltd.
Roche Products Ltd., Welwyn 
Garden C ity , Herts.
SIGMA Chemical Co. Ltd.
Plan Labora tories, 
Geneva, Sw itzerland.
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D. A n tise ra
E.
Cellulose-coated donkey 
anti-sheep.
Radiolabels
3
3
H -melatonin
H_ -m e la ton in
I 1 7 3Na
38.6 C i/m m ol
45.3 C i/m m o l
79 Ci/m m ol 
90 Ci/m m ol
F. O rganic solvents
M ethanol Anal R grade 
Isopropanol Anal R grade 
D ich lorom ethane Anal R grade 
n-Butanol Anal R grade 
Acetone Anal R grade
C h lo ro fo rm  AR grade 
E thy l acetate AR grade 
Toluene (sulphur free)
Ethanol, 99%
G. C hrom atography and f i lte r in g  m a te ria ls  
Merck Cellu lose F TEC plastic sheets 
S ilica  gel TEC plastic sheets 
Sephadex LH-20
Seitz f i lte rs
S te rile  disposable 0.2 pm f i lte rs
H. G lassware and plastic consumables
LP3 assay tubes
Guiidhay Antisera,
6 R ivers ide , 
Business Centre,
W alnut Tree Close, 
G u ild fo rd .
New England N uclear 
(United Kingdom),
2 New Road, Southampton.
Am ersham  International 
p ic .. W hite L ion  Road, 
Am ersham , Bucks.
BDH Chem icals Ltd.
May and Baker Ltd.,
Dagenham, Essex.
James Burrough L td . 
60 Montford Place, 
London S E ll .
BDH Chem icals L td .
Eastman Kodak, Liverpool.
Pharm acia (G reat B rita in ) 
Ltd.
Urbane L td ., Ipswich, 
S u ffo lk .
Gelman Sciences,
10 H arrowden Road, 
N ortham pton.
Luckham  L td ., V ic to r ia  
Gardens, Burgess H ill,
Sussex.
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LKB  po lye thy lene  s c in tilla t io n  
v ia ls
Lithium-heparin tubes (LH /10)
Glass homogenisers
Fisons pic., S c ie n tif ic  
Equipment Division,
Loughborough.
Sterilin L td ., Hounslow, 
M iddlesex.
Gallenkam p, Loughborough, 
Le iceste rsh ire .
I. Scintillation counting
Gptiphase safe s c in tilla t io n  flu id  
LKB 1216 Rackbeta liqu id  s c in t illa t io n  
counter
LKB  1260 Multigamma 11, gamma counter
PRO (2,5-Diphenyloxazoie)
POPOP (l,4-D i-2-(5-phenyloxazolyl)-
benzene
Pharm acia (G reat B rita in ) 
L td .
BDH Chem icals L td .
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2.1.2. DETERMINATION OF MELATONIN IN HUMAN PLASMA BY 
DIRECT RIA
2.1.2.1. In trod u c tion
A validated R IA for the direct measurement of melatonin in human plasma 
(Fraser et al, 1983a) was employed for the studies described in this thesis. The 
methods of validation have included a comparison in this laboratory with our
oLo
previously reported R IA requiring extraction (Arendt et al, 1977a) and , a 
comparison with a published GC-MS method (Fraser et al, 1983b). The 
characterisation of batches of 704 anti-m elatonin antiserum and the RIA procedure 
are described.
2.1.2.2. M aterials
W ater was d ou b le -d is tilled  in glass and used fresh fo r  the preparation of assay 
solutions.
The assay buffer was Tricine, 0.1 M, pH 5, containing 0.9% NaCl and 0.1%  
gelatine. The buffer was stored at 4°C  and was freshly prepared each week.
Standard melatonin stock solution (1.0 m g/m l, 4.3 mM) was made up by
dissolving 10 mg melatonin in 0.5 m l absolute ethanol and adjusting the volume to 
10 m l w ith  water.
T ritia te d  melatonin stock solutions, in it ia l ly  45.3 C i/m m o l and la te r
-+he roJf'o
79 Ci/m m ol were stored at -20°C . An intermediate dilution of ^ b e l  (1:100) in
absolute ethanol was stored at -20 °C  and was d ilu ted  fu r th e r to  give 4000 CPM 
per assay tube (38% counting efficiency), equivalent to 26 pg (45.3 Ci/m m ol) or
14 pg (79 C i/m m o l) o f melatonin.
Sheep anti-m elatonin antise ra  (batch numbers 704/189, 704/216, 704/6483, 
704/8483) were produced by one S uffo lk  Cross ewe (704) immunised w ith  N-acetyl 
5-methoxy tryptophan-porcine thyrog lobu lin  conjugate according to  the method of
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A rend t et al, (1975). The ewe was in jec ted  i.d . at several sites w ith  5 mg o f 
conjugate emulsified in 3 ml physiological saline/Freunds adjuvant (1:2). Booster 
injections (2 mg conjugate in saline/Marcol) (Marks et al, 1975) were given at 
monthly intervals and antiserum was harvested from 250 ml bleeds taken 8-10 days 
after each boost. The blood was allowed to clot at 4 °C  and the serum was 
separated by centrifugation. The antisera were stored in 50 pi aliquots freeze  
dried at a dilution of 1:10 in phosphate buffer pH 7.1, 0.1 M and diluted in assay 
buffer before use.
Dextran-coated charcoal was prepared from a suspension of activated  
charcoal (2%) in assay buffer, mixed for 1 h at room tem perature and centrifuged  
(500 X g, 5 min) to remove charcoal fines. The defined pellet was resuspended and 
mixed for 1 h in assay buffer with 0.02% Dextran T-70 before storage at 4°C .
S c in tilla tio n  f lu id  consisted o f 12.5 g PPO and 0.75 g POPOP in 2.5L toluene. 
The so lu tion  was stored at room temperature in the dark.
Where possible^ disposable plastic and glass apparatus was used. Otherwise 
glassware was sonicated in glass double-distilled water before use.
2.1.2.3. C h a rac te risa tion  o f antisera
(a) Methods
The titre , a f f in ity  and cross re a c tiv ity  o f antisera derived from  fou r separate
3bleedings of sheep 704 were compared. _ H J -melatonin (26 pg in 100 pi buffer, 
45.3 C i/m m o l) was incubated overnight at 4°C  w ith  d ilu ted  antiserum  (200 p i) and 
Tricine buffer in a final volume of 800 pi. Melatonin standard (2.5, 5, 12.5, 25, 50,
100 and 250 pg/tube) or indo lic  analogues (0.5 ng/tube - 0.5 pg/tube) were included 
in the b u ffe r volum e fo r  the construc tion  o f standard curves. The antibody-bound 
m e la ton in  was separated from the free fra c tio n  by incubation  fo r 15 m in w ith  
500 p i o f dextran-coated charcoal and ce n trifu g a tio n  (2000 x g, 4°C , 15 m in). 
Supernatant (700 p i) was counted in 4.0 m l s c in tilla n t.
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Melatonin standard curves were prepared in assay buffer with final 
antiserum dilutions of 1:4000 (704/189, 704/216), 1:8000 (704/6483), and 1:12000 
(704/8483). These titres were determined from dilution and displacement curves
r 7
as the titres required to bind 50% (13 pg) of [ H j  - melatonin added
(45.3 C i/m m ol). The average antibody affin ity  constants were calculated as K =
AgAbj /  [ Ag Al^ where [ AgAk^ is the concentration of antibody-bound
hapten and [ Ag| and Abj are the concentrations of free hapten and antibody at
50% displacement o f tra ce r by unlabelled antigen when antibody binding sites are 
at 50% saturation (M uller, 1979). S p e c ific ity  o f the antisera  was assessed by
comparing the displacement of antibody-bound -melatonin by 13 indolic
analogues. Measurable c ro s s -re a c tiv ity  was expressed re la tiv e  to  the q ua n tity  o f 
melatonin that displaced 50% of antibody-bound -melatonin.
(b) Results
F ig . 2.1 shows m e la ton in  standard curves constructed  in assay b u ffe r at the 
optim um  t i t r e  fo r each antiserum . Three batches o f antibody (704/189, 6483, 8483) 
provided sensitive standard curves w ith  de tec tion  lim its, defined as the least 
am ount o f m ela ton in  d istingu ishable  from  zero at the 95% confidence l im it ,  o f
2.5 pg m e la ton in /tube . A ntise rum  704/216 gave a l im it  o f de tec tion  fo r m elaton in  
in b u ffe r o f 12.5 pg/tube. A ll o f the bleeds were of high a f f in ity  (Table 2.1) in the 
range desirable fo r co m p e titive  binding assays (10^^ L /m o l).H ow ever, batch 8483 
dem onstrated the highest t i t r e  (1:12000 fin a l d ilu tion ) and highest a f f in ity  (K = 1.97 
X 1 0 ^ ^  L /m o l) and was the re fo re  chosen as the w orking antiserum  in the R IA 
procedure to be described. A high a c t iv ity  tra ce r (79 C i/m m o l) was availab le  at a 
la te r date and p e rm itte d  even higher t it re s  o f 8487 (1:18000 fin a l d ilu tion ) and 
im proved the se n s itiv ity  o f the standard curve (< 2 pg/tube) due to the presence o f 
few er labe lled  m e la ton in  m olecules com peting fo r binding sites.
Table 2.2 shows the re la tiv e  a b ilit ie s  o f 13 d if fe re n t indoles to com pete with
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100- Final dilution 
# - #  704 /189  1:4000
O—0 7 0 4 /2 1 6  1:4000  
O— ': j7 0 4 /6 4 8 3 1:8000 
» — ■ 704 /8483  1:12000
9 0 -
80 -
70 -
6 0 -
n 5 0 -
4 0 -
3 0 -
2 0 -
2.5 5 12.5 25 50 100 250
Melatonin pg/tube
F ig. 2.1 M ela ton in  standard curves constructed in T ric ine  b u ffe r w ith  d iffe re n t 
m e la ton in  antisera  from  sheep 704. The t itre s  were determ ined as the d ilu tio n  o f 
antiserum binding 50% of tracer (45.3 Ci/m m ol).
Antiserum A ffin ity  Constant L/m ol
7 0 4 /1 8 9 1.72 X 1 0^ °
7 04 /21 6 1.16 X 1 0^ °
7 0 4 /6 4 8 3 1.90 X 10^ °
7 0 4 /8 4 8 3 1.97 X 1 0^ °
Table 2.1 A ntibody a ff in ity  constants determ ined from  the standard curves 
above a t 50% in h ib itio n  o f tra ce r by unlabelled antigen.
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Percentage cross-reaction
Compound 704/216 704/6483 704/8483 704/189
M ela ton in 100 100 100 100
N -A cetyltryptam ine 0.94 0.91 0.97 0.35
6-Hydroxy melatonin 0.45 0.33 0.38 0.40
N-Acetyltryptophan 0.14 0.22 0.26 <0.007
N-Acetylserotonin <0.07 <0.06 <0.07 <0.07
6-Sulphatoxy m e la ton in <0.07 <0.06 <0.07 not tested
T ryp topho l <0.07 <0.06 <0.07 <0.07
5-M ethoxy tryp top h o l <0.07 <0.06 <0.07 <0.07
5-H ydroxy tryp ta m in e <0.07 <0.06 <0.07 <0.07
5-H yd roxy indo leace tic  acid <0.07 <0.06 <0.07 <0.07
5-M ethoxy tryp ta m in e <0.07 <0.06 <0.07 <0.07
Tryptophan <0.07 <0.06 <0.07 <0.07
T ryp tam ine <0.07 <0.06 <0.07 <0.07
Table 2.2 Cross-reaction o f various analogues o f m elaton in w ith  m ela ton in
antisera, de term ined re la tive  to  the q ua n tity  o f m ela ton in  (pg/tube) tha t displaced 
50% o f antibody-bound ; H j -melatonin. The data from  704/189 (Fraser e t al, 
1983a) is included for comparison.
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-m e la ton in  fo r binding sites on the antibody. The c ro ss -re a c tiv itie s  o f batch 
704/189 have been previously described (Fraser et al, 1983a). A il three later  
batches showed similar specificity for melatonin against the compounds tested. 
The measurable potential interfering compounds (N-acetyltryptam ine, 6- 
hydroxymelatonin and N-acetyltryptophan) demonstrated less than 1% cross­
reaction in the assay.
2.1.2.4. Sample c o lle c tio n  and prepara tion  o f plasma pools
Melatonin free plasma was obtained from healthy volunteers within the 
laboratory. Blood samples were taken in to  lith iu m -h e p a rin  tubes in the m id - 
afternoon when levels of melatonin are expected to be at a minimum. A ll plasma 
samples were individually assayed against a standard curve in b u ffe r and the low est 
(<20 pg /m l) were pooled and used fo r  preparing standards. C harcoa l-s tripped  
plasma was prepared by m ix ing  a po rtion  of the plasma pool w ith  10% D extran-T  
defined charcoal. The charcoal suspension was incubated overnight at 4°C  and 
separated from the plasma by centrifugation and f i l t r a t io n .  Standard curves 
prepared in stripped and unstripped plasma were compared.
Blood samples fo r analysis were taken in to  lith iu m -h e p a rin  tubes and 
ce n trifu g ed  at 1500 x g fo r 15 m in at 4°C  im m ed ia te ly  a fte r  collection. Plasma 
was stored frozen  at -20°C  u n til assayed.
Q ua lity  co n tro l samples conta in ing  endogenous m ela ton in  were prepared by 
pooling plasma from  healthy volunteers to provide medium  and low  concentrations 
o f m e la ton in . A fu r th e r con tro l, spiked w ith  unlabelled m e la ton in , provided a high 
concen tra tion  pool and a m on ito r o f m ela ton in  recovery. A ll qua lity  contro ls  were 
stored in a liquots o f 1200 p i at -20°C .
79
2.1.2.5. R IA  procedure
(a) Methods
Duplicate tubes were set up for all samples, standards, total and non-specific 
binding determinations. To 500 pi of each sample or standard (2.5, 5, 12.5, 25, 50, 
100 and 250 pg/tube), 200 pi of antiserum (in itia l dilution 1:3000) was added. A fte r  
mixing and incubation at room temperature for 30 min, 100 pi of _ H , -melatonin  
was added to give a final volume of 800 pi. The tubes were mixed and further 
incubated overnight at 4°C . The antibody-bound melatonin was separated from the 
free fraction by incubation for 15 min with 500 pi of dextran-coated charcoal and 
centrifugation (2000 x g, 4°C , 15 min). Supernatant (700 pi) was counted in 4.0 ml 
scintillant and the results were determined from a smoothed spline plot (LKB 
package) by extrapolation.
Three q ua lity  control samples were processed at the beginning and end o f
each assay. The c o e ff ic ie n t o f interassay va ria tio n  (IS D /m ean x 100) was 
ca lcu la ted  from  the co n tro l sample values obta ined fro m  a ll the assays perfo rm ed 
fo r one com plete  study. Intraassay variability was determ ined by the measurement 
o f 6 rep lica tes  o f each plasma co n tro l in an assay o f 120 tubes in length (equiva lent 
to 50 samples).
(b) Results
The re p ro d u c ib ility  o f 8 m e la ton in  standard curves constructed in the mid­
afternoon plasma pool and assayed on separate occasions is illu s tra te d  in F ig . 2.2 
The curves demonstrate a sensitive and cons is ten tly  reproducib le  assay system. 
Standard curves constructed  in charcoal s tripped plasma were iden tica l to curves 
prepared in unstripped plasma. I f  endogenous m ela ton in  was present in the m id ­
a fte rnoon pools i t  was not detectab le  w ith in  the lim it o f th is  assay. Assay 
perform ance data is shown in Table 2.3. The mean m in im um  detectab le  leve l o f 
melatonin defined as the least amount o f m e la ton in  d istinguishable from  zero at
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Fig. 2.2 A com posite m elatonin standard curve in m id -a fte rnoon  plasma pool. 
The mean and SD fo r  each po in t o f 8 standard curves was assessed using antiserum  
8483 (1:18000 final dilution) and -melatonin (14 pg/tube) with a specific
a c tiv ity  o f 79 C i/m m o l.
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PLASMA M ELATO NIN
pg/ml % CV n
Intraassay CV 26 14.0 6
44 7.4 6
92 7.2 6
Interassay CV (a) 26 9 .6 10
60 6.7 10
107 5.5 10
(b) 18 11.8 14
50 8.1 14
88 7.8 14
Sensitivity 2.5 pg/tube 
5.0 pg/ml
N on-spec ific  binding <1.5%
Maximum binding o f
3
H - m elaton in 49.7% (+ 0.7 SEM)
Recovery o f added 
m e la ton in : 25-74 pg/ml 95-107'
Table 2.5 RIA of melatonin in human plasma : assay performance and data.
[ ~Z ']
Interassay CV's are shown for quality control pools (a) assayed with  ^ H| -
I 5 1melatonin, 45.3 C i/m m ol (1984) and (b) assayed with _ HJ -melatonin, 79 Ci/m m ol 
(1986).
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the 95% confidence lim it was 2.5 pg/tube = 5 pg/ml plasma. Intraassay variation  
was acceptable over an assay length of 120 tubes. However, assay d rift was 
apparent in RIA's of a larger size and therefore the number of samples processed in 
each assay was restricted to 50.
2.1.2.6. Discussion
The characterisation of batches of 704 antisera and the use of a validated 
direct RIA is described. Assay performance has improved with the availability of 
higher specific activ ity  tritia ted  tracers and this method is more robust than 
former RIA's. Low in tra - and interassay variability has been demonstrated and is 
o f importance since psychiatric research invo lv ing  pineal func tion  has required the 
determination o f relatively small changes in the m e la ton in  secretion pattern. The 
success o f th is  R IA  compared to others requiring prior extraction of m ela ton in  is 
due mainly to the production of an antibody specific for the recognition of 
m e la ton in . N -a ce ty ltryp ta m in e , 6 -hydroxym e la ton in  and N -a ce ty ltryp to p ha n  
weakly cross-react w ith  m ela ton in , however p o te n tia l interference by other 
compounds not tested cannot be excluded. The presence o f heparin in sm all 
amounts (around 50 units used for plasma co lle c tio n ) is reported not to interfere  
(Webley et al, 1985) but commercial heparin preparations in larger concentrations 
a ffe c t the antibody's binding capacity  (Johansson e t al, 1984).
A more recent pub lica tion  (Webley e t al, 1985) describes the use of antiserum  
8483 in a direct assay w ith  second - antibody p re c ip ita tio n . A lthough more costly, 
th is spec ific  separation procedure allows counting o f the precipitate thereby 
rem oving the quenching problem s caused by heavily  coloured plasma samples. 
However, a discrepancy between the tw o d ire c t R IA  methods was reported in th is 
study in which sample values previously determ ined in our laboratory were 
compared w ith  values obta ined by their assay at the In s titu te  fo r Hormone and 
F e r t i l i ty  D isorders, Ham burg. Sample m ela ton in  concentrations were determ ined
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in th e ir  m od ified  assay from a standard curve constructed  in assay b u ffe r and 
despite good correlation^ were almost tw ice those obtained in our laboratory. 
D iffe rences  in the preparation o f standard curves and in the separation procedures 
may account for the disagreement in the results reported.
V aria tions between some labora to ries  in the physiological leve ls o f m ela ton in  
obtained by RIA demonstrate a need for robust and carefully validated assays. The
in it ia t io n  o f a n a tio n a l/in te rn a tio n a l m e la ton in  q ua lity  co n tro l scheme would be of 
b en e fit to p ineal research.
2.1.3. DETERMINATION OF MELATONIN IN RAT SERUM AND 
PINEAL GLAND BY DIRECT RIA
2.1.3.1. In troduc tion
The R IA  discussed previously (Section 2.1.2.) was fu r th e r va lida ted  fo r  the 
measurement o f p ineal and serum m ela ton in  in the rat. Minor m od ifica tio n s  to  the 
method were made because o f the nature of the m a te ria l i.e. the  serum obtained 
fro m  the anim al studies was o ften  heavily  haemolysed and sm all in volum e. The 
RIA procedures and validation tests are described.
2.1.3.2. Materials
A ll m a te ria ls  were as previously described (Section 2.1.2.2.) except th a t the
3 i
greater specific activity of _ H j -melatonin (90.5 C i/m m ol = 12 pg
m ela ton in /tube ) p e rm itte d  a f in a l d ilu tio n  o f 1:20000 fo r antiserum  8483. A m ulti­
purpose liq u id  s c in tilla t io n  c o c k ta il 'Optiphase Safe' was used fo r counting ra t 
serum samples. Tris buffer (50 mM, 3mM MgCI^, 1 mM EDTA, pH 8.0) was 
prepared fo r  the hom ogenisation o f p ineal glands. This buffer was required fo r 
subsequent ^ ^ h J -D H A binding m ethodology.
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2.1.3.3. Sample co lle c tio n  and serum pool p repara tion
Adult male Wistar/albino rats (200-250 g) were killed by cervical dislocation 
fo llow ed  immediately by decap ita tion .
The pineal gland of each animal was removed with forceps (within 30s), 
wrapped in parafilm  and aluminium foil and placed into liquid nitrogen before 
storage at -80°C . Trunk blood was collected into sterile plain glass tubes and 
allowed to clot at 4°C  and after centrifugation at 1500 x g for 20 min the serum 
was removed and stored at -20°C  before assay.
M elatonin-free serum was prepared by stripping with charcoal. Charcoal (10%) was
incubated overnight at 4 °C  with pooled serum taken from animals killed in the
afternoon. The charcoal was separated by centrifugation (40000 x g, 30 min) and
2
the supernatant was passed through sterile 0.2 pm, 7.5 cm f ilte rs .  The serum pool 
was a liquo ted  in to  2.5 m l stoppered plastic tubes and stored at -20°C .
A serum pool conta in ing  around 60 pg /m l m ela ton in  was obtained from  
anim als k ille d  at 0800 h.
2.1.3.4. R IA  procedure fo r  p ineal m elaton in
Pineals were individually homogenised in 1.0 m l Tris b u ffe r using hand-held 
glass homogenisers and 50pl aliquots (1/20 pineal) were dispensed in to  dup lica te  
assay tubes w ith  450 p i o f T ric ine  b u ffe r. Standards (2.5, 5, 12.5, 25, 50, 100, 
250 pg/tube) were prepared in 500 p i o f T ric ine  b u ffe r conta in ing  50 p i Tris buffer. 
The assay m ethod from thereon was as described in Section 2.1.2.5.
P ara lle lism  was assessed by comparing the d isplacem ent obtained in the RIA 
from vary ing  a liquots o f p ineal homogenate (5-50 p i) w ith  the standard curve in 
b u ffe r. The add ition  o f unlabelled m elaton in  to  d ilu ted  a liquots o f pineal 
homogenate provided an estimate o f m elaton in  recovery.
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2.1.3.5. R IA  procedure fo r ra t serum m ela ton in
(a) Assay method
The m ethod was m od ified  to  provide the sensitivity required for the 
determination of melatonin in 200 pi aliquots of rat serum.
Standards prepared in charcoal-stripped rat serum (2,5,10,15,25,50 pg/tube) 
and serum samples were dispensed into duplicate assay tubes in 200 pi volumes. 
Non-specific binding was determined in 200 pi normal ra t serum. Antiserum 8483 
was added at a higher in itial dilution of 1:6000 and the volume of dextran-coated  
charcoal required for separation was reduced to 250 p i. Otherwise the procedure 
was as described in Section 2.1.2.5. Aliquots of the final supernatant (500 pi) were 
counted in 4.0 m l o f Optiphase Safe and the results were obtained as DPM from  a 
quench calibration curve (LKB DPM Package).
Q ua lity  control samples were included at the beginning and end o f each assay.
(b) P ara lle lism  and recovery
P ara lle lism  o f norm al rat serum and spiked rat serum a liquots was 
determined by comparison w ith  standard curves constructed in buffer and charcoal 
stripped serum.
The recovery o f 5, 15 and 35 pg o f m e la ton in  /2Ü0 p i serum was determ ined 
by assay o f spiked norm al rat serum.
(c) Comparison w ith  ex trac ted  samples
A comparison was made between resu lts obta ined from  direct RIA and those 
obtained using p rio r sample e x tra c tio n  and R IA .
Method : 5 m l d ich lorom ethane was added to 500 p i sample and m ixed for 60s 
by vo rtex in a disposable 10 m l glass tube. A fter ce n trifu g a tio n  (1500 x g, 10 m in) 
the aqueous laye r was aspirated and 4.5 m l o f solvent was transfe rred  to a clean
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glass tube and evaporated under a stream of nitrogen at room tem perature. The 
residue was dissolved in 1.2 m l Tricine buffer and 2 x 500 p i aliquots were assayed 
as described in Section 2.1.2.5. Solvent blanks (5 ml dichloromethane) and serum 
blanks (500 pi charcoal-stripped serum + 5 ml dichloromethane) were extracted to 
measure baseline interference.
R ecoveries o f m ela ton in  were determined from spiked serum samples and 
parallelism of aliquots of extracted sera were determined against a standard curve 
(1,2,5,10,15,20,25,50 pg/tube) constructed in Tricine b u ffe r.
Results were multiplied by a factor of 5.34 to obtain pg melatonin/ml serum.
2.1.3.6. Results
A m e la ton in  standard curve constructed in heavily  haemolysed, charcoal- 
stripped rat serum was similar to  a curve in T ric ine  b u ffe r (F ig. 2.3). The results 
(DPM) obta ined by quench correction fo r  the m axim um  binding tubes (zero points) 
were the same for both curves. S en s itiv ity  o f the direct R IA in rat serum was 
2 pg/tube (10 pg/ml), non-spec ific  binding was 4% and 47% o f tracer added was 
specifically bound by 8483 (1:24000 fin a l d ilu tio n ). D ilu te d  a liquots o f rat serum 
conta in ing  a high leve l o f endogenous m ela ton in  displaced H j -melatonin  
pa ra lle l to th a t o f the standard curve (F ig. 2.3). Parallelism was also displayed by 
varying quan tities  o f ra t serum extract and the standard curve (F ig. 2.5). 
R ecoveries o f m e la ton in  fro m  spiked ra t serum were s im ila r fo r the d ire c t and 
ex trac ted  methods (Table 2.4). The l im it  o f de tec tion  fo r  the ex trac ted  method 
was higher (3 pg/tube, 16.5 pg/ml) because extraction blanks measured 1-
1.5 pg/tube  (5.4 -7.7 pg /m l) and the re fo re  assay se n s itiv ity  was determ ined as the 
least am ount o f m ela ton in  d istingu ishable fro m  the 1 pg/tube po in t.
Seria l d ilu tions  o f p ineal homogenate (F ig. 2.4) showed para lle lism  w ith  the 
standard curve in Tricine b u ffe r. The s e n s itiv ity  was 50 pg/p inea l, non-specific  
binding was less than 1% and 50% o f tra ce r added was bound by 8483 (1:24000 fin a l
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Fig. 2.4 Parallelism of dilutions of rat pineal homogenate with a standard curve 
in buffer.
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Fig. 2.5 Parallelism of diluted aliquots of extracted rat serum with the standard 
curve in Tricine buffer.
M ela ton i
serum
n pg/ml 
added measured
Recovery % n
D irect 20 25 58 85 + 11.0 5
RIA 20 75 90 95 + 10.5 5
20 175 184 94 + 8.6 5
E x trac te d 17 25 56 85 + 10.8 5
RIA 17 75 84 91 + 11.6 3
17 175 175 90 + 9.8 3
S e n s itiv ity  : D ire c t 2 pg/tube Extracted 5.0 pg/tube
10 pg/ml 16.5 pg/ml
Table 2.4 Quantitative recovery (% + SD) of melatonin added to haemolysed rat
serum using direct and ex trac ted  RIA methods.
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dilution). The presence of 10% Tris buffer, pH 7.8 did not a ffec t the binding or
se n s itiv ity  o f the m ethod.
Coefficients of variation (interassay) for pooled serum samples were 10.5%  
and 7.8% at 21.7 pg/ml and 54.8 pg/ml respectively and for pooled (diluted) pineal 
homogenates, were 9.9% and 15.2% at 52.5 pg/tube and 66.1 pg/tube respectively.
2.1.5.7. Discussion
A d ire c t R IA  for the de te rm ina tion  o f m e la ton in  in the rat pineal gland and 
serum is described with m inor modifications to  the o rig in a l method o f Fraser et al, 
(1985a). P a ra lle lism  between sample a liquo ts and the standard curve was 
demonstrated and the recovered levels of melatonin from serum samples compared 
well w ith  e x tra c te d  levels.
The problem s o f determining m ela ton in  directly, in sm all volumes o f 
haemolysed rat serum were overcome because the R IA described was sufficiently  
sensitive, and the antiserum specific. Furthermore, quench corrections were 
accurate  across the range o f the quench curve. Haemolysis o f sheep plasma 
samples has been shown to  produce fa lse ly  elevated m ela ton in  leve ls p ropo rtiona l 
to the op tica l density o f the sample (English, 1986, unpublished results), therefore  
it is more likely that the apparent increase in melatonin measured was due to 
decreased counting e ffic ie n c y  rather than to an e ffe c t o f haem upon the antibody 
binding mechanism.
An adapta tion  o f the R IA  o f Fraser and colleagues was described by Webley 
et al, (1985) using antiserum 8485 for the measurement of melatonin in the 
periphera l c irc u la tio n  o f the ra t. This method achieves a leve l o f de tec tion  
equ iva lent to  the present assay. M ela ton in  concentrations in rat, hamster, sheep 
and to rto ise  pineals have been reported  (Skene et al, 1986) using the present 
m ethod. The successful validation o f the direct RIA for interspecies pineal and 
serum/plasma melatonin is due m ain ly  to  the antiserum's low cross-reactivity w ith
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other indoles. The sensitivity of the assay could theoretically be improved (ideally 
to subpicogram levels) by the introduction of an iodinated tracer, achieving 90% 
sample counting efficiency instead of 25% efficiency for tritium  counting in 
heavily quenched samples.
2.1.4. DEVELOPMENT OF A DIRECT MELATONIN RIA USING 
RADIOIODINATED M ELA TO N IN  AS TRAC ER
2.1.4.1. In troduc tion
Iodinated tracers have spec ific  a c tiv it ie s  40-50 times greater than 
corresponding tritia ted  tracers. This, combined with high efficiency gamma 
counting, potentially allows fo r the development o f a more sensitive, rap id  and less 
costly R IA . The m ela ton in  molecule has been radioiodinated d ire c tly  (Vakkuri et 
al, 1984a) and successfully used in the developm ent o f a m ela ton in  R IA  w ith  
antiserum  raised according to the m ethod o f A rend t e t al, (1975). However, the 
R IA  o f Vakkuri and co-workers requires p rio r e x tra c tio n  o f m e la ton in  fro m  samples 
and u tilises  am monium sulphate precipitation o f the antibody-bound melatonin. 
Their s im p lifie d  method for the p roduction  o f rad io iod ina ted  m e la ton in  and its  
efficacy as tracer in our direct RIA was investigated.
2.1.4.2. M ateria ls
Assay solutions and methods fo r plasma co lle c tio n  were previously described 
in Section 2.1.2.2. except:
A saturated solution of ammonium sulphate was prepared in glass double- 
distilled w a te r and stored at room temperature.
Cellulose-coated donkey anti-sheep (DAS) second antiserum was suspended 
(1 g/20 ml) in phosphate buffered saline (0.15 M, pH 7.5) and stored at 4°C .
Tween 20 was stored at room tem pera tu re  and d ilu ted  w ith  T ric ine  b u ffe r
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p rio r to  assay according to requirem ents.
2.1.4.3. Methods
125a) P repara tion  o f I - m e la ton in
The method was slightly modified from that of Vakkuri et al, (1984a). lodo- 
Gen (1 pg in 10 pi chloroform) was added to an Eppendorf tube and the chloroform
was allowed to evaporate to dryness. Ten pg melatonin (1 g/L in 0.05 m ol/L
125 'sodium phosphate, pH 6.0) and 2 pi Na Ij(0.2 mCi) were added to the tube. A fter  
2 min, 100 pi chloroform were added, the mixture was vortexed and then stored 
overnight at 4°C . The ch lo ro fo rm  phase was subjected to th in  layer 
chromatography (TLC) using pre-washed silica gel plates with ethyl acetate as the
so lvent. The TLC  run was performed twice (2 x 13 cm) and the fra c tio n  conta in ing
125I -melatonin (R^, 0.54, Vakkuri et al, 1984a) was eluted with methanol and
stored at 4 °C . This stock solution of tra ce r was diluted w ith  T ric ine  b u ffe r prior 
to assay.
b) A n tise rum  t i t r e  and sensitivity
r 125 IA ntise rum  8483 was tested fo r its  ability to bind 11 -melatonin. Serial
dilutions of 8483 (200 pi) were set up in duplicate assay tubes containing 500 pi
0 123T ric ine  buffer. The tubes were incubated overnight at 4 C w ith  I -
m e la ton in  (100 p i; 4000 CRM). Two procedures were compared fo r  the separation 
o f bound and free  tracer (i) 500 pi o f dextran-coated charcoal was added and 
incubated fo r 15 min, 4°C  (ii)  saturated ammonium sulphate (800 pi) was added to 
p rovide 50% saturation in the assay tube.
F o llow ing  centrifugation at 1500 xg fo r 15 m in the supernatants were 
aspirated and the pe lle ts  were counted fo r 100s in a 12-channel gamma counter. 
The a b ility  o f unlabelled m e la ton in  to  displace the antibody-bound tra ce r was 
tested by the add ition  o f 100 pg m elaton in  to pa ra lle l series o f antiserum  d ilu tions.
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c) R IA procedure: comparison of three separation methods
Following evaluation of the antiserum titre  from dilution and displacement 
curves, three different precipitation methods were compared fo r  the separation o f 
bound and free tracer in the  R IA .
(i) D extran -coa ted  charcoal
Standards (2.5 - 250 pg/tube) prepared in buffer, or mid-afternoon human 
plasma were dispensed (200 pi) into assay tubes and made up to 500 pi with Tricine  
buffer. Antiserum 8485 (200 pi) was added at a final dilution of 1:4000. The 
method from that point was as previously described for antiserum titre  evaluation.
( ii) Am m onium  sulphate
Since am m onium  sulphate precipitates a ll plasma proteins,the standard curve 
(2.5 - 250 pg/tube) was prepared in b u ffe r only. An antiserum  d ilu tio n  o f 1:24000 
was used otherwise the method was as described in Section 2.1.4.3.(b).
( ii i)  Double-antibody p re c ip ita tio n  w ith  cellulose-coated DAS
Standards (2-40 pg/tube) were prepared in either 500 p i buffer, in b u ffe r 
conta in ing  100 pi or 200 p i o f mid-afternoon human plasma, or in 500 p i plasma. 
Antiserum 8483 (200 p i; 1:24000 fin a l dilution) was added and three dilutions o f 
tracer (4000, 5000 and 10000 CPM) were compared in the assay. A fter overnight 
incubation at 4°C  a series o f DAS and Tween wash combinations were tested fo r 
optimum assay performance. DAS (300, 400 or 600 pl/tube) was added and 
incubated for 30 min at 4°C  followed by a Tween (0.4%; 500 or 600 pi) wash for 10 
m in at room temperature. C e n tr ifu g a tio n  and counting were as previously 
described.
2.1.4.4. Results
TLC o f the ch lo ro fo rm  e x tra c t o f the iod ina tion  mixture gave three
rad ioa c tive  peaks (Fig. 2.6) o f which only one was im m unoreactive . The Rp value 
125 'o f the I ] -m e la ton in  peak was 0.53 and tha t o f m elaton in  was 0.34. The
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Fig. 2.6 TLC profile for purification of radioiodinated melatonin developed on
silica gel with ethyl acetate. The mobilities of standard melatonin (aMT) and
1 25iod inated tracer ( I-aM T) are shown.
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iod ina tion  e ff ic ie n c y  determ ined as the percentage incorporation of radioactivity  
compared to the to ta l was app rox im a te ly  75%. Results from  a blank run of 
Na (without melatonin) confirmed that the first peak was unreacted
Na > 2 5 ,^  .
As seen in F ig . 2.7 the  antiserum  titres and se ns itiv itie s  obta ined using
125 Ij -melatonin were quite different depending upon the separation method
used. D extran-coa ted  charcoal separation a llowed an optim um  assay s e n s itiv ity  for 
8485 at a final dilution of 1:6400 (compared to 1:24000 for -melatonin)
resulting in only 35% binding o f the radiolabel. Non-specific binding was 3% o f the 
ra d io a c tiv ity  added. Am m onium  sulphate p re c ip ita tio n  however, a llowed a much 
higher f in a l antiserum d ilu tio n  o f 1:25600 resu lting  in 50% sp ec ific  binding (non­
specific was 9.5%) and good displacement with 100 pg m e la ton in . The resu lting  
standard curve prepared in buffer using am monium sulphate separation (F ig. 2.8) 
ind ica ted  high se n s itiv ity  (<2 pg/tube) and was comparable w ith  the tritium  assay. 
C harcoal separation however (F ig. 2.9) produced insensitive  standard curves in both 
buffer and plasma w ith  a 15% reduction  o f binding in plasma, resu lting  in only 20% 
binding o f the tra c e r and a low l im it  o f detection (25 pg/tube).
A more spec ific  method o f separation (double-antibody) was considered a 
b e tte r choice fo r  binding methods in plasma and a summary o f the resu lts  obtained 
from standard curve assays w ith  double-antibody separation is given in Table 2.5. 
The m axim um  specific binding was very low  fo r a ll curves constructed and 
decreased with increasing plasma concentrations (19.5% - 7.0%) hence the 
antibody-bound CPM were too low (around 700). The m aximum se n s itiv ity  was 
2 pg/tube but th is  was reduced in the presence o f the increased concentrations of 
tracer or antiserum required to improve binding and increase CPM. Various 
concentra tions o f DAS and Tween wash were tested in an a tte m p t to improve 
spec ific  binding and to  decrease non-specific binding but these were not successful.
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Fig. 2.8 Melatonin standard curve in Tricine buffer with antiserum 8483 (1:24000
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Fig. 2.9 Melatonin standard curves in buffer and human plasma with antiserum 
8483 (1:6400 final dilution) and dextran-coated charcoal precipitation.
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2.1.4.5. Discussion
M ela ton in  was d ire c tly  iod inated using the m ethod o f Vakkuri e t al, (1984a) 
and antiserum dilution curves and melatonin standard curves were set up to 
investigate the feasibility of using the iodinated tracer in a direct RIA for plasma 
melatonin. Three separation procedures were investigated but the assay 
performance o f the iod inated tracer in plasma was poor in comparison w ith  a 
tritia ted  tracer. It is un like ly  th a t the radiolabel was contam ina ted  w ith  m ela ton in  
since a clear separation between labelled  and unlabelled melatonin was achieved.
The Rp results from the chromatogram were comparable with those reported by
125Vakkuri and co-workers and the incorporation o f [ IJ was high (75%). The 
difference in se n s itiv ity  and binding obtained using the various separation 
procedures suggests tha t the label was not av id ly  bound to  the antibody and was 
therefore susceptible to  d if fe re n t precipitation methods. I t  appears th a t the 
presence o f plasma prote ins in high concentrations in te rfe re d  w ith  the binding 
mechanism. A high concen tra tion  o f charcoal was required to m ain ta in  low non­
specific binding in plasma and th is  probably con tribu ted  to  s tripp ing  o f the weakly 
bound m e la ton in . The sensitive standard curve obtained w ith  ammonium sulphate 
precipitation would be o f practical use in de te rm ina tion  o f m elaton in  in plasma or 
serum e x tra c ts  according to the method o f Vakkuri et al, (1984a).
D ouble-antibody p re c ip ita tio n  is a spec ific  separation method which is less 
affected by serum and plasma than charcoal separation. However^ the low specific 
binding achieved with DAS was not encouraging for further developm ent o f a 
robust R IA . I t  is un like ly  th a t binding sites on the antiserum were already occupied 
w ith  endogenous m ela ton in  since a ff in ity  stripped (m ela ton in  free) 8483 did not 
improve the binding (not described). I t  is possible th a t the position o f iodine on the 
m ela ton in  m olecule prevented high a ff in ity  binding to  the active site  o f the 
antibody. I t  has been established by Vakkuri and co-workers, (1984b) th a t the 
iod inated p roduct is 2-iodomelatonin. Perhaps the size o f the m olecule in relation
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to the binding site is critica l and the introduction of a bulky iodine ^ ives  steric 
hinderance whereas t r i t iu m  conserves the structure. Since the structure o f the 
immunogen determines the specificity of the antibody, antisera raised using 
different conjugation procedures may be more receptive to the iodinated tracer. A 
direct RIA for melatonin in sheep plasma has been reported (Ravault, personal 
communication, 1987) using the iodination procedure described. The antiserum was 
raised against melatonin conjugated to a protein carrier via the Mannich reaction, 
(Brown et al, 1983) with the site of protein attachment being probably on the 2- 
position of the indole ring. This method offers assay sensitivity superior to other 
melatonin RIAs to date.
2.1.5. R IA  OF 6-SU LPH A TO XYM ELA TO N IN  IN  H U M A N  
PLASMA A N D  URINE
2.1.5.1. In troduc tion
Until recently long term clinical studies of pineal function were restricted  
because the sampling regimes necessary for the investigation o f melatonin 
secretion were unacceptable. Measurement o f the major urinary  metabolite of 
m e la ton in , aMT6s provides a non-invasive method for circadian and seasonal 
studies particularly in pediatric and psychiatric medicine. Previouslv only one 
quantitative study of aMT6s in man has been published. 
Fellenberg et al, (1980) described a GC-MS assay which required a large sample 
volum e and extensive sample p u r if ic a tio n . We have developed a sim ple RIA for the 
measurement of aMT6s in sm all volumes of human plasma and urine w ithou t prior 
extraction (Arendt et al, 1985). The synthesis of aMT6s (not commercially 
ava ilab le ) was required fo r  the preparation of the im m unogenic conjugates. 
Tritia ted  aMT6s was prepared according to the method described by Bojkowski, 
(1988). Extensive validation of the RIA including a good correlation with GC-MS  
de te rm ina tion  was reported by Bojkowski et al, (1987b).
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A sensitive, specific and reproducible RIA for aMT6s is described.
2.1.5.2. M a te ria ls
Ehrlich's reagent was prepared as a solution of 4-dimethylaminobenzaldehyde, 
10% in conc. H C l, diluted 1:5 with acetone before use.
Dimethylformamide was dried overnight with anhydrous sodium sulphate.
Krebs solution ( IL )  containing : NaCl (6.9 g), KCl (0.35 g), M gS0^.7H20
(0.29 g), NaHCO^ (2.1 g), CaCl^, 0.5 M (5 ml), KHgPO^ (0.16 g) and glucose (2.0 g) 
was oxygenated, 95% 02-5% CO2 and kept ice-cold until use.
A ll assay solutions were as described fo r the m ela ton in  RIA in Section
2.1.2.2.
The assay scintillation cocktail was Optiphase Safe.
2.1.5.3. Synthesis o f aMT6s
Fellenberg et al, (1980) o r ig in a lly  reported  the synthesis o f aMT6s from a 
procedure described by B a illie  e t al, (1975) fo r s tero id  sulphates. The method was 
based upon the reaction of sulphuric acid with an alcohol and 
d icyc lohexy lca rbod iim ide  (DCC) in a polar so lvent to produce sulphate esters. The 
molar ratios commonly used for the preparation of sulphates are alcohol-sulphuric 
acid, 1:1 and sulphuric acid-DCC, 2:5. If  the reaction temperature is kept as close 
to 0 ° C  as possible no major side reactions take place. A number of reactions with 
d if fe re n t m olar ra tios  were investiga ted  u n til the p repara tion  was successful and 
relatively free  from  side products. aMT6s was synthesised (F ig. 2.10) from  6- 
hydroxym ela ton in , a particularly lab ile  compound and therefore the reaction 
tem pera tu re  and pH required ca re fu l m on ito ring .
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F ig. 2.10 Synthesis o f 6-su lphatoxym eia ton in .
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(a) Method
6-Hydroxymelatonin (10.0 mg; 0.041 mmole) and DCC (75 mg; 0.36 mmole) 
were dissolved in 1.08 ml anhydrous dimethylformamide (DM F). The solution was 
mixed on ice in a 5 ml glass tube. A mixture of conc. sulphuric acid (35 pi) and 
DMF (600 pi) was cooled to ice bath temperature and 120 pi of this mixture was 
added dropwise slowly with the formation of a white precipitate. The mixture was 
continuously stirred on ice for one hour and was then treated with 75% aqueous 
ethanol (2 m l) and neutralised with 0.2 M KOH. A f te r  centrifugation (1500 x g, 30 
min) the supernatant was removed and the residue washed three times with aqueous 
ethanol (2 ml). The combined washings were added to the above supernatant and 
the mixture was taken to dryness in vacuo. The residue was chrom atographed on 
an 8 g column o f Sephadex LH -20 (I.D . 40 x 1 cm) w ith  an e lu ting  solvent o f 
methanol-chloroform 1:1, saturated with potassium ch lo ride  and 5 m l fra c tion s  
were collected. Fractions were taken to  dryness (37°C , N^) and resuspended in 
1.0 m l m e thano l-ch lo ro fo rm , 1:1. Twenty pi o f fractions 1-40 were subjected to 
TLC  using a s ilica  gel sheet (20 x 20 cm) w ith  chloroform-methanol, 9:1 as solvent. 
6-Hydroxy melatonin (1 m g /m l) was chromatographed fo r standard id e n tif ic a tio n  
and the presence o f indoles in each fra c tio n  was assessed by reaction w ith  E hrlich 's 
reagent.
(b) C hrom atograph ic analysis
Following TLC the fractions containing aMT6s and unreacted 6- 
hydroxymelatonin were identified by the typical blue coloured stain obtained with
the E hrlich 's -indo le  reaction. 6-Hydroxy melatonin (Rp, 0.5) and breakdown or side 
products (Rp's, 0.44, 0.35, 0.22, zero) were a ll e luted w ith in  the f ir s t  f ive  fra c tion s . 
The separation o f aMT6s (Rp, zero) was c le a rly  contained in fra c tion s  21-25 which 
were pooled and dried (37°C , N^). The product was taken up in methanol 
conta in ing  0.1% ascorbic acid and was analysed fu rth e r. The presence o f polar
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indo lic  contam inants  in the pooled e luate was investiga ted  using TLC  w ith  th ree  
solvent systems : cellulose, butanol-acetic acid-water (4:1:1.5); silica gel, 
isopropanol-5% ammonia (4:2) and silica gel, n-butanol saturated with water. If 
necessary, further purification of the product by TLC (n-butanol saturated with  
water) was performed. The Rp values obtained for the synthetic aMT6s are shown 
in Table 2.6 (with 6-hydroxymelatonin and melatonin for reference). The yield of 
aMT6s estimated by weight was approximately 40%" however some contamination 
with potassium chloride (10%) was evident from potassium ion analysis. 
Q u a lita tive  GC-MS o f the product according to  the method o f Fe llenberg e t al, 
(1980) was performed by Dr. G. King, Queen Charlottes M aternity Hospital, 
London. The method required derivatization o f the compound w ith  
pentafluoropropionic (PFP) anhydride. This reac tion  u n fo rtu na te ly  resu lts in the 
loss o f the sulphate group and the re fo re  6-hydroxymelatonin-PFP is measured. 
The spectra  obta ined compared very w e ll (see F ig . 2.11) w ith  the published spectra  
o f Fe llenberg et al, (1980).
The so lu tion  o f aMT6s in m ethanol w ith  0.1% ascorbic acid was stored at - 
20°C . Under these conditions aMT6s was stable fo r at least 2 years as assessed by 
TLC.
: 3
2.1.5.4. P repara tion  o f [ H | -aMT6s
A series o f preliminary a ttem p ts  to produce rad io labe lled  aMT6s were 
unsuccessful. Inco rpo ra tion  o f 5 via rad io labe lled  su lphuric acid in the synthesis 
o f aMT6s from  6-hydroxym e la ton in , resulted in a large number o f side products and 
an unstable tracer. A h is tid ine  bridge attached to  aMT6s via the Mannich reac tion  
(Section 2.1.5.5.) was iod inated using e ithe r lactoperoxidase/hydrogen peroxide or 
lodo-Gen as oxid is ing agents. The resu lting  radiolabels did not bind to the
antiserum . R at urine was co llec ted  fo llow ing  administration i.p. o f 200 pC i
i  3,H J -m e la ton in  and 50 mg benserazide (to suppress endogenous m e la ton in
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Solvent system
Rp values 
aMT6s aMT6H aMT
C h lo ro fo rm  : m ethanol 
9:1 (silica gel)
Isopropanol : 5% am monia 
4:2 (s ilica  gel)
Butanol : a ce tic  acid : w a te r 
4:1:1.5 (cellu lose)
n-butano l sat. w a te r 
(s ilica  gel)
0.72
0.46
0.25
0.50
0.79
0.80
0.70
0.60
0.83
0.93
Table 2.6 TLC of 6-sulphatoxymeiatonin (aMT6s), 6-hydroxymelatonin
(aMT6H) and m elaton in  (aMT): Rp values using d if fe re n t so lvent systems.
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Fig. 2.11 Mass spectra of PFP-derivatised aMT6s (6-hydroxymelatonin-PFP). (A) 
shows the spectra obtained from aMT6s synthesised in our labora to ry  according to
the method described in Section 2.1.5.3. (B) shows the published spectra of 6- 
hydroxym ela ton in -P FP  (Fe llenberg et al, 1980).
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T
secre tion ) and the H -aMT6s excre ted  was e x tra c te d  and p u rifie d  but binding
to the antisera was poor and non-displaceable.
3 '' 3 1-aMT6s was however successfully prepared from i H j -melatonin
(Bojkowski, 1988) using rat liver slices in v itro .
(a) Method
Fem ale W istar ra ts  (150-200 g) were used. Phénobarb ita l (0.1%, w /v ) was 
added to the drinking water for seven days to induce liver enzymes. On the 
seventh daw animals were killed by cervical dislocation and the liver was rapidly 
removed and placed in ice-cold Krebs solution. Liver lobe ends were removed and 
cut into slices (<1 mm). Liver slices (1.4 g) were incubated with 250 pCi i^ H  - 
melatonin (38.6 C i/m m ol) in 4 ml RPMI-1640 containing niacinamide (1 mg/ml), 
glutathione (1 m g/m l), N ADPH (0.5 m g /m l) and magnesium ch lo ride  (0.5 m g/m l) at 
37°C under 95% 0^-5%  COg, for 2 h w ith  gentle  shaking. The incubate was cooled 
and homogenised w ith  3 x 3 m l m ethanol using a hand-held glass homogeniser. 
A f te r  ce n trifu g a tio n  (1500 x g, 15 m in) the pooled supernatants were dried under 
N^, 37°C . The residue was taken up in 600 pi ch lo ro fo rm -m e thano l (1:1) and 
p u rified  on an LH -20 colum n as described in Section 2.1.5.3. One hundred, 2 ml 
fra c tion s  were co llec ted  and 10 pi o f each fra c tio n  were counted in 4.5 ml 
Optiphase Safe for 30 s.
(b) C hrom atograph ic analysis
The LH-20 colum n p ro file  fo r  p u r if ic a tio n  of the crude e x tra c t showed three 
peaks (F ig. 2.12). M id-peak fra c tion s  were subjected to TLC  using a cellulose plate 
and butanol-acetic a c id -w a te r (4:1:1.5). The th ird  peak corresponded to aMT6s (Rp 
= 0.46), the first peak was melatonin (Rp = 0.93) and the middle peak was probably 
6-hydroxymelatonin g lucuronide (Rp = 0.43), present in an unusually large amount
i 3 1
probably due to phénobarb ita l induction  o f ra t liv e r enzymes. The l HJ -aMT6s
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' 3Fig. 2.12 LH-20 column profile for purification of _ H j -alviT6s from a crude 
liver homogenate extract. Fractions in peaks 1 and 3 correspond to melatonin 
(aMT) and aMT6s respectively, fractions in peak 2 are probably 6-hydroxymelatonin 
glucuronide (aMT6G).
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fractions (44-64) were pooled and dried and stored in methanol containing 0.1%  
ascorbic acid. Chromatography of the purified product showed one peak (Fig. 2.13) 
identical to chemically synthesized aMT6s. The product was stable for at least 8
months when stored at -20°C .
2.1.5.5. P roduction  o f antisera
aMT6s was conjugated to an immunogenic protein via the Mannich 
(formaldehyde) reaction. The method has been shown to stimulate specific 
antisera: the site of conjugation to protein and the structure of the bridging
m a te ria l are po ten t determinants o f specificity o f the resulting antisera. Cross- 
reactiv ity  studies have indicated that the Mannich reaction w ill couple melatonin 
to the protein on the carbon-2 position of the indole ring (Brown et al, 1983). 
F ig . 2.14 shows the probable re a c tion  o f aMT6s w ith  form aldehyde and protein.
Method
4 mg o f aMT6s (12 pm ole) in 2.0 m l H2O was added to  55 mg ovalbum in 
(1.2 pmole) in a solution of 3 ml 2 ml of formaldehyde (7.5%) and 2 ml of
sodium aceta te  (3 M). The reaction m ix tu re  was s tirre d  at 4°C  fo r 4 h and pH was 
adjusted to 6.2 with g la c ia l ace tic  acid. P ro te in  bound and unbound aMT6s and 
form aldehyde were separated by dialysis. The fin a l concen tra tion  o f unbound 
aMT6s in the dialysate was determined as 1 pg/m l (1 m g/L) against a standard 
curve of aMT6s (10 pg/mg - 100 ng/ml) using fluorescence specrophotometry with 
an a c tiva tio n  w avelength o f 305 nm and an emission wavelength of 340 nm. 
A pp rox im a te ly  3 mg o f aMT6s was coupled to 55 mg ovalbum in provid ing  a m olar 
ra tio  o f aMT6s to p ro te in  o f 6:1. I t  should be stressed th a t the chemical synthesis 
o f aMT6s did not result in a com p le te ly  pure c rys ta llin e  product and the re fo re  the 
w e ight o f aMT6s and the ca lcu la ted  m olar ratio may have been overestimated. 
However a low  m olar ra t io  (<20:1) genera lly resu lts in a good immune response 
(Aherne, personal com m unication).
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Fig. 2.13 TLC tritium  profile for H j -aMT6s (Rp = 0.46) developed on
cellulose with butanol - acetic acid - water (4:1:1.5).
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Fig. 2.14 Model reaction of aMT6s with formaldehyde and an immunogenic 
protein (Mannich reaction). From Brown et al, (1983).
Ill
Six Suffolk Cross ewes were immunised with 500 pg conjugate emulsified in 
3 ml Freund's adjuvant: saline (2:1) by s.c. injection at six sites on the back and
X 1
legs. Seven months later, 9 days after boosting with 200 pg conjugate H_ - 
aMT6s-binding antibodies were detected in all six sheep by RIA.
Antiserum 1118 proved to be the most sensitive and was further 
characterised for specificity (Arendt et al, 1985). 6-Hydroxymelatonin and 
melatonin were found to  be weak cross-reactants and cross-reactivity w ith  tw enty- 
one d ifferent indoles, catecholamine metabolites and steroids was negligible.
2.1.5.6. RIA procedure
The assay procedure was based on the method of Fraser et al, (1983a) for 
determination o f melatonin in human plasma, detailed in Section 2.1.3.
Plasma and urine pools fo r standard curve p repara tion  were co llec ted  from  
norm al vo lunteers, in the mid-afternoon. aM T6s-free plasma and urine were 
prepared by charcoal stripp ing . D efined dextran-coated charcoal was incubated 
(10% w /v, overn igh t, 4°C ) w ith  e ith e r pooled heparin ized plasma or pooled urine. 
The charcoal was separated by centrifugation (2000 x g, 30 m in) fo llow ed by 
f i lt ra t io n .
C on tro l samples were plasma and urine pools conta in ing  high, medium and 
low levels of endogenous aMT6s, stored in 500 pi aliquots at -20°C .
The aMT6s standard was quan tita ted  by a com parison o f its  displacem ent in
7 1
the RIA with H i -aMT6s of known specific activ ity  (Bojkowski, 1988). Two
^ 3 1  3batches o f [ H j -aMT6s prepared from  : H : - m ela ton in  batches o f d iffe re n t
specific activity gave identical results. Aliquots of the standard aMT6s solution
(48 pg/ml) were d ilu ted  1:400 w ith  T ric ine  b u ffe r to provide a f in a l concen tra tion
o f 280 ng /m l and were stored at -20°C .
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(a) Plasma alvlT6s RIA
Duplicate tubes were set up for all samples, standards, to tal and non-specific 
binding determinations. 200 pi of each sample or standard (2.5, 5, 10, 20, 40, 70, 
140, 280 pg/tube) were dispensed into assay tubes and the volume was made up to 
500 pi with buffer. 200 pi of antiserum 1118 (1:1000 final dilution) was added and 
after incubation (room temperature, 30 min), 100 pi  ^ -aMT6s (4000 CPM) was 
added and the assay was further incubated at 37°C , 20 min, followed by 4 °C , 90 
min. The antibody-bound aMT6s was separated from the free aMT6s by incubation 
fo r 15 min, 4°C , with 100 pi dextran-coated charcoa l and centrifugation (2000 xg, 
15 min, 4°C ). The supernatant (500 m l) was counted in 4.0 m l Optiphase Safe and 
the results were determined from a smoothed spline p lo t o f the standard curve 
(LKB package).
(b) Urine aMT6s RIA
The procedure described fo r the assay of plasma samples was used except 
that urine samples were diluted 1:50 (or 1:100 for some subjects) with buffer prior 
to assay. Charcoal stripped aMT6s-free urine was diluted accordingly for 
preparation of standards.
2.1.5.7. Results : assay performance
The mean and SD fo r each point (2.5 - 280 pg/tube, plasma; 2.5-200 pg/tube,
urine) o f 6 standard curves were assessed (F ig. 2.15). The mean overa ll coefficient 
o f va ria tio n  was 4.7% (plasma) and 5.9% (urine). In ter- and intraassay coefficients 
o f variation fo r urine and plasma control samples are shown in Table 2.7. The 
s e n s itiv ity  o f the assay, defined as the least amount o f aMT6s distinguishable from  
zero a t the 95% confidence l im it  was 2.6 pg/tube equ iva lent to  14 pg /m l plasma or 
0.65 ng /m l urine. Non-specific binding was less than 3% and m axim um  binding was 
52.4% + 2.6 (mean + SD) fo r urine and plasma assays.
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Fig. 2.15 Composite aMT6s stanciard curves (+ SD) in (A) charcoal-stripped urine 
1/50 (n = 6) and in (B) charcoal-stripped plasma (n = 6).
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Interassay
Plasma Urine
Intraassay
QC 1 QC 2 QC 3 QC 1 QC 2 QC 3
Mean pg/tube 8 28 74 10 48 113
CV% 3.5 3.3 3.4 6.5 3.3 4.1
n 5 5 5 5 5 5
Mean pg/tube 40 60 14 32 83
CV% 8.8 10.6 14.7 9.9 12.9
n 8 8 10 10 10
The lim it of detection is 2.6 pg aMT6s/tube = 13 pg/ml plasma
= 0.65 ng/ml urine
Added Recovery
Recoveries of added 18.7 - 238 pg/ml 83 - 120% (plasma)
aMT6s 2.2 - 31 ng/ml 83 - 122% (urine)
Table 2.7 RIA of aMT6s : assay performance data.
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2.1.5.8. Discussion
A simple, sensitive and precise RIA is described for the measurement of 
aMT6s in plasma and urine. Extensive validation of the method (Arendt et al, 1985;
Bojkowski e t al, 1987b) included GC-MS and TLC  comparisons, plasma and urine 
parallelism w ith  the standard curves and comparisons o f R IA  performance using 
aMT6s preparations synthesised in other laboratories. The assay is accurate and 
sensitive to physiological levels of aMT6s and is particularly valuable, since the
high s p e c ific ity  o f antiserum 1118 p e rm its  d ire c t aMT6s measurement in sm all 
volumes of plasma and urine without prior sample extraction. To d a t^ a ll assays
fo r  u rinary melatonin have required an e x tra c tio n  procedure. The present assay fo r 
aMT6s is more reproducib le  and less tim e  consuming than methods fo r melatonin 
de te rm ina tio n  and is more cost effective than GC-MS methods fo r aMT6s and 6- 
hydroxy m e la ton in .
This R IA  o ffe rs  a unique opportunity to  study changes in u rinary  aMT6s 
excretion over long periods o f t im e . Since both plasma and urine aMT6s levels 
have been shown to  s ig n ific a n tly  correlate w ith  plasma m ela ton in  (A rend t e t al, 
1985), the measurem ent o f aMT6s may provide a good m arker o f the m ela ton in  
rhy thm  and total 24-hour secretion in many cases where plasma sampling is not 
possible (children, psych ia tric  pa tien ts) and in cases where saliva collection is 
d ifficu lt (patients receiving antidepressant drug therapy). The assay described is 
the first published method for aMT6s determination in plasma and provides a tool 
fo r  the basic investiga tion  o f m ela ton in  metabolism in man. Consequently a 
properly validated aMT6s assay fo r  o ther species w ill be o f b en e fit to  p ineal 
research.
Recentlv the assay has been improved by the introduction of an iodinated 
tracer (Aldhous and Arendt, 1988). aMT6s has been iod inated directly according to 
the method o f Vakkuri e t al, (1984a) and the assay achieves a sensitivity of 
1 pg /tube  w ith  a higher antiserum  t i t r e  (1118, 1:80000 fin a l d ilu tion ). The method 
o f Aldhous and A rend t is less expensive in tim e  and reagents compared to the 
t r it iu m  R IA  described here.
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2.2. g-A DRENERG IC  B INDING  METHODS IN  MEMBRANE
PREPARATIONS FRO M  R AT BRAIN A N D  PINEA L G LAND
2.2.1. CHEM ICALS REAGENTS A N D  EQ U IPN EN T
A. B u ffe r components and o the r chem icals
T ris -H C l
EDTA
F o lin -C ioca lte u  reagent 
Coomassie Brilliant Blue G-250
d i-p roprano lo l
Sodium /potassium  ta r tra te  
Copper sulphate. 5H _0  
Sodium carbonate 
Sodium hydroxide 
Magnesium chloride. 6H2O
Suppliers
SIGMA Chemical Co. L td ., 
Fancy Road, Poole, Dorset.
BDH Chem icals Ltd., Poole, 
D orset.
B.
C.
D.
E.
Radioligands 
' 3.H DMA 60 Cl/m m ol
90 C i/m m o l
Equipm ent 
F ilt ra t io n  manifold
Whatman GF/B glass fibre filters
P o ly tron  type PT 10
M icrotiter plates ( f la t  
bottom ed, untrea ted)
S c in tilla tio n  counting
Unisolve E
In te rn a tion a l standard (^H -G ) 
capsules (LKB)
C om puter Program m e
'ENZPACK'
Am ersham  In te rna tiona l p ic .. 
W hite L ion  Road, Amersham, 
Bucks.
M illipore (U .K .) Ltd., 
Millipore House, Abbey Road, 
London NWIO.
Whatman International L td ., 
Maidstone, Kent.
Northern Media Supply Ltd., 
New Port Road, Brough,
N. Humberside.
Dynatech Laboratories, 
Billinghurst, Sussex.
K och -L ig h t L td ., H ave rh ill, 
Suffolk.
Pharm acia (G reat B rita in ) 
Ltd., Milton Keynes, Bucks.
Elsevier-BIOSOFT, 68 Hills 
Road, Cambridge.
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2.2.2. MEASUREh4ENT -DM A B IN D IN G
2.2.2.1. In troduc tion
The current availability of high specific radioactivity preparations of 
-D H A  (maximum 120 C i/m m ol) combined with extensive documentation of
3
binding characteristics made -DH A the radioligand of choice for binding
studies in rat cortex and pineal preparations. _ HJ -D H A  binding was performed
by the methods of Bylund and Snyder, (1976) in cortex and Greenberg and Weiss,
/ \
(1978) in pineal homogenates ( with some modifications^ Many researchers
confronting the problems of performing binding experiments w ith  very small
quantities o f tissue, such as the ra t pineal, have chosen only one ligand
concentration fo r the assay o f membrane preparations derived fro m  at least two
pineals. To obta in  meaningful binding data from  the m inim um  number o f pineals
possible, tw o  ligand concentrations per homogenate o f tw o pineals were chosen fo r
routine experiments (described later in Chapter 5). Pineal HJ -D H A  binding as
a function o f increasing concentrations of ligand was evaluated in an homogenate
o f six pineals.
A D ire c t Linear Plot o f the data (E isenthal and Cornish Bowden, 1974) was 
performed and was compared with the Scatchard linear transformation (Scatchard, 
1949) in order to calculate the density of the specific binding sites (B ) and the 
apparent dissociation constant (K ^).
2.2.2.2. Materials
(a) Buffers and reagents
Assay buffer was T ris -H C l 50 mM, pH 8.0 containing 3 mM MgCl^ and 1 mM
E D TA . B u ffe r was prepared fresh ly  each day and kept on ice. d l-P roprano lo l 
(0.1 m g/m l) was prepared p rio r to  use in assay b u ffe r.
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H -D H A  (60 & 90 C i/m m oi) was stored at -20°C  and diluted in assay 
buffer prior to use.
Copper ta rtra te  reagent was 1 litre  of 2% Na^CO? mixed with 20 ml 0.5%  
Cu50^.5H2O in 1% N a/K  ta rtra te .
Folin - Ciocalteu phenol reagent was diluted 1:1 before use.
'Bradfords' reagent was prepared by dissolving Coomassie B rilliant Blue G-250 
(100 mg) in 50 ml, 95% ethanol. To this solution 100 ml, 85% (w /v) phosphoric acid
was added. The resu lting  solution was d ilu ted  to a f in a l volume o f 1 l i t r e  and was 
filtered before storage at room tem pera tu re .
(b) Animals and tissue collection
A d u lt male W is ta r/a lb ino  ra ts  weighing between 200 and 250 g were housed in 
a temperature controlled room (21-23°C ) with a regular 12 h light: 12 h dark cycle
(ligh ts  on 0700 h and o f f  at 1900 h da ily). Rats were k ille d  during the light phase 
(0900 h -1100 h) and fo llo w in g  decapitation^ the brains and pineals were rap id ly  
rem oved. The cerebra l co rtices  were dissected and e ith e r chilled in ice-cold assay 
b u ffe r before hom ogenisation or were wrapped in p a ra film  and frozen in liquid 
n itrogen  before storage at -80°C . Frozen pineals were stored in the same way, and 
for studies in fresh tissue pineals were placed with a drop of ice-cold buffer into ay
cooled p la s tic  tube.
2.2.2.3. L^ HJ -D H A  binding assays
(a) Cortex assay
The cerebra l co rtices  from  one anim al were weighed (around 400 mg each) 
and homogenised in ice -co ld  b u ffe r (36 ml) using a P o ly tron  (se tting  6,20 s) and 
ce n trifu g ed  at 48000 x g fo r 15 m in. The pe lle t was rehomogenised (se tting  6, 10 s) 
in the same volume o f b u ffe r and cen trifuged  as before . The p e lle t was f in a lly  
resuspended (se tting  6,10 s) in 40 volumes o f b u ffe r per o rig ina l w et w eight o f
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tissue.
Samples of the above homogenate (200 pi) were incubated for 1 h at room 
tem perature in a final volume of 500 pi buffer with various concentrations (0.25,
0.5, 1, 3 and 5 nM) of -DH A (60 C i/m m ol). A schematic diagram of the
assay is presented in Table 2.8. The extent of non-specifically bound HJ -D H A  
was estimated from parallel assay tubes which contained a large excess (20 pM) of 
dl-propranolol. A ll assays were conducted in t r ip lic a te  in plastic LP3 tubes. The 
incubation  was te rm ina ted  by the add ition  o f 1.5 m l ice-cold b u ffe r and rapid 
f ilte r in g  o f the reaction  m ix tu res  under reduced pressure through pre-wetted  
Whatman G F/B glass fib re  filters. The filters were rinsed five  tim es in quick 
succession w ith  4 ml o f ice -co ld  T ris b u ffe r and placed in p las tic  scintillation vials 
w ith  5 m l Unisolve E. The via ls were mechanically shaken fo r 1 h and the 
ra d io a c tiv ity  counted fo r 5 m in per tube. F ilte r  binding was determ ined as the
3
amount o f Hj -D H A  bound by the f i l t e r  in the absence o f tissue. The efficiency  
o f counting (36.6%) was m onitored w ith  an in te rna l standard capsule conta in ing  a 
t r it ia te d  solid s ta te  organic compound o f known DPM (177800 DPM at tim e  o f use). 
S pecific  binding was determ ined as the d iffe re n ce  between to ta l and non-specific  
b inding. Two methods o f binding analysis were compared; a line o f best f i t  was 
obtained (com puter program m e 'L IN E F IT ') subsequent to Scatchard analysis o f the 
data and a D ire c t L inear Plot o f the data was ca lcu la ted  from  a com puter 
programme 'ENZPACK'.
The binding p roperties o f membrane preparations from  frozen and fresh 
co rtices  were compared and the lability o f the recep to r binding sites was
3 I
investigated by determination of  ^ HJ -D H A  binding (2 nM) a fte r 1, 2 and 3 h
storage o f the homogenate (at 4°C ). Three assay incubation  cond itions were 
compared : 15 min, 23°C (Bylund and Snyder, 1976); 10 m in, 37°C  (A lexander et al, 
1975) and 1 h, room tem pera tu re  (chosen to p e rm it m u ltip le  assays w ith  staggered 
s ta rtin g  tim es). The e ffe c t o f d if fe re n t volumes o f b u ffe r washes upon non-
120
Tubes
Reagents
Total
binding
Non-specific
binding
-DHA^
dl-propranoloT
B u ffe r
Honnogenate
B u ffe r (ice-cold)
S c in tilla tio n
fluid
100 pi
200 pi 
200 pi
100 pi 
30 pi 
170 pi 
200 pi
INCUBATE : 1 h, room  tem p.
1 .5  ml 1.5 m l
FILTER IM M ED IA TELY
WASH FILTERS : 5 x 4 ml buffer
5 ml 5 ml
SHAKE : 1 h
COUNT FOR R A D IO A C TIV ITY
1. [ H j -D H A  was diluted in assay buffer to provide final concentrations of 0.25, 
0.5, 1, 2, 3 and 5 nM/assay tube.
2. d l-p roprano lo l (0.1 m g/m l) was 20 pM/assay tube.
' 3 1Table 2.8 Scheme of the H | -D H A  binding in rat cortex 
membrane preparations.
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specific and specific binding was determined using 3,4,5 and 6 x 4 ml washes at the
f i l te r in g  stage.
Protein concentration was determined by the method of Lowry et al, (1951). 
A schematic representation of the method is shown in Table 2.9. Bovine serum 
albumin (BSA) was chosen as a standard and the absorbance of blanks, standard and 
sample reaction solutions was read at 700 nm using a Cecil spectrophotometer.
(b) Pineal assay
3
A higher specific activ ity  preparation of -D H A  (90 C i/m m ol) was
obtained to provide an optimum measure of specific binding in the small quantities 
o f pineal membranes availab le .
Single pineals were homogenised in 1 ml ice-cold buffer, using five  pestle
passes in a glass homogeniser. A f te r  rem oval o f 115 pi fo r m ela ton in
de te rm ina tion  the homogenates from  two pineals were pooled and cen trifuged
along with 4 x 1 ml buffer washes (48000 x g, 15 min). The resulting pellet was
 ^3resuspended in 1300 pi of buffer. Ten 100 pi aliquots were used for ' H -DH A  
binding while 2 aliquots o f 100 pi were removed fo r protein de te rm ina tion . Each 
100 p i aliquot represented approx im ate ly  l /7 th  pineal.
Samples o f the membrane homogenates (100 pi) were incubated fo r 10 min,
; _  j
37°C  in a f in a l volume o f 500 pi buffer conta in ing  100 p i ■ H I -DH A. In rou tine  
binding assay^ligand concentra tions o f 2 and 8 nM were used. Non-specific binding 
was determined by the addition of 20 pM dl-propranolol to parallel assay tubes. To
provide s u ff ic ie n t tissue, groups o f 3 total but only 2 non-specific binding 
determinations were used at each ligand concen tra tion . The separation o f bound 
and free  ligand and counting o f radioactivity was as described fo r the co rtex 
assay.
For sa tu ra tion  binding analysi^ pineal glands from  6 ra ts  were pooled and the 
entire homogenate was washed (5 m l ice-cold bu ffe r), cen trifuged  as above and
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REAGENTS BLANK STANDARDS HOMOGENATE
Homogenate
T risb u ffe r
BSA soin. (0.5 m g /m l)
W ater
MNaOH
100 pi 
50-300 pi
400 pi 
500 pi
100 pi
adjust to  400 p i 
500 pi
100 pi
400 pi 
500 pi
INCUBATE : 37"'C, 15 min. 
ALLOW TO COOL
Copper ta r tra te  
Soin. 5.0 ml 5.0 ml 5.0 ml
M IX and LEAVE:
10 min., room tem p.
F o lin -C ioca lte u  
Phenol Reagent
500 pi 500 pi 500 pi
M IX , LEAVE for 30 min.
read at 700 nm
Table 2.9 Scheme for the de te rm ina tion  o f p ro te in  (Low ry et al, 1951)
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resuspended in 3.6 ml buffer. 100 pi aliquots of tissue homogenate were added to 
incubation tubes containing different concentrations of H | -D H A  (0.5, 1, 2, 4, 8, 
16 nM) and buffer up to a final volume of 500 pi. Non-specific determinations and 
incubation, filtra tio n  and counting procedures were as above.
3
The e ffec t of freezing and thawing upon pineal H -D H A  binding 
parameters was investigated in groups of fresh pineals (n=8) and frozen pineals 
(n=8). A ll the pineals were removed from animals killed at the same tim e.
The Low ry  method o f protein determination was considered to be insensitive 
fo r accurate measurement o f p ro te in  in d ilu te  p ineal homogenates. Therefo re  an 
alternative method (Bradford, 1976), involving direct binding of Coomassie Brilliant 
Blue G-250 to protein was tested and modified for small volumes. 50 pi of sample 
or standard (1-10 pg BSA) were incubated (room temperature, 5 m in) in wells 
(300 p i size) o f polystyrene m ic ro t ite r  plates w ith  250 pi Bradford  reagent. The 
absorbance was determ ined at 570 nm using a M icroe lisa  au tom a tic  p la te  recorder 
and was p lo tte d  against standard concentrations. Unfortunately, this sim ple method 
was subject to  assay d r i f t  and not s u ff ic ie n tly  reproducib le  fo r the required  precise 
de te rm ina tion  o f p ineal p ro te in . Therefore  binding data was calculated and 
expressed per pineal gland.
2.2.2.4. Results
(a) _^H ! -D H A  binding to cortex
Storage experim ents using fresh co rtex prepara tions (stored on ice) revealed
' 3that the specific binding of _ H j -D H A  (2 nM) was decreased slightly (to 70% 
specific binding) 3 hours a fte r initially homogenising the tissue, in comparison to 1
and 2 hours post hom ogenisation (74% and 75% spec ific  binding respective ly). Non­
spec ific  binding was not a ffe c ted  by storage at 4°C  but was increased markedly 
(50% o f to ta l b inding) when homogenates were frozen  (-80°C ), thawed and re ­
assayed. Three d if fe re n t incubation conditions a ll y ie lded an equivalent leve l o f
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specific binding, (73-76% at 2 nM ligand concentration) and consequently an assay 
incubation of 1 hour room temperature was chosen for routine binding assays in 
cortex tissue.
The optimum number of filte r  washes required to produce a constant level of 
specific binding with the maximum reduction in non-specific binding was 5 (5 x 
4 ml). F ilte r binding was always less than 0.5% of the radioactivity in the assay 
tube or 10-16% of total binding. Therefore,about 50-60% of non-specific binding 
comprised o f rad io labe l s tick ing  to  the f ilte rs .  The f i l te r  and non-spec ific  bindings 
were not reduced significantly when filters with a looser matrix (Whatman G F/C), 
commonly used in binding studies, were compared with the filters  (GF/B) used in 
the present method.
3A saturation curve showing H ; -D H A binding as a func tion  o f 
concen tra tion  is presented in F ig . 2.16.A . The d ire c t p lo t o f the data illustrates 
to ta l binding, non-spec ific  binding (in the presence o f 20 pM d l-p roprano lo l) and 
specific binding. S atu ra tion  o f co rtex  binding sites was dem onstrated a t about
9 nM with half-m axim al binding at 1 nM. As expected, non-specific binding was
r 3 "
not saturable and showed a linear increase w ith  increasing H j -D H A  
concentration. The linear Scatchard p lo t (F ig. 2.16.B.) ind icated a single binding
component with a calculated Kr-. (1/slope) of 0.91 nM and B (amount of ^H-Lj max
DHA bound at saturation) of 178 fmol/mg protein. A comparison with the
alternative D irect Linear Plot (Fig. 2.16.C.) provided data in close agreement (K ^ ,
0.90 and B , 177 fmol/mg protein), max ^
The means + SEM from four similar experiments comparing fresh and frozen
co rtices  are shown in Table 2.10.A. There was c le a rly  no change in measured 
and no loss o f binding following freez ing  and thaw ing (once) o f tissue p rio r to  assay. 
However the values obtained from  frozen tissues dem onstrated a higher v a r ia b ility . 
The resu lts  were processed using a D irect L inear P lo t.
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A.
CORTEX
^ D Bmax
(nM) (fm ol/m g protein)
Fresh tissue 0.83 (+ 0.025) 143 (+ 8.4)
Frozen tissue 0.87 (+ 0.048) 174 (+ 12.7)
B.
PINEAL ( n =
^ D Bmax
(nM) (fmol/pineal)
Fresh tissue 2.2 (+ 0.45) 68 (+ 5.8)
Frozen tissue 2.3 (+ 0.44) 61 (+ 12.1)
: ^
Table 2.10 Comparison of L H j -D H A  binding characteristics (using the D irect 
Linear Plot analysis of data) in membranes prepared from fresh and frozen tissues. 
A. Binding assays in cerebral c o rtic a l preparations were perform ed w ith  increasing
'"3 1concentrations of H j -D H A  (0.25, 0.5, 1, 3, 5 nM). B. Binding assays in pineal
' 3homogenates were performed using 2 concentrations of  ^ HJ -D H A  (2 and 8 nM).
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(b) -D H A  binding to  pineal glands
Examination of Fig. 2.17.A. indicates that the specific binding of ^H - 
DHA to pineal membranes was saturable at about 16 nivi, corresponding to 1400 
CPM/assay tube. The CPM obtained were highly reproducible at each ligand
concen tra tion . One-half m axim al binding occurred at app rox im a te ly  2.75 nM 
providing 75% specific binding (non-specific 25%). The non-specific binding rose to
50% o f the to ta l binding at sa tu ra ting  concentrations o f radioligand, thus
3
preventing accurate quantitative analysis at high _ H_ -D H A  levels. The
Scatchard p lo t (F ig. 2.17.B) o f the ind iv idua l data points was linear and ind ica ted  a
Kr-\ of 2.6 nM and B of 81 fm ol/pineal gland. The D irect Linear Plot (Fig. U max  ^ ^
2.17.C) provided a slightly lower of 2.4 nM and a comparable of
80 fm o l/p in e a l, which upon inspection corresponded to the in te rsec tion  o f binding
' 3 1at 2 nM and 8 nM ligand concentra tions. There fo re  l HJ -D H A  concentra tions o f 
2 nM and 8 nlv| (equivalent to approximately and 4K ^) were chosen for routine
binding studies.
Binding data (mean + SEM) from frozen (n=4 assays) and fresh (n=4 assays)
tissue comparisons are shown in Table 2.10.B. and B values wereD max
ex trapo la ted  from  spec ific  binding obta ined at just two concentra tions and 
the re fo re  were subject to g rea te r e rro r and higher v a r ia b ility . There was no 
d iffe re n ce  between the means o f each group, however the SEM's were again la rger 
in studies w ith  frozen tissue.
2.2.2.5. Discussion
3H DHA binding methods were used to  label 3-adrenergic receptor sites
3
in ra t b ra in  and pineal tissue. Specific H j -D H A  binding in the ra t co rtex  was 
saturab le  at approximately 9 nM and was displaced by the 3-antagonist propranolol. 
Analysis of the data indicated a single class of high a ffin ity  binding sites with
observations o f (0.90 nM) and B ^ ^ ^  (177 fm o l/m g  pro te in ), in agreem ent w ith
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previous reports (Bylund and Snyder 1976, Banerjee et ai, 1977). Noradrenaline 
and adrenaline have been shown to possess similar a ff in it ie s  fo r -D H A
binding sites in the cerebral cortex (Bylund and Snyder, 1976), suggesting that the 
receptors labelled, are of the 6^-subtype. Furthermore salbutamol and terbutaline,
both o f which are se lective  6_-agonists have low  a ff in it ie s  fo r the binding sites 
(C u llum  et al, 1969). ^H^ -D H A  binding in the p ineal reached sa tu ra tion  at about
16 nM and this finding compared well v/ith observations by Greenberg and Weiss,
(1978) and Friedman and Yocca, (1981). Kr^ and B values were similar to those’ D max
reported by Skene, (1985).However there were clear discrepancies in Kj^'s obtained 
from the present study (2.5 nM) and those of earlier studies (around 5 nM). A major
3
difference was the h igher H -D H A  and tissue concentra tions used in some
3
former procedures. Negative cooperative effects between H j -D H A  binding
sites have been reported in red blood ce ll membranes w ith in  higher concen tra tion  
ranges studied (Limbird and Lefkow itz, 1976) and this may account for the lower
a ff in it ie s  previously reported. The cu rren t availability o f high spec ific  
ra d io a c tiv ity  ligands has p e rm itte d  binding studies in pineal preparations w ith  
low er concentra tions o f tissue and ligand thereby m a in ta in ing  low  non-specific  
binding and p rovid ing  more meaningful data. Bylund and Snyder, (1976) reported
' 3 '
linear increases in H -D H A  binding w ith  increasing tissue concen tra tion  over 
the range 0.1-0.8 mg membrane p ro te in  /m l; however at higher tissue 
concentra tions the binding was not linear. The present assays were ro u tin e ly  
conducted w e ll w ith in  the linear range.
Incubation conditions and f i lte r in g  procedures were investiga ted to provide
' 3
optim um  sp ec ific   ^ H^ -D H A  binding and optim um  reduction  in non-specific  
binding. N on -spec ific  binding has been shown to fa l l about 3 -fo ld  between pH 6.8 
and 8.0 with no major variations in specific binding (Bylund and Snyder, 1976), 
th e re fo re ,rou tine  assays were conducted at pH 8.0 in order to  maxim ise the ra tio  
o f spec ific  to non-spec ific  b inding. The nature o f non-specific  binding is unknown
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although a portion (about 50%) of non-specific binding was clearly represented by 
physical trapping o f the radioligand in the filte r discs.
In general receptor binding sites are labile; however binding activ ity  was 
retained when preparations were stored (unfrozen) for up to 3 hours. Quick 
freezing and storage at -80°C  of tissues also preserved binding activ ity . The 
ability to store tissue was an important factor in the design of circadian 
experiments since large numbers of samples would be generated in one 24-hour 
period.
Two methods of data analysis were compared and the D irect Linear Plot was
chosen for routine determinations. The com m only used Scatchard p lo t results in a
distortion of experimental errors and consequently an over-estimation of observed
Kp. and B values (Munson, 1984). The Direct Linear Plot is more robust since U max
it allows equal w eighting  fo r all data points. However, the v a lid ity  o f using th is 
method fo r the de te rm ina tion  o f binding characteristics in p ineal glands from  only 
tw o ligand concentrations is open to discussion. Small va ria tions  in binding 
produced la rger e rrors in the de te rm ina tion  o f resu lts due to ex trap o la tion  from  
only one in te rsec tion  po in t.
Idea lly  i t  would be advantageous to obtain sa tu ra tion  binding data in
membrane preparations derived from single pineals. A radioiodinated ligand such 
175
as _ L  -IC Y P  with higher affin ity  and specific activity (20 x tritia ted  ligands)
! 3 !
may provide the tool for future investigations. The recent report of L H j -CGP  
binding to cell surface receptors in single pineals (Wilkinson and Wilkinson, 1985)
has provided the means to study recep to r recyc ling  in fresh intact tissue. 
However, the use o f one pineal per data po in t per ligand concen tra tion  lim its  the 
app lica tion  o f the m ethod because o f the large numbers o f anim als required.
CHAPTER 3
M ELATO NIN  IN  H EA LTH , A N O R EXIA  NERVOSA  
AND AFFECTIVE DISORDER
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3.1. 24-HO UR M ELA TO N IN  PROFILES IN  H E A LTH Y  ADULTS
3.1.1. In trod u c tion
It is important to establish adequate 'normal' values of a physiological 
parameter in order to derive meaningful data from clinical studies. This is of 
particular importance in  the investigation o f m e la ton in  secre tion  in man since the
large in te r in d iv id u a l v a ria tio n  in reported  levels (Section 1.3.2.) necessitates the 
study o f large groups o f subjects. The nature o f m e la ton in  secre tion  requires 
night-tim e blood sampling at frequent intervals and in consequence relatively small 
groups o f vo lunteers have been studied to  date.
We have established 24-hour m ela ton in  p ro file s  in 81 hea lthy adults. The 
data reported  here was co lle c ted  over a 4 year period.
3.1.2. Materials and methods
(a) Subjects
H ea lthy drug free vo lunteers participated as con tro ls  in circadian studies 
fro m  May 1983 - March 1987. The to ta l number o f subjects investiga ted  was 81 
and o f these, 16 females and 44 males were m a in ly s ta f f  and students at the 
Maudsley Hospital, London and 5 fem ales and 16 males were s ta f f  and students at 
the University o f Surrey. O f the total, 5 fem ales and 30 males were sampled 
during summer months (A pril-S ep tem ber) and 16 fem ales and 30 males were 
sampled during w in te r months (October-March). Age, w e igh t and height data were 
obta ined from  a ll Surrey subjects and from  40 Maudsley subjects (see Table 3.1).
D aytim e  blood samples were usually drawn hourly (3 hourly  in 12 subjects) 
in to  lith iu m -h e pa rin  tubes by venepuncture (Surrey) or via an indw elling  ca the te r 
(Maudsley). N ig h t- t im e  samples from a ll subjects were drawn hourly in to  lith iu m - 
heparin tubes v ia  an indw e lling  ca th e te r. During the da>j subjects continued norm al 
w ork ing and d ie ta ry  habits. N ig h t-tim e  sampling took place in hospita l 
investigation wards (Maudsley H osp ita l and St. Lukes H osp ita l, G u ild fo rd ). Hospital
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lig h tin g  was of low  in ten s ity  (around 300 lux) and subjects re tire d  to  bed at 2300 h, 
rem a in ing  in  darkness u n til 0700 h. A d im  red lig h t (<1 lux) was used when samples 
were drawn at n igh t.
Men Range Women Range
(n=42) (n=18)
Age (years) 29.7 + 1.2 23 - 55 41.0 + 3 23 - 63
Weight (kg) 74.7  + 2.4 59 - 110 61 .3  + 2.3 53 - 75
Height (m) 1 .78  + 0.02 1.60 - 2 .00  1.67 + 0.02 1 .56  - 1 .77
Table 3.1 Age, w e igh t and height data fo r norm al vo lunteers (mean + SEM)
(b) R IA  o f m ela ton in
Plasma m e la ton in  was determ ined by the m ethod o f Fraser et al, (1983a) 
described in Section 2.1.2. The interassay coefficient of va ria tio n  fo r quality- 
co n tro l samples assayed over the fou r year period was 10.5 + 0.7% (x + SEM, n=74 
assays) over the range of the standard curve. The mean detection l im it  was 5 
pg /m l.
(c) Analysis o f data
Acrophases (estim ated  peak tim es) o f the 24-hour rhythm  data were 
calculated using a cosine-curve fitting  programme (Monk and Fort, 1983). 
Melatonin leve ls a t chosen tim es o f the mean 24-hour p ro files  fo r male and fem ale  
subjects were compared using unpaired, tw o -ta ile d . Student's t - te s t.  The onset, 
o ffse t and to ta l duration of the noctu rna l e leva tion  o f m elaton in  was selected at 
the 15 pg /m l leve l (accord ing to Lewy et al, 1985c) and male and female groups 
were compared using unpaired, tw o-tailed. Student's t - te s t.
3.1.3. Results
Mean hourly  plasma m e la ton in  leve ls were determ ined in 21 women (F ig . 3.1), 
60 men (Fig. 3.2) and the combined group of 81 subjects (F ig. 3.3). 'N orm al' ranges
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Fig. 3.1 Plasma melatonin (x + 2 SD) in a group of 21 healthy female adults at 
hourly intervals for 24 hours. The highest and lowest profiles (subjects J and R 
respectively) indicate the range. The shaded area indicates 95% confidence limits. 
The mean acrophase of the 24-hour rhythm was determined as 0235 h.
134
2 0 0 -
mean
+ 2SD 
Subject P
Subject L
150-
o
E 1 0 0 -
50-
16 18 20 22 24 02 04 06 08 10 12 14
Time(h)
Fig. 3.2 Plasma melatonin (x + 2 SD) in a group of 60 healthy male adults at 
hourly intervals for 24 hours. The highest and lowest profiles (subjects P and L 
respectively) indicate the range. The shaded area indicates 95% confidence limits. 
Subject P exhibits clear episodic secretion. The mean acrophase of the 24-hour 
rhythm was determined as 0326 h.
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Fig. 3.3 Plasma m elaton in  (x + 2 SD) in a group of 81 healthy adults (21 fem ale, 
60 male) at hourly in te rva ls  fo r 24 hours. The mean acrophase o f the 24-hour 
rhy thm  was determ ined as 0320 h.
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fo r  plasma m e la ton in  leve ls were ca lcu la ted  as 2 SD from  the mean value at each 
tim e  po in t (95 per cent l im its ) .  M e la ton in  p ro file s  from  subjects w ith  the low est 
and highest levels in each group were p lo tte d  to  provide the range. Inspection o f 
the data in Fig. 3.2 indicates a marked double peak in the melatonin profile of 
subject P. The occurrence o f episodic secre tion  has been reported (A rend t, 1985). 
There was remarkable s im ila r ity  between mean peak heights fo r the men 
(48.8 pg/ml + 5.2 SEM) and the women (53.4 pg/ml + 9.1 SEM), furthermore both 
groups displayed an equivalent plasma m ela ton in  range from  undetectable n ight 
t im e  leve ls to  around 185 p g /m l. However, the tim in g  o f the peaks (acrophase) was 
almost one hour e a rlie r in the women (0235 h) compared to the group o f men 
(0326 h). When the mean plasma p ro file s  fo r men and women were superimposed 
(F ig. 3.4) there  was a s ig n ifica n t d iffe re n ce  between the tw o groups in the m orning 
decline o f m ela ton in  secretion (p<0.05 at 0700 h and p<0.01 at 0800 h, 0900 h and 
1000 h) w h ils t re ta in ing  rem arkable  conformity in the evening rise . The dura tion  o f 
elevated noctu rna l plasma m e la ton in  was not s ig n ific a n tly  d iffe re n t between males 
(8.97 hours + 0.37 SEM) and fem ales (8.12 hours + 0.33 SEM). The o ffs e t o f the 
nocturnal rise  was s ig n ific a n tly  e a rlie r (p<0.001) in females (0648 h + 0.30 SEM) 
compared to  males (0824 h + 0.20 SEM) whereas the onset o f the noctu rna l rise 
tended to be earlier in females (2254 h + 0.17 SEM) compared to males (2324 h + 
0.23 SEM) but this did not reach significance (p<0.07). Daytim e levels were slightly 
h igher in the male group due to  two subjects who were subsequently ignored 
(outside 95% l im its )  fo r s ta tis t ic a l ca lcu la tions.
There was no co rre la tio n  between plasma melatonin, e ith e r the area under 
the curve or peak height, with age, weight and height of the volunteers. Two of
the fem ale  and six o f the male subjects displayed p ro files  o f e ithe r undetectable  to 
very low  leve ls o f m ela ton in  or no detectable rhy thm  in secre tion . This sub-group 
comprised 10% o f a ll the subjects. The ir mean age was 31.6 years + 3.4 SEM and 
they were o f norm al w e ight fo r heigh t.
Two ind iv idua ls were sampled on tw o separate occasions (one month apart).
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Fig. 3.4 Plasma melatonin (x + SEM) in male (n=60) and female (n=21) volunteers 
at hourly intervals for 24 hours.
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The p ro file s  fo r each ind iv idua l were very reproducible (F ig. 3.5) since both the 
areas under the curves and the double peaks obtained were consistent on each 
occasion.
3.1.4. Discussion
The collected plasma melatonin p ro files  from 81 norm al volunteers are 
described. This is the largest reported investigation of melatonin levels throughout 
24 hours in normal volunteers and is o f value in the determination of re ference  
levels for comparison with pathological states. Much of the data is consistent with 
that described in the lite ra tu re . In te rin d iv id ua l va ria tio n  in m e la ton in  secre tion  in 
contrast to intraindividual s ta b ility  was in agreement w ith  reports by Arendt,
(1979) and A ra to  e t al, (1984). Episodic secretion w ith  tw o and sometimes more 
secre to ry  episodes during the n ight was previously described by Arendt, ( 1985) and 
was clearly evident in some ind iv idua ls in th is  study. The m arked s ta b il ity  in 
duration o f the noctu rna l m e la ton in  elevation between subjects was consistent w ith  
the find ings o f Waldhauser and Steger, (1986).
S ign ifican t effects of age, w eight and height upon m e la ton in  levels were not 
apparent in th is  un ifo rm  group of subjects. Since a number o f reports suggest a 
re la tionsh ip  between m e la ton in  and body parameters (see Section 1.3.2.), a study o f 
populations displaying greater body weight or height differences may yield more 
m eaningfu l data. Bojkowski, (1988) measured u rinary  aMT6s levels in hea lthy 
volunteers and reported a similar lack of correlation. An effect of age upon 
m e la ton in  would have been unlikely in th is study since the sample groups were 
chosen from populations of young adults thereby excluding elderly and adolescent 
subjects.
Since 10% o f the volunteers showed no detectab le  plasma m e la ton in  rhythm  
i t  is apparent th a t a de tectab le  leve l o f m e la ton in  in the plasma is not a necessity 
fo r norm al human fun c tio n .
I t  is d i f f ic u l t  to  in te rp re t the d iffe rences obtained in the mean m orning levels
139
January
February
a 30“
2 0 -
10-
1224 0820 0416
Time (h)
80i
#— #  G January  
0 - - Q G  F eb ru ary
70-
60-
E
O)
50-
1
E
CO
E
:  30-
CL
20-
10-
16 20 1224 0 4 08
Tim e (h )
F ig. 3.5 Plasma m ela ton in  levels at hourly in te rva ls  fo r 24 hours in two normal 
hea lthy men (B aged 44 and G aged 23) a t two d iffe re n t tim es of the year.
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and the mean o ffs e t tim e  o f noctu rna l m e la ton in  secre tion  between the male and 
female groups. Acrophase analysis suggested a phase advance of around one hour 
in the tim in g  o f the mean m ela ton in  peak in the female group. I t  is possible tha t 
the previous environmental lighting history of this group had determined the 
observed d iffe re n ce  or perhaps grea te r se n s itiv ity  to  m orning lig h t resu lted  in 
suppression of morning melatonin levels. Volunteers were not controlled for time  
o f the m onth and the re fo re  the re la tionsh ip  between the m enstrua l cyc le  and 
m e la ton in  secretion was not tested. A possible seasonal e ffe c t was un like ly  since 
over 70% o f the women were sampled in w in te r months when the rhy thm  is delayed 
compared to summer months (Illnerova et al, 1985; Broadway et al, 1987; Bojkowski 
and Arendt, 1988). Conclusions cannot be drawn however from  the differences 
observed, since the fem ale  subjects were considerably o lder than the male subjects 
and were obta ined from  d iffe re n t sources and sampled on d iffe re n t occasions.
3.2. M ELA TO N IN  SECRETION IN  A N O R EXIA  NERVOSA
3.2.1. Introduction
The study o f m e la ton in  in anorexia nervosa is of in te res t fo r reasons re la ted  
to  the m u lt ifa c to r ia l nature o f the syndrom e. R elationships have been described 
between m e la ton in  and puberty, body w e ight and the m enstrual cyc le  (Section 
1.3.3). Disturbances of endocrine and neuroendocrine rhythms, feeding and 
sleeping habits, body w e ight and the sexual cyc le  have been described in anorexia 
nervosa (G a rfin ke l and Garner, 1982) and the pineal gland plays a cen tra l ro le  in 
co-ordinating such rhythms in animal species (Section 1.1). Furthermore, the 
association between a ffe c tiv e  disorders and anorexia nervosa (Cantwell et al, 1977) 
suggests tha t m e la ton in  secre tion  in anorectics may be abnorm al since depressives 
are reported  to d isplay low  am plitude m e la ton in  rhythm s (Section 1.4.4). To date 
reports  o f m e la ton in  in anorexia nervosa are c o n flic tin g  (Section 1.3.4.(g)) and 
investiga tions have lacked su itab le  controls.
Studies o f m ela ton in  secre tion  and aMT6s excre tion  in groups o f patien ts and
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con tro ls  are described.
3.2.2. Methods
(a) Subjects
Exeter Study. Eleven female patients aged 15-24 years fu lfilled  criteria  
(Russell, 1983) for anorexia nervosa and were admitted to RAE, Exeter under 
the care of Dr. S. Bhanji. They had at least 25% loss of premorbid weight 
and all exhibited amenorrhoea. The duration of weight loss ranged from 2 to
96 months and the dura tion  o f amenorrheoa from  pre-menarche to  56 months. 
A ll patients had been m ed ication  free  fro m  the onset of the illness. Plasma 
samples were obtained by venepuncture three  hourly fo r  one 24-hour period 
and were stored at -20°C  u n til assayed fo r m e la ton in . A dim red lig h t (< 1 
lux) was used when samples were drawn at n igh t. A ll subjects were sampled 
between the months o f Decem ber and A p r il.
Surrey Study. D r. M. Sm ith (St. Luke's H osp ita l, G u ild fo rd ) agreed to  allow us
access to  inpa tien ts  w ith  anorexia nervosa and to p a rtia lly  recovered and 
fu l ly  recovered ou tpa tien ts . T h irteen  fem ale  ou tpa tien ts  were contacted  and 
e igh t consented to  participate in the study. Eleven low  w e ight (less than 50 
kg), healthy, fem ale  volunteers o f norm al height, from s ta ff  and student 
populations at the U n ive rs ity  o f Surrey were asked to  p a rtic ip a te  as con tro ls  
and nine consented to  take pa rt. A ll subjects were asked to provide a urine 
co lle c tio n  over one 24-hour period and to com plete  a short questionnaire 
(Table 3.2). Seven ou tpa tien ts  and nine con tro ls  com plied w ith  the study and 
a fu r th e r fou r 24-hour urine co llec tions were obtained from  inpatients. One 
co n tro l (not drug free) and one p a tien t w ith  alcoholism and c irrhos is  
com p lica tions was re jec ted  from  each group.
The low  w e ight hea lthy con tro ls  (n=8) were aged 18-33 years w ith  a w e ight 
range o f 44.3 - 49.6 kg. A ll hea lthy subjects ate regu la r meals, experienced regu la r
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m enstrua l cycles and s lept w e ll. Three of the con tro l women were tak ing  ora l 
con tracep tives . P atien ts  diagnosed w ith  anorexia nervosa (n=6) were aged 13-39 
years with a weight range of 31-44.5 kg and duration of amenorrhoea from 2-13 
years. Recovered subjects (n=4) were aged 19-27 years w ith  a w e igh t range o f 54- 
72 kg. Menstrual cycles and eating habits were still irregular in this group.
Urine samples from  a ll subjects were collected in the months Ju ly-Septem ber 
and were stored in 5.0 ml a liquots a t -20°C  before assay fo r aMT6s.
Maudsley Study. Ten inpa tien ts  under the care o f D r. J. Bearn, Maudsley 
Hospital, were diagnosed using Russell's c r ite r ia  fo r anorexia nervosa (Russell,
1983). Patients conformed to the selection criteria  if they were fem ale, aged 18- 
45 years and i f  sym ptom s had been present fo r a t least one year p rio r to  the study. 
A ll pa tien ts  were assessed for accom panying features of depression using the 
m od ified  Hamilton R ating Scale (Ham ilton, 1967). A 24-hour urine co lle c tion  was 
obta ined fo r  es tim a tion  o f aMT6s excre tion  and a venous blood sample was taken 
fo r  measurem ent o f plasma LH, estrad io l and FSH. These measures were repeated 
when m axim um  w eight gain had been achieved. A con tro l group consisted o f 10 
hea lthy fem ale  volunteers v/ho were in d iv id ua lly  age m atched w ith  the pa tien t 
group (range 21-35 years). All controls were drug free, and not taking oral 
con traceptives . Each provided a 24-hour urine co lle c tion  fo r es tim a tion  o f aMT6s. 
A ll collections were made between day 26 and 30 o f the m enstrua l cyc le . Two 
pa tien ts  rece iv ing  am itriptyline and one pa tie n t rece iv ing  th io rida z in e  tre a tm e n t 
were excluded from  s ta tis t ic a l analyses. One con tro l subject w ith  a raised urinary 
aMT6s level of more than 4SD from the mean of the control groups was also 
re je c ted .
Serial 24-hour urine co llec tions were taken from tw o pa tien ts  fo r  8 
consecutive days to  assess re p ro d u c ib ility  o f aMT6s excre tion  in anorexia nervosa.
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(b) Assays
Plasma melatonin was measured by RIA (Fraser et al, 1983a) using the 
procedure described in Section 2.1.2. The tritia ted  tracer had a specific activ ity  of
45.3 C i/m m ol and the lim it of detection was 5 pg m elatonin/m l plasma. Interassay 
coefficients of variation were 10.2, 9.3 and 11.4% at 21.9, 54.1 and 234 pg/ml 
respectively (n=8 assays).
U rina ry  aMT6s was determined by R IA  (Arendt et al, 1985) as described in
3
Section 2.1.5. The tr it ia te d  aMT6s was prepared from  H -melatonin w ith  a 
spec ific  a c t iv ity  o f 45.3 C i/m m o l. The l im i t  o f assay detection was 0.65 ng 
aMT6s/ml urine. Interassay coefficients of variation were 12.9 and 9.9% at 20.8 
and 8 ng /m l respec tive ly . A ll samples from  the Surrey study were processed in one 
assay and likewise for the Maudsley study.
FSH, LH and estrad io l estim ations fo r  the Maudsley Study were performed by 
Mrs. L. W alters in the C lin ic a l C hem istry  D epartm en t o f St. Thomas' H osp ita l 
using R IA  m ethodology.
(c) Analysis of data
Plasma m e la ton in  data from  11 patients (E xe te r study) were compared w ith
data from  21 hea lthy female adults (presented in Section 3.1.3.). The dura tion  of
e levated noctu rna l plasma melatonin was determined at the 15 pg/ml leve l (Lewy
et al, 1985c). Statistical analysis of data was performed using unpaired, two-
tailed. Student's t - te s t.  The e ffe c t o f increasing body w e ight upon aMT6s
excre tion  in anorectics was determ ined using paired, tw o-tailed. Student's t- te s t.
2
Body mass indices were ca lcu la ted  as w e igh t/he igh t .
3.2.3. Results
Plasma m e la ton in  leve ls in 11 pa tien ts  w ith  anorexia nervosa (F ig. 3.6) were 
s ig n ific a n tly  h igher a t 2400 h and at 0300 h (p<0.05) compared to  m e la ton in  levels 
o f 21 hea lthy women. A w ide r va ria tion  in n ig h t-tim e  m e la ton in  values was
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Fig. 3.6 Plasma melatonin (+ SEM) in 11 female patients with anorexia nervosa 
(mean age 18 + 0.8 years, mean weight 35.7 + 1.5 kg) sampled at three hourly 
intervals for 24 hours, compared to plasma melatonin (+ 2SD) in 21 healthy women 
(mean age 35.7 + 4.4 years, mean weight 62.5 + 2.7 kg), sampled hourly for 24 
hours.
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observed in the patients with peak levels ranging from 53 to 300 pg/ml. Six 
patients had values outside the 95% l im it  fo r  the norm al range whereas the other 
five patients were well within the range. Three subjects displayed high daytime 
melatonin levels (20-46 pg /m l). Fu rthe rm ore , there was greater v a r ia b ility  in peak 
tim es compared to  those o f normal volunteers. A possible phase advance o f the 
m e la ton in  rhy thm  in tw o o f the patien ts  m igh t have been c la r if ie d  by using m ore 
sampling points. There was no correlation between peak levels o f m ela ton in  and 
either the patients' w eight (range 27.7-41.1 kg), the percentage w eigh t loss (range 
25-45%) or the duration of amenorrhoea (range 4-56 months). The duration of 
noctu rna l m e la ton in  secre tion  was s ig n ific a n tly  longer (p=0.05) in the patient group 
(9.46 hours + 0.5 SEM) compared to controls (8.12 hours + 0.33 SEM).
Table 3.3 lis ts  the ages, weights and body mass indices fo r subjects 
participating in both Surrey and Maudsley studies. W eights and body mass indices 
o f low w e ight controls were s ig n ific a n tly  less (p<0.05) than those o f the age 
matched contro ls  and recovered subjects but were s ig n ific a n tly  h igher (p<G.0Gl) 
compared to  the amenorrhoeic patien ts . There was no difference in the ages of 
subjects between the groups.
Serial 24-hour urine co llec tions from tw o subjects X and Y demonstrated 
reasonable stability of daily aMT6s excretion in anorexia nervosa. Subject X with a 
mean aMT6s leve l o f 14.3 pg/24 h showed a 9% c o e ff ic ie n t o f va ria tion  and 
subject Y with 6.9 pg/24 h showed a 23% coefficient of variation over an eight day 
period. Interassay variation of 9.9 - 12.9% could account for much of the daily 
f lu c tu a tio n s  in aMT6s levels observed.
A sca tte r d iagram  (F ig. 3.7) illustrates a greater spread of aMT6s levels in 
pa tien ts  compared to  con tro ls . A norectics  displayed s ig n ific a n tly  h igher levels 
(p<0.05) of urinary aMT6s (12.4 )jg /24h  + 1.7 SEM) compared to both low weight 
controls (7.8 pg/24 h + 1.2 SEM) and age m atched and low  w eight controls 
combined (8.4 pg/24 h + l.G ). This re la tionsh ip  also held when the recovered 
subjects were added to  the pa tien t group (12.4 pg/24 h + 1.4 SEM). C lea rly
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Fig. 3.7 Scatter diagram - 24-hour urinary aMT6s in patients (Surrey and
Maudsley) w ith  anorexia nervosa : comparison w ith  healthy fem ale  contro ls.
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approximately 50% of the anorectics showed aMT6s levels within the range 
displayed by norm al controls whereas the rem ain ing  50% demonstrated increased 
a!vlT6s levels. There was no difference in aMT6s levels between patients and 
recovered subjects and no difference between alvlT6s levels in low weight controls 
(Surrey) compared to age matched controls (Maudsley). There was no correlation  
between aMT6s levels and either weight, body mass index, duration of amenorrhoea 
or Hamilton Rating Scale scores for depressive symptoms.
Weight gain in anorectics (Maudsley) was accompanied by increases in plasma 
LH, estrogen and FSH levels (Table 3.4) and a decrease in the Hamilton Rating 
Score. There was no difference however, in aMT6s excretion before and after 
weight gain although there  was a trend tow ards higher values at maximum w eight. 
There was no correlation between aMT6s excretion and body mass index or between 
aMT6s e xc re tion  and FSH, LH  or estrad io l levels at e ithe r m in im um  or m axim um  
weight.
3.2.4. Discussion
M ela ton in  secretion and aMT6s excre tion  was s ig n ific a n tly  increased in 
groups of patients with anorexia nervosa compared to female controls. 
Furtherm ore^ the  observed variance in melatonin and aMT6s values from pa tien t 
groups was large with at least 50% of anorectics falling within the normal 
melatonin and aMT6s range (within 2SD). The excretion of aMT6s in female 
con tro l groups, in particular the low  w e ight volunteers, compared w e ll w ith  the 
reported range of values for aMT6s in the urine of healthy women (9.5 pg/24-hour +
4.3 SD; n=31) (Bojkowski, 1988).
Our study is in agreement with the findings of Ferrari et al, (1987) who 
described s ig n ific a n tly  h igher m e la ton in  leve ls during the afternoon and n ight in 14 
pa tien ts  w ith  anorexia nervosa. These authors also observed a greater 
in te r in d iv id u a l variation in the tim in g  of the m e la ton in  nocturnal peak in pa tien ts . 
I t  is possible th a t the m e la ton in  rhythm  in some patien ts is poorly entrained, w h ils t
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at the same tim e  high am plitude  is m ain ta ined. A d isturbance of the m ela ton in  
rhy thm  m igh t be expected in anorexia nervosa since sleeping, feed ing, re s t /a c t iv ity  
and sexual cycle rhythms are altered or impaired (Garfinkel and and Garner, 1982).
A report of low nocturnal serum melatonin in anorexia nervosa (Birau et al,
1984) was clearly not supported by our findings. These authors suggested that 
melatonin displays a body weight dependence but we found no evidence for this, 
either in patients at low body mass or after maximum weight gain. This is 
discrepant with reports suggesting positive and negative relationships with body 
weight (Section 1.3.3). There was no relationship between aMT6s and body height 
since body mass indices were unrelated to melatonin levels.
Baranowska and co-workers, (1986) reported normal melatonin levels in 
anorexia nervosa; however, the daytime concentrations o f melatonin found in 
healthy women (over 80 pg/ml) raises doubts concerning the specificity of the assay 
method. D alery and associates, (1985) found normal melatonin levels in a group o f 
patients rated as depression-free. A recent in ves tiga tion  by Brown and colleagues 
(personal com m unica tion) indicated th a t anorectic patien ts  m an ifesting  symptoms 
o f endogenous depression produced s ig n ific a n tly  less m ela ton in  compared to non­
depressed patients end contro ls . Despite an observed reduction in H am ilton  rating 
scores concomitant with weight gain we found no relationship between aMT6s 
levels and the rating scores in the patients studied. Altshuler and Weiner, (1985) 
have questioned the relevance of recent publications suggesting a relationship 
between anorexia nervosa and affective disorder and although W inokur e t al, (1980) 
postulated a subgroup of anorexic patients with a genetic loading for affective  
disorder the evidence for anorexia nervosa as a variation of depression is at present 
unclear.
I t  is possible th a t the ex trem e ly  high plasma m elaton in  leve ls obtained in 
some pa tien ts  re fle c te d  a reduced blood volume due to dehydration and starvation. 
M oreover, despite a close co rre la tion  between m ela ton in  and urinary aMT6s 
(A rendt e t al, 1985) i t  is also possible th a t m ela ton in  m etabolism  was a lte red  in
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patients. Excretion of aMT6s from day to day in the two patients studied was quite 
consistent. Carr et al, (1981) have shown a dramatic increase of plasma melatonin 
during strenuous exercise in women although th is  has not been con firm ed  by others 
(Vaughan 1984). Exercise is often adopted by patients to maintain a low weight and 
may have contributed to increased values in some outpatients.
Previous studies in animal species have indicated that melatonin has anti-
gonadotrophic effects (Section 1.1). In man, reports o f low m e la ton in  at ovu la tion  
(Section 1.3.3) and high plasma melatonin in prepubertal children falling to lower 
levels in pubescence (Das Gupta et al, 1983; Waldhauser et al, 1984) have suggested
th a t m ela ton in  may be invo lved in the mechanism o f gonadotrophin release. I t  is 
tem pting  to  speculate tha t high melatonin levels, in anorexia nervosa, are re la ted  
to the 'p repube rta l' gonadotrophin status o f the patien ts . However^ s ig n ifica n t 
increases in plasma LH , FSH and estradiol occurred w ith  w e igh t gain but there was 
no decrease in aMT6s excre tion . A trend  towards even higher aMT6s levels was 
observed w ith  increasing w eigh t. F u rthe rm ore^the re  was no co rre la tio n  between 
gonadotrophin or es trad io l levels and aMT6s concentra tions.
In summary we have described higher levels o f m e la ton in  and aMT6s in groups 
o f pa tien ts  w ith  anorexia nervosa. M ela ton in  levels were not related to w e ight 
changes, dura tion  o f illness or depression ra tings. Increases in gonadotrophin levels 
upon recovery were independent o f m ela ton in  and aMT6s production. The 
p oss ib ility  th a t high m e la ton in  leve ls provide a m arker fo r a subgroup o f anorexia 
nervosa patien ts  and th a t the m e la ton in  rhy thm  in th is disease is disturbed 
w arran ts  further in ves tiga tion .
3.3. M ELATO NIN  SECRETION IN  DEPRESSION A ND SEASONAL 
AFFECTIVE DISORDER
3.3.1. In trod u c tion
I t  is not surprising tha t a m enta l disorder w ith  seasonal occurrence such as
SAD has been o f in te re s t in p ineal research (see Section 1.4.5.). An in it ia l report
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by Rosenthal et al, (1986) showed raised early evening melatonin levels in four 
patients with SAD, although subsequentlv there have been no controlled studies of
the p a tte rn  o f m e la ton in  secretion in th is disorder.
In contrast many research groups have independently published melatonin 
secretion profiles in endogenous depression. These studies have indicated a
decreased noctu rna l am plitude in m ela ton in  secretion and/or a phase s h ift in the 
rhythm (see Section 1.4.4.). However, none of the studies to date have fully  
accounted for the m a jo r variables known to  a ffe c t melatonin secretion.
We have compared melatonin secretion in depressed patients (Thompson et al, 
1988) and in pa tien ts  w ith  SAD w ith  in d iv id ua lly  m atched groups of normal 
volunteers.
3.3.2. Methods
(a) Subjects
Depression study. Four male and fou r female patien ts  under the care o f D r. 
S.A. C heckley and D r. C. Thompson, were recruited from  the Maudsley, Beth lem  
Royal and Brooke Hospitals. Depression had been diagnosed using the Research 
D iagnostic  C r ite r ia  o f Spitzer et al, (1978) w ith  add itiona l assessment using the 
Newcastle ra tin g  scale (Carney et al, 1965): a ll pa tien ts  met c r ite r ia  fo r  m ajor 
endogenous depression. The severity of depression was rated using the scale of 
H am ilton , (1967) achieving a mean score (25.1) in the severe range. A ll pa tien ts  
had been drug free  fo r a t least 6 weeks before blood sampling. Some pa tien ts  
however, received benzodiazepines for n ig h t-tim e  sedation. This was acceptable, 
since we have found in a double blind study tha t diazepam (10 mg, oral 
a dm in is tra tion ) had no s ig n ifica n t acute e ffe c t upon 24-hour m e la ton in  secre tion  in 
six norm al vo lunteers (Palazidou , Franey, A rend t, Checkley, unpublished results, 
1986).
Control subjects were hea lthy, drug free  and were in d iv idua lly  matched w ith  
pa tien ts  fo r  age, sex, m enstrual status (pre- or post-menopause; week of m enstrual
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cyc le ) and season o f sam pling. I t  was not possible to  m atch a ll pairs for w eight and 
height, however there was no d iffe re n ce  between the w e ight and height means fo r  
p a tie n t and co n tro l groups (see Table 3.5. below). A ll pairs were tested  in autum n, 
1983 (October-November), with two exceptions: one pair was sampled in November, 
1982 and another pair was sampled in April, 1984.
Patients Controls
Age 45.5 + 3.9 years 46 + 3.8 years
W eight 68.5 + 3.8 kg 67.6 + 3.8 kg
H e ight 1.67 + 0.03 m 1.70 + 0.03 m
Table 3.5 Age, weight and height data (mean + SEM) for depressed patients
and m atched contro ls .
SAD study. F ive fem ale  and tw o male pa tien ts  were diagnosed fo r SAD using 
Rosenthal's c r ite r ia  (Rosenthal et al, 1984) and were adm itted  under the care o f 
D r. S.A. C heckley to  the M etabo lic  Ward at the Maudsley Hospital. They had been 
drug free  fo r a t least one m onth and were not su ffe rin g  fro m  any other serious 
m edical or psychiatric cond ition . The ir mean age was 50.7 years + 4.5 SEM and 
sam pling took place during the months o f severe depression : January and February, 
1987.
Control subjects were matched for sex (5 female, 2 male), age (44 years + 5 
SEM) and month of sampling (January or February, 1987).
(b) Sampling procedure
P atien ts  and controls fo r  both studies rem ained in the m etabo lic  wards fo r 
the duration  o f tes ting . D aytim e  a r t i f ic ia l lig h tin g  was around 400 lux in in ten s ity . 
Hourly blood samples, for one 24-hour period were obtained via an indwelling, 
intravenous cannula. A fte r discarding the first 2 ml of blood (contaminated with 
heparin wash so lu tion) a fu r th e r 8 m l o f blood were taken fo r plasma separation and 
storage as described in Section 2.1.2.4. All subjects retired to bed at 2300 h 
rem ain ing  in darkness u n til 0700 h, they a te  norm al meals, but alcohol and vigorous
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exercise were not a llowed. Sleep was un in te rupted  by the sam pling procedure.
(c) Assays
Plasma melatonin was measured by R IA (Fraser et al, 1983a) using the 
procedure described in Section 2.1.2. Assay performance details are presented
below in Table 3.6.
Date Tracer L .D .
(C i/m m ol) (pg/ml)
High
Interassay CV%
Medium Low
Nov 1982 
Nov 1983
A p ril 1984 
Feb 1987
34.5
45.3
45.3 
81.7
10
5 *
5 *
13.5 (339)
11.4 (234)
3.2 (103)
11.0 (91)
16.5 (7.5)
9.3 (54.1) 
9.0 (45.6)
7.4 (44.4)
10.2 (21.9)
19.1 (16.1)
12.5 (23.2)
*  using antiserum 704/189 * *  using antiserum  8483
L .D . = l im it  o f de tec tion
Table 3.6 Assay performance data fo r groups o f m e la ton in  R IAs from November
1982 - A p r il 1984 (depression study) and fo r  February 1987 (SAD study). Q ua lity  
co n tro l plasma m e la ton in  values are ind ica ted  in brackets (x, pg /m l).
(d) Analysis of data
Plasma m e la ton in  differences between p a tie n t and control groups were tested 
at set t im e  points using unpaired, tw o-tailed. Student's t - te s t.  The onset, o ffse t 
and dura tion  o f e levated noctu rna l plasma m e la ton in  was selected at the 15 pg /m l 
level. Area under the night-tim e profile was ca lcu la ted  using a computer 
program m e 's tripe ' (Johnston and Woollard, 1982).
3.3.3. Results
(a) Depression study
F ig . 3.8 shows the mean plasma m ela ton in  p ro file s  o f endogenously depressed 
pa tien ts  and matched control subjects. In both pa tie n t and co n tro l groups the onset
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Fig. 3.8 Plasma melatonin (x + SEM) in eight depressed patients (4 M, 4 F) and
e igh t matched controls, sampled at hourly in te rva ls  for 24 hours.
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o f noctu rna l m e la ton in  p roduction  occurred between 2100 h and 2200 h, leve ls were 
m axim al between 0200 h and 0500 h and re turned  to  baseline (undetectab le) levels 
between 0900 h and 1000 h. Daytim e (1000 -2100 h) levels for both patient and 
co n tro l groups were m ostly  below the sensitivity l im it  o f the assay and were 
therefore plotted at the 5 pg/ml detection lim it. There were large interindividual 
variations in both groups; however it was clear that melatonin secretion in 
depressed subjects was not significantly lower compared to controls, in fact the 
trend was towards slightly higher levels in the depressives. Furthermore, there was 
no indication of phase abnormalities of the melatonin rhythm in depression. It 
should be noted tha t the control subjects displayed a low er mean nocturnal 
m e la ton in  secretion than has been previously described in th is  thesis fo r much 
larger groups of normal subjects (see Section 3.1.3). This was due to tw o controls 
who showed very low  to  undetectable plasma melatonin throughout the 24-hour 
period. Therefore .a fu r th e r comparison was made between the mean m elaton in  
profile obtained from 81 normal vo lunteers (see F ig . 3.3) and th a t o f depressed 
pa tien ts . F ig . 3.9 shows tha t there  were s t i l l  no d iffe rences between the 
depressives and this much la rge r group o f hea lthy subjects. M oreover, there was no 
c o rre la tio n  between peak m e la ton in  levels and the severity  o f depression as 
determined by scores on the H am ilton  R ating  Scale fo r depression.
A peak height o f 135 pg /m l was achieved by one p a tien t w ith  severe 
endogenous depression, who subsequently underwent surgical p re fro n ta l leucotom y.
(b) SAD study
M ela ton in  rhythm s in pa tien ts  w ith  SAD demonstrated (i) larger 
in te r in d iv id u a l va ria tion  in am plitude and tim in g  and (ii)  significantly higher early 
m orning levels compared to  the m atched con tro l group (F ig. 3.10). Mean m ela ton in  
values were higher in patients at 0700 h, 0800 h (p<0.01), 0600 h and 0900 h 
(p<0.05). The offset, but not the onset o f nocturna l m ela ton in  secretion, was 
s ig n ific a n tly  later (p<G.01) in the p a tie n t group (0824 h + 0.28 SEM) compared to
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Fig. 3.9 Plasma melatonin (x + SEM) in eight depressed patients (4 4 F) and
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the  co n tro l group (0636 h + 0.48 SEM). Baseline leve ls in pa tien ts  were raised due 
to one subject with daytime values of around 18-20 pg/ml (patient M, Fig. 3.11). 
Inspection of the data suggests that the duration of melatonin in SAD may be 
longer, although this was not statistically significant compared to the control
group. There were also no d iffe rences in to ta l n ig h t-tim e  m ela ton in  secre tion  
(area under the curves) between the groups.
Two profiles were chosen (Fig. 3.11) to illustrate the heterogeneity of 
rhythms in the patient group. Subject H was apparently phase delayed compared to 
the  mean profile o f controls, whereas increased duration of m ela ton in  secre tion  
was found in subject M w ith  a d is tin c t double peak in m e la ton in  production. O f the 
five remaining patients (not shown! one displayed an earlier plasma melatonin peak 
tim e  o f 0100 h compared to 0300 h o f the control group and fou r pa tien ts  showed 
the expected noctu rna l elevation w ith  peak m e la ton in  secre tion  tim ed  at around 
0300 h-0400 h.
3.3.4. Discussion
M e la ton in  secretion in endogenously depressed patien ts  was found to  be no 
d if fe re n t fro m  m ela ton in  secretion in m atched controls, however early  morning 
melatonin values in patients with SAD were significantly increased compared to
those o f m atched contro ls .
The resu lts  obtained in depressed patien ts  were consistent w ith  an early study 
o f Jim erson and co-w orkers, (1977) and th a t o f J a rre tt and colleagues, (1985) who 
more re ce n tly ^  found norm al noctu rna l m ela ton in  secre tion  in a group o f 16 
depressed women. F u rthe rm ore , a lthough D ie tze l and co-workers, (1986a) found no 
evidence of a 'low melatonin syndrome' in depressed patients^ these authors 
reported an abnormal seasonal variation in melatonin secre tion  in depression. It 
was not possible however, to  tes t seasonal changes in the present study. There was 
no evidence of a phase advance of the m elaton in  rhy thm  in depression as has been 
previously reported  (Lewy, 1983b; N a ir et al, 1984) or o f a phase delay (Van C auter
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Fig. 3.11 24-hour plasma melatonin in two patients with SAD (subjects H and M) 
compared to the mean melatonin profile of seven control subjects.
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et al, 1985).
Our study was not consistent w ith  the hypothesis o f lowered m e la ton in  as a 
t r a i t  m arker o f depression (W ette rberg  et al, 1984) and was c le a rly  in contrast w ith  
the findings of a number of group^which to date^have supported the hypothesis of 
Wetterberg and colleagues. Some of the early studies investigated small sample 
numbers without control subjects (Mendlewicz et al, 1980; Branchey et al, 1982) or 
em ployed single tim e  point sam pling (W irz -Jus tice  and A rend t, 1979) and therefore  
are d ifficu lt to  interpret considering the high in te r in d iv id u a l variation in m ela ton in  
secre tion  found in man.
Wetterberg, B eck-F riis  and associates, in a series of experim ents (W ette rberg  
et al, 1982; 1984; Beck-Friis et al, 1984; 1985a; 1985b) investiga ted  re latively la rge 
patient groups (12-30 subjects) and related their low  m ela ton in  secre tion  to
hypercortisolaemia and dexamethasone non-suppression, however the pa tien ts  were 
not drug free and the control subjects were not adequately matched. Although a 
su itab le  period o f drug withdrawal is necessary fo r  m eaningfu l in te rp re ta tio n  o f 
data; short drug fre e  periods o f only 2 days (Boyce, 1985), 7 days (Brown et al, 
1985a) and 10 days (C laus tra t e t al, 1984) have been described in pa tien ts
d isp laying low melatonin. In the present study a ll pa tien ts  had been drug free  fo r 
a t least 6 weeks and some for one year.
I t  is possible th a t certain subsections o f the depressed popula tion display a 
low  m ela ton in  syndrome. Brown et al, (1985a) found th a t a subgroup o f
m elancho lic  pa tien ts  had lower melatonin compared to  non-melancholic depressives 
and con tro ls . In contrast to o ther studies however these authors found no
co rre la tio n  between m elaton in  and cortisol in these patien ts . The severity  o f 
depression ratings in our pa tien t group corresponded to the 'm e lancho lic ' ca tegory 
and there fore^w ould  have been equiva lent to  the subgroup o f Brown and colleagues. 
In a recen t pub lica tion  these researchers, (Brown et al, 1987) reported  an inverse 
co rre la tio n  between m elaton in  secretion at 2300 h and depressed mood ra tings o f 
the  H am ilton  R ating  Scale in 28 patien ts . This was c le a rly  not the case in the
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present study since the highest recorded plasma melatonin levels were obtained 
from  one of the most severely depressed patients. The use of single tim e point 
sampling at 2300 h (Brown et al, 1987) raises methodological problems since this 
tim e coincides with the onset of melatonin elevation when levels are low and 
variable.
I f  low melatonin is a tra it marker for a subgroup of depressiorrits importance 
is questionable^since we have shown that around 10-20% of normal subjects have no 
detectable melatonin or no detectable rhy thm  in melatonin secretion (Section 3.1.)
The present report has described the f ir s t  controlled investiga tion  o f 24-hour
m ela ton in  secre tion  in SAD. Despite great va ria tion  in the m e la ton in  p ro files  o f 
pa tien ts^ there was no evidence o f reduced nocturnal m ela ton in  secre tion . In 
contrast to  the find ings o f Rosenthal et al, (1986) higher leve ls were found in the 
early  morning and not in the  early  evening as reported  by Rosenthal's group.
The m orning decline o f m e la ton in  secre tion  in the con tro l group may have 
been unusually early . These matched contro ls  (5 F, 2 M) were predom inantly  
women and i t  is possible th a t women secrete less m ela ton in  in the early  m orning 
hours compared to  men. This has been discussed in Section 3.1.4. and may be due 
to  increased se n s itiv ity  to  morning light, e ith e r on the day o f sampling or from  
previous days prior to the investigation. It is therefore possible that patients with 
SAD are comparatively insensitive  to early  m orning lig h t.
P a tien ts  w ith  bipolar affective  disorder appear to  be more sensitive than 
normals to the melatonin suppressing properties of light (Lewy et al, 1981).
E qu iva len t studies in SAD have not been published to date but we have shown in a 
p re lim in a ry  study tha t pa tien ts  w ith  SAD were not insensitive to  the m ela ton in  
suppressing e ffe c ts  o f d im  lig h t (500 lux, fu l l spectrum , a r t if ic ia l lig h t) given at 
0200 h - 0400 h. A t the same tim e  these pa tien ts  were significantly insensitive to 
lig h t fro m  p a tte rn  recogn ition  tests and visual evoked response tests (M urphy, 
F raney, A rend t, Checkley, unpublished resu lts, 1987).
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Lew y and colleagues (1985b; 1987) proposed th a t w in te r depressives display a 
phase delay in the  tim e  o f m e la ton in  onset. This was apparent in only one p a tie n t 
in our study, furtherm ore at least tw o  subjects showed a phase advance in the tim e  
o f m e la ton in  onset. Lewy's group found th a t melatonin onset in the  SAD pa tien ts  
advanced more in response to  morning lig h t and delayed less in response to evening 
lig h t than contro ls  (Lew y e t al, 1987) suggesting th a t the phase response curve to  
lig h t is a lte red  in SAD.
Our findings o f e levated early  m orning m e la ton in  secre tion  in SAD do not 
necessarily ind ica te  a ro le  fo r  melatonin in th is  disorder. Recent pub lica tions have 
shown th a t the mechanism o f lig h t tre a tm e n t in SAD is independent o f its  e ffe c ts  
upon m ela ton in  (Rosenthal e t al, 1986; Checkley e t al, 1986a).
A c ircad ian  rhy thm  in the d e te c ta b ility  o f d im  lig h t by man has been reported  
(Bassi and Powers, 1986Thowever i t  is not known at present w hether th is  rhy thm  is 
abnormal in SAD.
CHAPTER 4
EFFECT OF ACUTE ANTIDEPRESSANT TR EATM ENT
ON M ELATO NIN  SECRETION IN  M AN
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4.1. EFFECT OF D M I A N D  O XAPR Q TILINE ON M ELATO NIN  
SECRETION IN  M AN
4.1.1. In trod u c tion
Antidepressant drugs have been shown to a ffect melatonin production in 
experimental animals (Section 1.2.5.) and in man (Section 1.3.2.2.). The acute 
effect of many antidepressant drugs is to increase intrasynaptic noradrenaline 
concentrations. Melatonin secretion provides a convenient model for the 
measurement o f anti depressant-induced changes in noradrenerg ic fu n c tio n  (Section
1.5.1.).
We have studied the s tim u la to ry  effects of DMI and a more recent 
antidepressant, oxaprotiline, upon plasma m e la ton in  in norm al subjects. A lthough 
D M I is a re la tiv e ly  sp ec ific  in h ib ito r o f noradrenaline uptake it exerts secondary 
effects at other receptors and binding sites (see Fig. 1.8). Oxaprotiline is a 
racem ic  compound, and both o f its  enantiom ers b lock h istam ine  receptors but only 
the  (f)-enantiom er is a potent and se lec tive  in h ib ito r o f noradrenaline uptake. By 
com paring the e ffe c t o f both enantiom ers upon m e la ton in  p roduction  the spec ific  
effects o f pineal noradrenaline uptake in h ib itio n  can be measured.
There is s t i l l  no c lin ic a lly  established s tim u la to ry  te s t o f m ela ton in  secre tion  
(Section 1.3.2.2.) therefore we have determined whether the melatonin response to 
an appropriately timed single oral dose of DMI is related to an individual's
endogenous m e la ton in  ou tpu t.
I t  has been shown that DM I modifies the metabolism of certain steroids 
(Morselii, 1977) and inhibits the metabolism of amphetamine (Dingell and Bass, 
1968). Consequently it was important to establish that the stimulation of
m ela ton in  is not due to an in h ib itio n  o f its  m etabolism  by DMI.
Three re la ted  studies (A , B and C) are reported  here: A. The e ffe c ts  o f a 
single 24-hour period of administration of DM I, and also (+) and (-) oxaprotiline
tre a tm e n t on plasma m e la ton in  levels in norm al vo lunteers are reported  (Checkley 
e t al, 1985). B. The s tim u la to ry  e ffe c t o f a single dose o f DMI upon plasma
166
m ela ton in  and aMT6s leve ls in norm al subjects is described (Franey et al, 1986) 
toge the r w ith  (C) the e ffe c ts  o f DM I adm in is tra tio n  during the day upon the 
m etabolism  of exogenously adm inistered m e la ton in  (Franey et al, 1986).
4.1.2. Methods 
Study A
(a) Subjects and tre a tm e n t
Six hea lthy  m ale vo lunteers were re c ru ite d  from  the Maudsley H osp ita l s ta ff .  
The subjects aged 24-31 years were w ith in  10% o f th e ir  ideal body w e igh t. A ll 
subjects were drug free and showed no abno rm a lity  on m edical exam ination  and 
screening. The study was conducted during O ctober 1983 w ith  the excep tion  o f one 
subject who p a rtic ip a te d  in  April 1983.
Subjects received in random order (double b lind design) (+ )-oxap ro tiline  25 
m g, (-)-o xa p ro tilin e  25 mg, DM I (P e rto fra n , Geigy) 75 mg and id e n tica l placebo 
tab le ts . Two week in te rva ls  were inserted between each tre a tm e n t. Each drug 
tre a tm e n t was given at 0900 h and 2100 h on the f ir s t  day of the study and at 
0900 h on the second day.
The m ydriatic response to tyramine pupil tests (Shur and Checkley, 1982) was
in h ib ite d  by DM I and (+ )-oxap ro tiline  trea tm en ts  only. This provided evidence of 
an e ffe c tiv e  antidepressant-induced blockade of noradrenaline uptake.
(b) Sampling
Blood samples were removed via an indwelling cannula at hourly in te rva ls  
from  2200 h on the first day of each tre a tm e n t to  0800 h on the second day o f each 
treatm ent,^thereafter samples were taken at 4-hourly in te rva ls  u n til 2100 h on the 
second day. Plasma was separated and stored as previously described (Section
2.1.2.4.). Subjects were housed in the Metabolic Ward, Maudsley H osp ita l under the 
conditions described in Section 3.3.2.
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(c) Assays
Plasma melatonin was measured by RIA (Fraser et al, 1983a) using the 
procedure described in Section 2.1.2. The tritia ted  tracer (NEN) was 80 C i/m m ol 
and the antiserum was 704/189. The lim it of detection ranged from 5 - 1 0  pg/ml 
plasma and the interassay coefficients of variation were 10.2, 9.3 and 11.4% at 
21.9, 54.1 and 234 pg/ml respectively.
(d) Analysis of data
For calculations the lower lim it of melatonin detection was set at 10 pg/ml. 
The areas under the melatonin secretion profiles were determined using a computer 
programme 'Stripe' (Johnston and Woollard, 1982) and statistical differences 
between the treatments were determined by two-way analysis of variance and post 
hoc analysis using Duncans multiple range test. Analysis of variance and post hoc 
analysis were also used to determine differences at selected time points.
Study B
(a) Subjects and treatm ent
E igh t healthy male volunteers were recruited from s ta f f  at the Maudsley 
H osp ita l. The subjects were aged 20-35 years and were within 10% of their ideal 
body weight. A ll subjects were drug free. The study was conducted during Ju ly 
and August 1984.
DM I administration was timed to ensure maximum plasma concentrations two 
hours before the onset of nocturnal melatonin secretion. Subjects received on one 
occasion DMI 100 mg orally at 1600 h and on the other a matching placebo tablet. 
The study design was double blind and the two treatments were separated by a one 
week period.
(b) Sampling
Plasma samples were taken from  an intravenous cannula at hourly intervals
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from 1500 h until 1900 h on the next day. Overnight urine was collected between 
2200 h and 0700 h on each occasion. Plasma samples were separated and stored as 
described in Section 2.1.2.4. Subjects were housed in the Metabolic Ward, 
Maudsley Hospital under conditions described in Section 3.3.2. Samples were 
assayed for melatonin (plasma) and aMT6s (plasma and urine).
(c) Assays
Plasma samples were assayed for melatonin by RIA (Fraser et al, 1983a) using 
the procedure described in Section 2.1.2. The tritia ted  melatonin tracer (NEN) was
45.2 C i/m m o l and antiserum 704/189 was used. The s e n s itiv ity  ranged from 5 -10 
pg/ml plasma and interassay coefficients of variation were 12.1 and 8.5% at 62 and 
28 p g /m l respectively. aMT6s was measured using the m ethod o f A rend t et al, 
(1985) described in Section 2.1.5. The se n s itiv ity  was 13 pg/m l plasma and 0.65 
ng /m l urine. Interassay coefficients of va ria tio n  were 8.8 and 10.6% at 40 and 61 
pg /m l (plasma) and 12.9 and 9.9% at 21 and 8 ng /m l (urine) respectively.
(d) Analysis o f data
The lower l im it  o f de tec tion  for m ela ton in  was set at 10 pg /m l for a ll 
calculations. The effect o f DMI tre a tm e n t compared to placebo on plasma 
m e la ton in  leve ls was determined at each tim e  po in t using paired, tw o -ta ile d  
Student's t-tes t. T o ta l m e la ton in  secre tion  was ca lcu la ted  by area under the night­
tim e p ro file  from  1500 h to  0900 h using a com puter programme 'Stripe' (Johnston 
and Woollard, 1982). Linear regression analysis was performed to compare the 
melatonin response to  DM I w ith  the ind iv idua l n ig h t-tim e  endogenous secretion.
Study C
(a) Subjects and tre a tm e n t
Four healthy volunteers (3M,1F) from the University of Surrey participated in
the  study. Subjects were aged 22-27 years and were drug free. The study was
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conducted under labo ra to ry  conditions in Decem ber 1984. A t  w eekly in te rva ls  
subjects rece ived e ithe r (a) DMI 100 mg a t 0900 h fo llo w ed  by m e la ton in  200 jig a t 
1300 h, (b) matching (DM I) placebo tablets at 0900 h followed by melatonin 200 pg 
a t 1300 h, (c) DM I 100 mg a t 0900 h fo llow ed  by m atch ing  (m ela ton in) placebo 
preparation at 1300 h. A ll preparations were administered orally. Melatonin, 
200 pg was prepared in 5 ml 2% ethanol and corn oil (for pharmacokinetic 
comparison see Aldhous et al, 1985). Melatonin and placebo (vehicle only) were 
ingested w ith  a glass o f w ater. The study design was double-b lind.
I gratefully acknowledge the help of Margaret Aldhous (University of Surrey)
fo r  assistance w ith  m e la ton in  preparations, blood sam pling and the measurement o f 
plasma m e la ton in .
(b) Sampling
An in travenous cannula was inserted at 1215 h on each occasion and blood 
samples were removed at -0.25, 0, 0.25, 0.5, 0.75, 1, 2, 3 and 4 h a fte r  
adm in is tra tio n  o f m e la ton in  or placebo.
S ix-hourly  urine samples were collected sequentially fo r  24 hours from each 
subject before treatm ent. Three urine samples were co llec ted  sequentia lly  u n til 
the fo llo w in g  day from  1300 h - 1700 h, 1700 - 1200 h, 1200 h - 1700 h.
Samples were stored as previously described (Sections 2.1.2.4. and 2.1.5.4.)
(c) Assays
The plasma and u rine  samples were assayed fo r  aMT6s by R IA  - de ta ils  are 
provided in Study B (c).
(d) Analysis of data
D iffe re nce s  in u rinary  aMT6s leve ls between trea tm en ts  were determ ined 
using paired, tw o -ta ile d . Student's t- te s t.
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4.1.3. Results
Study A
Fig. 4.1 shows plasma melatonin concentrations (mean + SEM) during each 
drug treatm ent. There was no difference between the secretion of melatonin after 
placebo and the secretion of melatonin after (-)-oxaprotiline either comparing area 
under the curves or the means at each time point. The mean nocturnal melatonin 
levels were lower than those found in a larger group of normal male volunteers (see 
Section 3.1.). One of the subjects displayed low to undetectable levels throughout 
the sampling period and two of the rem ain ing five  subjects displayed low amplitude 
rhythms in melatonin secretion. The total secretion of melatonin during treatm ent 
w ith  (+ )-oxap ro tiline  was g rea te r than tha t during tre a tm e n t w ith  (-)-o xa p ro tilin e  
(p<0.05). Total melatonin secretion during treatm ent with DM I was also greater 
than th a t during tre a tm e n t w ith  (-)-o xa p ro tilin e  (p<0.01). DMI s ig n ific a n tly  
increased melatonin secretion at 2200 h (p<0.05), 2300 h and 2400 h (p<0.01) 
whereas (+ )-oxap ro tiline  caused a significant increase at 2300 h and 2400 h (p<0.05) 
only. A lthough tw o subjects displayed raised daytim e leve ls a fte r  DMI and (+)- 
oxap ro tilin e  th is  was not s ig n ific a n tly  different from  p la ceb o /(-)-o xa p ro tiline  in the 
group as a whole.
Study B
F ig. 4.2 shows mean hourly plasma m e la ton in  concentra tions fo r e ight norm al 
vo lunteers one hour before and 17 hours a fte r  one ora l dose of DM I or placebo. 
In te rin d iv id u a l va ria tio n  in  plasma m ela ton in  leve ls was high w ith  peak values 
ranging from  undetectab le  to 188 pg /m l, in tra in d iv id u a l secretion however was 
consistent. M ela ton in  concentra tions were s ig n if ic a n tly  increased at 2100 h, 
2200 h, 2300 h (p<0.05) and at 2400 h (p<0.01) a fte r  DM I adm in is tra tion  compared 
to  placebo. T ota l m e la ton in  secretion (area under the curve) was not s ig n ific a n tly  
d iffe re n t a fte r  DM I tre a tm e n t. M ela ton in  peak heights were achieved 2-4 hours 
e a r lie r fo llo w in g  DMI adm in is tra tio n  and inspection o f the p ro files  suggests tha t
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Fig. 4.1 Mean plasma melatonin concentrations SEM) after treatm ent with (+)- 
oxaprotiline, (-)-oxaprotiline, DMI, and placebo. Melatonin secretion was increased 
by D M I at 2200 h (p<0.05), 2300 h and 2400 h (p<0.01) and also by (+)-oxaprotiline at 
2300 h and 2400 h (p<0.05) (Duncans multiple range test).
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173
DM I treatm ent induced a phase advance of the rhythm in melatonin secretion. 
However, no significant differences were found during the morning decline in 
melatonin secretion although a trend towards lower morning levels was evident 
afte r D M I.
The response of each subject to DM I was compared with their individual 
capacity to secrete melatonin. The ratio of a subject's increase in plasma 
melatonin after DM I compared to placebo at the 2200 h tim e point (Fig. 4.3) was 
proportional to the individual's total melatonin secretion a fte r placebo (p<0.001, r = 
0.972). This was also significant at 2100 h (p<0.001, r = 0.934) but not at 2300 h or 
2400 h.
F ig . 4.4 shows the e ffec t o f DMI on the production o f aMT6s. Plasma aMT6s 
levels a fte r DM I were significantly increased at 2300 h and 2400 h (p<0.05) 
compared to placebo indicating that the m etabolite itself is a good index of the 
early evening increase. Total aMT6s excretion a fter DM I (area under the curve) 
was not significantly different from to ta l excretion a fte r placebo. These results 
com bined, suggest th a t DMI has no m a jo r e ffe c t upon the metabolism of m e la ton in  
in man.
Urinary aMT6s results (Fig 4.5) were in agreement with the findings in 
plasma. DM I had no significant e ffe c t upon to ta l urinary aMT6s excretion from  
2200 h - 0700 h.
Study C
The e ffe c t o f DMI on the m etabolism  o f exogenous m ela ton in  was assessed 
and results from the urine co llec tions are shown in F ig. 4.6. The amount o f 
exogenous aMT6s produced was determined in each ind iv idua l by subtracting (a) 
endogenous aMT6s e xcre tion  (before treatm ent) from to ta l aMT6s excretion 
fo llo w in g  placebo (DMI) and melatonin and (b) aMT6s excretion (a fter DM I only) 
from to ta l aMT6s e xcre tion  following DMI and m e la ton in . No s ig n ifican t 
differences were found in excre ted  endogenous aMT6s before treatm ent and a fte r
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DM I treatm ent and no significant differences were found in excreted exogenous
aMT6s fo llow ing  DM I or placebo. The m a jo r ity  o f exogenous m ela ton in  was 
metabolised and excreted within the first two collection periods.
The administration of DMI alone (100 mg) at 0900 h showed no significant 
stimulatory e ffec t of the drug on daytime endogenous plasma melatonin or aMT6s 
leve ls (not shown). The absorption o f melatonin in tw o  subjects was delayed and 
therefore plasma aMT6s levels were too variable for meaningful interpretation.
The urinary data (F ig. 4.6) c le a rly  demonstrated th a t the m etabolism  of 
melatonin was not inhibited by DM I. On the contrary there was a trend (not 
significant) towards increased aMT6s excretion in the presence of DM I.
4.1.4. Discussion
We have shown th a t in norm al subjects the secre tion  o f m e la ton in  (area under 
the curve) increased after one day of D M I (2 x 75 mg) or (+)-oxaprotiline (2 x 25
mg) treatm ent. The increase was s ig n ifica n t at early  evening tim e  points only 
whereas (-)-oxaprotiline tre a tm e n t had no apparent e ffe c t upon plasma melatonin 
leve ls. This dem onstra tion  o f an acute DMl-induced s tim u la tio n  o f m e la ton in  is in 
agreem ent w ith  previous reports in the rat that pineal and serum m ela ton in  are 
increased fo llo w in g  a single in je c tio n  o f DMI (W irz -Jus tice  et al, 1980c) Heydorn 
and co-workers, (1982) were unable however to acutely stimulate melatonin 
p roduction  in the ra t w ith  DM I.
We have also shown that a single dose o f DMI (100 mg) a t 1600 h increases 
plasma m e la ton in  in the early  evening. Peak m e la ton in  levels were achieved 2-4 
hours earlier a fter DM I than a fte r placebo administration. Whereas total 
melatonin secretion (area under the curve) was not increased after a single dose of 
DM I. Moreover the resu lts from DM I a dm in is tra tion  at 1600 h may be in te rp re te d  
as a phase sh iftin g  o f the endogenous rhythm of m e la ton in . The discrepancy 
between the tw o studies (2 x 75 mg, Fig . 4.1 and 1 x 100 mg. F ig. 4.2) may have 
been due to  d iffe rences  in the tim in g  o f DM I adm in is tra tion  or in the to ta l dose of
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D M I given.
Although melatonin (Kveder and Mclsaac, 1961) and DM I (Potter et al, 1984) 
are metabolised by hepatic hydroxylation it is unlikely that the increase is due to 
DM I inhibition of melatonin metabolism since there was no significant inhibitory 
effect of DMI treatm ent on plasma or urinary aMT6s levels. Furtherm ore  
measurement of plasma aMT6s itself provided a good index of the early evening 
increase. In addition DM I had no significant e ffec t upon the metabolism and 
excretion of an exogenous dose o f melatonin. Since aMT6s is the m a jo r m etabolite  
of melatonin in man (Jones et al, 1969Fit is unlikely that possible effects of DM I 
upon the production  o f metabolites o ther than aMT6s would have been of 
significance.
It is likely th a t the increase reflected enhanced noradrenergic transmission as 
a result of DM I blockade of noradrenaline uptake into pineal sympathetic neurones. 
The net effect o f (+)- and (-)-oxaprotiline treatments provided a particularly  
selective measure o f the e ffe c t o f acute noradrenaline uptake blockade upon 
m e la ton in  secre tion . The evening increase was probably dependent upon the 
com bination  o f high plasma drug levels coincident w ith  increased pineal 
sym pathe tic  a c t iv ity  and increased pineal 6-adrenoceptor s e n s itiv ity  (shown in the 
rat to be highest at the end of the light phase, Romero et al, 1975). Cowen and 
colleagues, (1985b) administered DM I orally to normal volunteers at 2200 h and 
found an acute increase in plasma melatonin levels just two hours later at 2400 h.
Our results (Study B) may a lte rn a tiv e ly  indicate a D M l-induced phase advance 
of the m e la ton in  rhythm. In contrast, longer term antidepressant tre a tm e n t is 
reported  not to  phase advance but to phase delay c ircad ian  rhythms in 
experimental animals (W irz-Justice et al, 1980b).
The m easurem ent o f early  evening plasma m e la ton in  fo llo w in g  a single dose 
o f DM I may provide a su itab le  pineal func tion  tes t since s tim u la ted  plasma 
m e la ton in  leve ls a t 2100 h - 2200 h were p roportiona l to  each ind iv idua l's
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integrated endogenous secretion. This study would have to be extended to larger 
numbers o f subjects to confirm the re liab ility  of the response.
4.2. EFFECT OF ROLIPRAM UPON THE URINARY EXCRETION
OF aMT6s IN MAN
4.2.1. Introduction
In the ra t, cyclic AMP regulates the synthesis of melatonin (see Klein, 1979) 
via the action of noradrenaline at pineal 6-adrenoceptors (see Section 1.2.3.). In 
man, 6-adrenoceptor blockers suppress melatonin production (Cowen et al, 1983a; 
Arendt et al, 1985) whereas noradrenaline uptake inhibitors stimulate melatonin 
p roduction  (th is  Section, 4.1.). I t  is possible therefore, th a t in man, c y c lic  AMP is 
the second messenger through which noradrenaline regulates the synthesis of 
m e la ton in .
R o lip ram  is a potent, selective, c y c lic  AMP phosphodiesterase in h ib ito r : i t  
has been shown to increase noradrenaline-induced cyclic AM P production in rat 
b ra in (Schwabe et al, 1976). Behavioural studies in experimental animals have also 
ind ica ted  th a t ro lip ram  may have p o te n tia l c lin ic a l use as an antidepressant 
(Wachtel, 1982). For these reasons we have investigated the effect of rolipram  
upon aMT6s excretion in normal volunteers (Checkley et al, 1987). Urinary aMT6s 
de te rm ina tio n  provides a convenient non-invasive measure o f changes in human 
m ela ton in  production.
4.2.2. Methods
(a) Subjects and tre a tm e n t
The study was perfo rm ed on ten hea lthy male volunteers, aged 20-35 years, 
recruited from  s ta f f  a t the Maudsley Hospital, London. A ll subjects had been drug 
free  fo r  at least 3 weeks, were w ith in  10% o f th e ir  ideal body w e ight and showed 
no b iochem ica l abnorm a lity  on blood screening.
The vo lunteers were adm itted  to  the Metabolic Ward, Maudsley H osp ita l fo r
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tw o  24-hour periods under cond itions previously described (Section 3.2.1.). On one 
occasion they rece ived ro lip ra m  1 mg a t 0700 h, 1500 h and 2300 h on the f ir s t  day 
and 0700 h on the second day. The dose was equivalent to that used in clinical 
t r ia ls  fo r  tes ting  the antidepressant e ffic a c y  o f ro lip ra m . On the second occasion 
subjects received a matching placebo. The study design was double blind and the 
interval between treatments was one m onth. Subjects were studied from  Ju ly to  
August 1985.
(b) Sampling
Six hourly  urine samples were co llec ted  sequentia lly  from  each subject on 
each occasion, from  1800 h to 2400 h on the f ir s t  day, and from  2400 h to  0600 h, 
0600 h to 1200 h and 1200 to 1800 h on the second day. Five ml sample aliquots 
were frozen  a t -20°C  u n til assayed.
(c) Assays
Samples were assayed fo r  aMT6s by R IA  (A rend t et al, 1985) using the 
procedure described in Section 2.1.5. Interassay c o e ffic ie n ts  o f va ria tion  were 
13.6 , 11.6 and 9.8% at 23.9, 7.8 and 2.6 ng/ml urine respectively. The assay 
se n s itiv ity  was 0.65 ng/m l urine (2.5 pg/tube).
(d) Analysis o f data
A ll  results are expressed as mean + SEM. Tw o-w ay analysis o f variance was 
used to  tes t w hether d iffe rences between excreted aMT6s at each co lle c tion  period 
were significant. D iffe rences between means were assessed post hoc using 
Duncans m ultiple range test.
The e ffe c t o f ro lip ram  tre a tm e n t on each tim ed  urine co lle c tio n  was tested 
using tw o-tailed, paired. Student's t- te s t.
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4.2.3. Results
F ig . 4.7 presents the u rina ry  exc re tion  o f aMT6s in each c o lle c tio n . The data 
suggest both an increase and a phase-advance of aMT6s a fte r rolipram. The 
normal rhythm of aMT6s excretion (during placebo treatm ent) was observed (F = 
4.79; d.f. 4, 27; p<0.01) as previously described (Arendt et al, 1985) with the bulk 
o f aMT6s excre tion  occurring  in the 2400 h - 0600 h and 0600 h - 1200 h 
collections. Both night-tim e and early morning collections contained significantly 
higher concentrations of aMT6s, p<0.01 (2400 h - 0600 h); p<0.05 (0600 h - 1200 h) 
compared to daytime (1200 h - 1800 h) and evening collections (1800 h - 2400 h). A 
marked rhy thm  in urinary aMT6s was observed a fte r  rolipram adm in is tra tio n  (F = 
11.2; d .f. 3,37; p<0.G01) w ith  peak aMT6s leve ls iso la ted in the n ig h t-tim e  
c o lle c tio n  only : aMT6s excretion from  2400 h - 0600 h was significantly higher 
(p<0.01) compared to the o ther co lle c tion  periods.
R o lip ram  tre a tm e n t significantly increased mean u rina ry  aMT6s leve ls during 
the 2400 h - 0600 h period (p<0.05). During th is  collection period a ll but one of the 
10 subjects excre ted  m ore aMT6s a fte r  rolipram adm in is tra tio n  than after placebo. 
However, between 0600 h and 1200 h ro lip ram  significantly reduced (p<0.05) the 
mean urinary  concen tra tion  o f aMT6s to leve ls not significantly d iffe re n t from  
those in the daytime (1200 h - 1800 h) or early evening (1800 h -2400 h). Rolipram  
had no e ffe c t on daytim e  or early  evening aMT6s p roduction. Furthermore 
rolipram did not significantly a ffe c t the to ta l amount of aMT6s excre ted over the 
24-hour period.
4.2.4. Discussion
The s tim u la to ry  e ffe c t o f rolipram, a phosphodiesterase inhibitor, upon night­
time aMT6s excretion is described. M orning u rinary aMT6s concen tra tion^ however 
were reduced by ro lip ra m  tre a tm e n t. Measurement o f the u rinary  excre tion  o f 
aMT6s has been shown to  provide a good index o f m e la ton in  secre tion  in man 
(A rend t et al, 1985). I t  is lik e ly  th a t rolipram had a d ire c t s tim u la to ry  e ffe c t upon
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Fig. 4.7 Mean (+ 5EM) urinary excretion of aMT6s in normal male volunteers (n = 
10). Six-hourly urine samples were collected sequentially for one 24-hour period 
after the administraton of rolipram (R) and placebo (P).
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the synthesis o f m ela ton in  in the evening by increasing pineal c y c lic  AMP 
concentrations. A lte rn a tiv e ly , i t  is possible th a t the observed effects were due to  
a drug-induced phase advance o f the m e la ton in  rhy thm . The m e la ton in  response to  
ro lip ram  tre a tm e n t was similar to th a t following acute DM I a dm in is tra tion , 
reported  e a r lie r in th is  chapter (Section 4.1.) This s im ila r ity  is o f in te res t since 
ro lip ram  has p o te n tia l antidepressant ac tion  in man.
A lthough ro lip ra m  is re la tiv e ly  sp ec ific  fo r  phosphodiesterase inhibition i t  has 
been shown in large doses to  increase noradrenaline leve ls in ra t brain (Kehr and 
Debus, 1983). An in fluence  o f these o the r pharm aco log ica l e ffe c ts  upon m e la ton in  
secretion cannot be excluded.
The observed reduc tion  in early  m orning aMT6s production  following ro lip ram  
may have reflected reduced a v a ila b ility  o f substrates fo r  m e la ton in  synthesis as a 
consequence o f increased m ela ton in  production  in the f ir s t  h a lf o f the night.
This re p o rt provides evidence th a t c y c lic  AMP may be a co n tro llin g  fa c to r  in 
the synthesis o f m e la ton in  in man. F u rthe r studies are required over 48-hour 
periods to establish w hether the e ffe c ts  of ro lip ram  are due to  c ircad ian  phase 
changes. The m easurem ent o f u rinary  aMT6s provides a p a rtic u la r ly  convenient 
too l fo r such investigations.
CHAPTER 5
EFFECT OF CHRONIC DMI TREATMENT UPON PINEAL 
FUNCTION IN THE RAT AND MAN
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5.1. IN TR O D U C TIO N
A t present i t  is unclear w hether the net e ffe c t o f adrenoceptor changes 
fo llo w in g  long te rm  anti depressant therapy is an increase or decrease in 
noradrenergic transm ission. The pineal gland provides a convenient model fo r the 
study of antidepressant drug effects at noradrenergic synapses (Section 1.5.1.).
In the ra t pineal, chron ic  DM I tre a tm e n t reduces both 6-adrenoceptor number 
and the m e la ton in  response to  isoprenaline, however reports  o f DM I e ffe c ts  upon 
the 24-hour rh y th m ic  p roduction  o f m e la ton in  are conflicting (Section 1.5.4.). I t  is 
not clear w hether the observed changes in recep to r se n s itiv ity  are due to the 
a b ility  o f antidepressants to  a lte r the phase position  o f c ircad ian  rhythm s in 
recep to r numbers (Section 1.5.3.). I f  the pineal gland is a suitable model fo r 
cen tra l adrenergic fun c tio n , then anti depressant-induced changes in m e la ton in  
secretion should re f le c t corresponding changes in cen tra l noradrenerg ic 
transm ission. I t  is s t i l l  not known however, i f  the 24-hour changes in p ineal 6- 
adrenoceptor num ber fo llo w in g  long te rm  DM I therapy re flec t 24-hour changes in 
ce n tra l 6-adrenoceptor number. W hether dow n-regu la tion  o f pineal 6- 
adrenoceptors occurs in humans during chron ic antidepressant tre a tm e n t is also not 
known (Section 1.5.4.2.).
We have investiga ted  the e ffe c t o f chron ic DM I a dm in is tra tion  upon 24-hour 
m e la ton in  production  in depressed pa tien ts  toge the r w ith  norm al controls 
(Thompson et al, 1985b). A further study was designed to assess, in the ra t, the 
e ffe c t o f ch ron ic DM I tre a tm e n t compared to  placebo upon circadian 6- 
adrenoceptor binding in cerebra l co rtices  and pineal gland toge ther w ith  serum and 
p ineal m e la ton in . These c lin ic a l and anim al studies are described.
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5.2. THE EFFECT OF DM I UPON M ELA TO N IN  SECRETION IN
DEPRESSED A N D  NO R M A L SUBJECTS
5.2.1. Methods
(a) Subjects
Six depressed patients (3 F, 3 M) were recruited from the Maudsley Hospital : 
four were inpatients and two were outpatients. Prior to treatm ent the mean 
Ham ilton Rating Score for depression (Ham ilton, 1967) was 21 (range 15-26). They 
had a mean age of 45 years (range 26-72), a mean weight of 61 kg (range 54-70) 
and a mean height o f 1.8 m (range 1.7-1.9). A ll pa tien ts  had been drug fre e  fo r  at 
least three weeks. Four subjects were tested in November, 1982 and two in May, 
1983.
Normal volunteers (six male) were selected from the Maudsley H osp ita l staff. 
They had a mean age o f 28 years (range 24-30), a mean weight of 84 kg (range 62- 
110) and a mean height o f 1.8 m (range 1.7-1.9). None had su ffe red from  
depression or any o the r psychiatric disorder and all had been drug free  for at least 
3 weeks. Two subjects were tested in May 1983 and fou r subjects were tested in 
August 1983.
(b) DM I treatm ent
DM I (2 m g/kg/day), was given to patients and controls in three divided doses 
for a three week period. Plasma DM I concentrations were measured by Sheila 
Dawling at St. Bartholomews Hospital, London, using gas liquid chromatography 
(B ra ith w a ite , 1979). Mean DMI levels were not s ig n ific a n tly  different between 
patients and controls or a fte r one week of treatm ent compared to three weeks of 
treatm ent.
Tyram ine  pupil tests (Shur and Checkley, 1982) showed an inhibited response 
to  ty ram ine  during treatm ent and the re fo re  provided su itab le  evidence for DMI 
blockade of noradrenaline uptake.
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(c) Plasma sampling
Plasma samples were taken hourly fo r  24 hours both in  depressed patien ts  and 
controls after 0, 1 and 3 weeks of DM I treatm ent. In normal subjects a fourth 24- 
hour sampling was performed one week after DMI was discontinued. Samples were 
taken through a cannula inserted into an antecubital vein. Subjects remained in the 
Metabolic Ward of the Maudsley Hospital for the period of sampling under 
conditions previously described (Section 3.3.2.). Samples were separated and stored 
as described in Section 2.1.2.4.
(d) Assays
Plasma melatonin was measured by R IA  (Fraser et al, 1983a) using the 
procedure described in Section 2.1.2. The tritia ted  tracer (NEN) was 45.3 C i/m m ol 
and the antiserum was 704/189. The l im it  o f detection ranged from  5 to  10 pg /m l 
plasma and interassay coefficients o f va ria tion  were 13.5, 16.3 and 14.6% at 339, 
75 and 26 pg /m l respectively.
Plasma cortisol was measured by Judie English at the U n ive rs ity  o f Surrey, 
using an RIA m ethod w ith  antiserum H P /A 63K -IF  (Guildhay A ntise ra ). The 
interassay coefficient of variation was 5.4 to  5.9% over the norm al range and the 
lim it of detection was 10 ng/ml.
(e) Analysis o f data
The area under the n ig h t-t im e  p ro file  (2100 h - 0900 h) was determined using 
a computer programme 'S tripe ' (Johnston and W oollard, 1982). Plasma m ela ton in  
d iffe rences between each stage o f DMI tre a tm e n t were tested using paired, tw o - 
ta iled , Student's t- te s t.
5.2.2. Results
F ig. 5.1 shows the mean hourly plasma m e la ton in  concentrations for contro ls  
(F ig. 5 .1 ,A) and depressed patien ts  (F ig. 5.1,8). There were no s ig n ifican t
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d iffe rences  between mean m e la ton in  levels before , during or a fte r  D M I 
a dm in is tra tio n  in the norm al volunteers. There was a m arked trend towards 
e levated melatonin leve ls in the  early  evening (2200 h - 2400 h) fo llo w in g  one and 
th ree  weeks of tre a tm e n t w ith  DM I. Mean daytime leve ls  were raised in the 
control group due to one subject with basal melatonin levels of around 60 pg/ml and 
peak n ig h t- t im e  leve ls o f 120 pg/m l. Interindividual v a ria tio n  was larger amongst 
con tro ls  than in the p a tie n t group.
In con tras t to  the co n tro l group, depressed patien ts  showed a s ig n ifica n t 
increase in noctu rna l m e la ton in  secre tion  a fte r th ree  weeks o f DMI therapy 
(p<0.05) but not a fte r  one week. The increase between one and th ree  weeks was 
also s ig n ifican t a t the leve l o f p<0.05. There was no apparent change in the phase 
position  o f the m e la ton in  rhy thm  a fte r one or three weeks o f tre a tm e n t.
There were no d iffe rences  in the am plitude or rhy thm  o f co rtiso l secre tion  
between patients and contro ls  or between any stage o f tre a tm e n t.
5.2.3. Discussion
This study has shown that m ela ton in  secre tion  in depressed patien ts was 
increased between one and three  weeks of tre a tm e n t w ith  D M I. We have 
previously reported  data from  three  o f the patien ts (Thompson et al, 1983) showing 
a s ig n ifica n t e leva tion  a fte r  one week o f tre a tm e n t, although th is  was c lea rly  not 
the case when the p a tie n t group was increased to  six subjects. Our find ings are in 
agreem ent w ith  the more recen t study o f Sack and Lewy, (1986). These authors 
found th a t DM I tre a te d  depressed patien ts displayed as much as a three-fold  
increase in u rinary 6 -hydroxy m e la ton in  excre tion  which persisted over a three 
week period o f tre a tm e n t.
The increase presum ably reflects reuptake blockade at the peripheral 
sym pa the tic  nerve innerva ting  the pineal. I t  is o f particular in te res t since i t  
coincides w ith  the t im e  period during which 6-adrenoceptor numbers are reduced in 
experim en ta l animals tre a te d  w ith  DM I (Sulser et al, 1978). Indeed, a
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corresponding reduction in nocturnal melatonin secretion might have been expected 
i f  the response at the 3-adrenoceptor is s im ila r in humans compared to ra ts . The 
normal volunteers also did not respond to DM I by a reduction in the nocturnal 
release of melatonin. If  the effects of DM I in the pineal are the same as those in 
the CNS^these results are contrary to the hypothesis of Sulser and colleagues, 
(1978) th a t dow n-regu la tion  o f 3-adrenoceptors and hence reduced noradrenergic 
transmission are of functional importance in the mode of action of antidepressant 
drugs.
We have shown (Section 4.1) th a t an acute dose o f DMI raises nocturnal 
plasma m e la ton in  leve ls in norm al subjects. It  is apparent from  the present study 
that any in it ia l increase was not sustained a fte r  m ore than 7 days o f tre a tm e n t. 
Cowen and co-workers, (1985b) have shown in a comparable study that although 
DM I adm in is tra tio n  raised plasma m e la ton in  leve ls in the f ir s t  week, m e la ton in  
production  had declined to baseline levels by the th ird  week.
The net e ffe c t  of DM I treatm ent was to m a in ta in  m e la ton in  production  in 
norm al subjects but to  increase m ela ton in  production  in depressed patients. I t  is 
possible tha t down-regulation occurs in normals as an adaptive response to 
m a in ta in  norm al m ela ton in  production  whereas th is  process in depressed pa tien ts  is 
im pa ired . A lte rn a tiv e ly , adaptive responses may occur in depressives but over a 
longer period o f time, since Brown and colleagues, (1985b) reported  no change in 
the 24-hour m e la ton in  secretion of depressed patien ts  a fte r fou r weeks o f DMI 
treatm ent.
I t  has been suggested th a t antidepressant drugs may ac t by slowing and 
the re fo re  phase delaying a number o f circadian rhythm s (W irz-Justice  and 
C am pbell, 1982). There was no apparent phase delay in the rhy thm  o f m elaton in  or 
of co rtiso l during the course o f DM I tre a tm e n t. On the co n tra ry  the trend  in norm al 
subjects was toward raised early  evening leve ls o f m ela ton in , although th is was not 
s ta t is t ic a lly  s ig n ifica n t. Cowen and colleagues, (1985b) also noted a tendency fo r 
the peak m e la ton in  concen tra tion  to  occur e a rlie r (2200 h - 0100 h) in  subjects on
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DM I treatm ent.
It was not possible to  m atch patient and co n tro l groups in th is  study fo r  the
cund
variables known to a ffec t melatonin production hence^ no comparison of pre- 
treatm ent melatonin secretion was made between groups.
It is of functional importance to establish whether DMI-induced changes in 
melatonin re flec t similar changes in CNS adrenergic systems.
5.3. EFFECT OF REPEATED DMI TREATMENT UPON 6-ADRENERGIC
BINDING  SITES IN R AT P INEAL A ND CEREBRAL CORTICES: 
COMPARISON W ITH PINEA L A ND SERUM MELATONIN
5.3.1. Materials and Methods
(a) Animals
Forty-eight m ale W istar a lbino ra ts , were housed in groups of 6 under a 
light-dark 12: 12 cyc le  (ligh ts  on at 0700 h, ligh ts  o ff  a t 1900 h). The animals, 
raised under the same photoperiod, were obtained at a w e ight o f around 120 g and 
were allowed 14 days fo r env ironm enta l adapta tion  before the study commenced.
Three animals from each group (n=24 in total) were treated repeatedly with  
i.p. injections of DMI-hydrochloride (generously supplied by Ciba-Geigy 
Pharmaceuticals, Horsham, Sussex). Animals received one injection daily (10 
mg/kg) at 1600 h for 22 days. The remaining animals (n=24) were designated as 
controls and received injections of an equivalent volume of physiological saline 
(0.9%) vehicle. Animals were weighed at 0, 7, 14 and 21 days and the drug dosage 
was adjusted accord ing ly .
Groups o f 12 anim als (6 co n tro l, 6 DMI treated) from  random ly selected 
cages were killed at tim es 2400 h, 0600 h, 1200 h and 1800 h after the fin a l dose of 
drug. The anim als killed at n ight (2400 h, 0600 h) were exposed to  dim  red lig h t 
only. Previous studies have shown th a t p ineal SNAT activ ity , sensitive to  w h ite  
lig h t, is not a lte red  by red lig h t (Section 1.2.4.).
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(b) Tissue co lle c tio n .
Anim als were k ille d  in random order by ce rv ica l d is loca tion  and the pineal 
glands and cerebral cortices were immediately dissected, wrapped and frozen in 
liquid nitrogen with subsequent storage at -80°C . Trunk blood was collected into 
10 ml plain glass tubes and allowed to clot at 4°C . A fte r centrifugation (2000 xg,
15 m in, 4°C ) serum was separated and stored in glass tubes at -20°C .
(c) -D H A  binding assays
Tissues were thawed, weighed and membrane homogenates were prepared as 
prev ious ly  described (Section 2.2.2.3.). P ineal binding assays were performed in the 
com bined homogenates from  tw o pineal glands. An aliquot (115 pi) o f each pineal 
homogenate was rem oved and stored a t -20°C  fo r subsequent m e la ton in  analysis. 
The binding o f -D H A (90 C i/m m o l) was determ ined in p ineal homogenates at
2 nM and 8 nM concentra tions o f radioligand as described in Section 2.2.2.3(b).
The binding o f H! -D H A (60 C i/m m o l) was determ ined in co rtex 
homogenates a t concen tra tions (0.25 - 5 nM) as previously described (Section 
2.2.2.3(a)). A liquo ts  o f co rtex  membrane were stored at -20°C  fo r p ro te in  
de te rm ina tion  (Low ry  et ai, 1951) using the m ethod shown in Table 2.11. The 
maximal number of cortical binding sites (B ) and equilibrium dissociation 
constant (K ^ ) were determined by the D irect Linear Plot, using the computer 
program m e 'E N ZP A C K ', and were expressed per mg protein.
(d) Melatonin assays
Pineal and serum m ela ton in  concentra tions were measured using the m od ified  
methods o f Fraser e t al, (1983a) described in section 2.1.3.4. (pineal) and 2.1.3.5. 
(serum). The t r it ia te d  tra ce r had a specific a c tiv ity  o f 90 C i/m m o l and the l im it  
o f assay detection  was 50 pg/p ineal and 10 pg/ml serum.
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(e) Statistics
Differences between the mean number of binding sites according to the tim e  
of day were tested by one-way analysis of variance. Duncans test was applied post 
hoc to  tes t for significant differences in  amplitude.
Differences between group means (DM I treated/control) in melatonin 
concentration at each tim e point were compared by use of unpaired, tw o-tailed, 
Student's t-tes t. Differences between group means in the number of 3-adrenergic 
binding sites were compared at each tim e point by use of unpaired, one-tailed. 
Student's t-tes t.
5.3.2. Results
(a) E ffe c t o f DM I treatm ent on body w e ight
A significant reduc tion  in the ra te  o f increase in body weight was observed in 
DM I treated animals (F ig. 5.2) w ith  the greatest w e ight loss occurring  at the end o f 
the th ird  week of tre a tm e n t (p<0.001). A f te r  the three week period the animals 
rece iv ing  DMI exh ib ited  an 18% w e ight loss (279 g + 5.5 SEM; n=22) compared to  
saline trea ted  controls (339 g + 4.7 SEM; n=24). DM I was not w e ll to le ra ted  by tw o  
anim als which fa ile d  to  thrive in the fin a l week o f the experim en t. A f te r  one week 
of in jection^at least 50% of DM I treated animals began to show signs of peritoneal 
discomfort fo llo w in g  each da ily  injection.
(b) E ffec t of DM I treatm ent on cortical 3-adrenoceptors
Fig. 5.3 presents the m axim al number of c o rtic a l 3-adrenerg ic binding sites
(B , mean + SEM) for D M I-treated  and control animals at each tim e of day. A max —
s ig n ifica n t difference between the points was id e n tif ie d  in saline trea ted  animals 
only (F=3.65; d.f. 3, 18; p<0.05). The values at 2400 h in control animals
were s ig n ific a n tly  less (p<0.05) than th e ir  values at e ithe r 1800 h or 0600 h.
Fo llow ing  repeated adm in is tra tio n  of DMI there was a s ig n ifica n t decrease in 
the number of c o r tic a l 3-adrenergic binding sites at 1800 h, 0600 h and 1200 h
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F ig . 5.2 Mean body w eights, + SEM fo r con tro l animals (n=24) and animals 
rece iv ing  DMI tre a tm e n t o f 10 m g/kg, once da ily  fo r 3 weeks (n=22-24). Group 
means were compared using unpaired, tw o -ta ile d  Student's t-te s ts .
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Fig. 5.3 Variation in the maximal number of cortical 6-adrenergic binding sites
(B ; mean + SEM: n=5-6) over one 24-hour period : e ffect of repeated DMI 
max -
treatm ent. A diurnal variation (p<0.05, analysis of variance) in the value of max
was identified in the control group with a nadir at 2400 h (p<0.05, Duncans multiple 
range test). DMI treatm ent significantly reduced B values (unpaired, one­
tailed, Student's t-test) at the time points shown.
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com pared to  con tro ls . A d iu rna l va ria tio n , in B values was not evident inmax
animals treated with DMI.
No changes in values (Table 5.1) were found between saline- and D M I- 
treated animals at any time point or within treatm ents.
(c) E ffe c t o f DMI treatm ent on pineal 6-adrenoceptors
3
Fig. 5.4 presents pineal H -D H A  binding at 2 nM and 8 nM ligand 
concentrations. Each po in t represents the mean (+ SEM) o f 3 determinations, w ith  
the exception of the  DM I tre a tm e n t group where the number was reduced, at 
2400 h and 0600 h, to only 2 determinations.
A s ig n ifican t d iffe re n ce  between the tim e points was id e n tif ie d  in saline 
treated animals at the 8 nM ligand concen tra tion  only (F=3.51; d .f. 3,8; p<0.06). 
The number of binding sites at 2400 h was s ig n if ic a n tly  low er (p<0.05) than values 
a t e ithe r 1800 h or 0600 h. This find ing  compared w e ll w ith  the observed d iu rna l 
v a ria tio n  in ce rebra l co rtex  tissue. Inspection of the data suggested th a t in 
con tras t to find ings in the cortex, there was a trend in the DM I group towards 
m aintenance o f the da ily  va ria tio n  despite the drug induced reduction  in pineal 6- 
adrenoceptor number. However, th is  variation did not reach sign ificance  probably 
due to  insufficient sample numbers at the 2400 h and 0600 h tim e  points. A 
s ig n ifica n t va ria tion  was not observed using the 2 nM ligand concentration. It is 
possible th a t the measurement of very low numbers o f CPM sp ec ifica lly  bound to 
pineal membranes (around 150-250 CPM/assay tube, at 2nM ^H -D H A) 
con tribu ted  tow ards greater errors in subsequent ca lcu la tions.
DM I treatm ent caused a decrease in the number of specific 6-adrenergic
binding sites. In con tras t to  findings in the co rtex , th is  was h igh ly s ig n ifica n t at 
2400 h (p<0.01, 8 nM). The reduction was also s ig n ifica n t at 0600 h (p<0.05; 2 nM 
and 8 nM) and at 1200 h (p<0.05, 8 nM; p<0.01, 2 nM).
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TIME (h) CONTROLS DMI TREATED
^ D Bmax ^ D Bmax
1800 0.70 + 0.03 183 + 9.1 0.73 + 0.04 126 + 3 .7 * * *
2400 0.66 + 0.03 147 + 6.0 0.78 + 0.07 130 + 10.3
0600 0 .70  +0 .06 173 + 9.9 0.71 + 0.04 127 + 8 .1 * * *
1200 0.73  + 0.07 164 + 5.4 0.81 + 0.06 124 + 3 .9 * * *
^ D nM
B = max fmol/mg protein
*  *  *  = p<0.001
n 5 - (o
Table 5.1 E ffec t of repeated DMI administration on rat cortical 6-adrenergic
binding sites over one 24-hour period. values were significantly
decreased in DM I trea ted  animals (p<0.001, unpaired, one-ta iled , 
Student's t-test).
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Fig. 5.4 Variation in the number of specific 6-adrenergic binding sites in the rat 
pineal gland (mean + SEM; n=2-3) over one 24-hour period : effect of repeated DMI 
treatm ent. Two concentrations (2 nM; 8 nM) of K  -DHA were used to 
determine the number of binding sites. The quantity of tissue was insufficient to
allow determinations at a range of ligand concentrations. A diurnal variation  
(p<0.06, analysis of variance) in the amount of _ Hj -D H A  bound was found in the 
control group at 8 nM concentration only : a nadir was identified at 2400 h (p<0.05, 
Duncans multiple range test). A DMI-induced reduction in the amount of H - 
DHA bound was significant (unpaired, one-tailed. Student's t-test) at the time 
points indicated.
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(d) E ffec t of DM I treatm ent on pineal melatonin concentrations
Fig . 5.5 shows the effect of DM I upon pineal melatonin leve ls over one 24- 
hour period (mean + SEM). N ight-tim e levels in the saline treated group were 
e levated at 0600 h but not at 2400 h. I t  appears tha t melatonin production  
occurred later than expected i.e. between 5 and 11 hours into the dark period. DMI 
tre a tm e n t s ig n ific a n tly  increased n ig h t- t im e  (2400 h; p<0.05; n=4) and daytim e 
(1200 h; p<0.05; n=6) levels of pineal melatonin. The interindividual variation in 
p ineal melatonin production was much greater in the DMI treated group compared 
to controls. The data therefore is also presented as a scatter diagram (Fig. 5.6). 
Melatonin values ranged from 400-1356 pg/p inea l a t 2400 h and from  330- 
2168 pg/p inea l a t 0600 h. This dramatic DM I induced increase did not correlate  
w ith  the changes in p ineal 6-adrenoceptor number. I t  is notable th a t fo llo w in g  DM I
3
administration the number of , H -D H A  binding sites were s ig n ific a n tly  reduced 
at 2400 h corresponding to  the tim e  when pineal m ela ton in  production  was 
s ig n ific a n tly  increased compared to the co n tro l group.
(e) E ffe c t o f DM I treatm ent upon serum m ela ton in  levels
F ig . 5.7 shov/s serum m ela ton in  leve ls (mean + SEM) fo r both groups of 
anim als at the fou r tim e  points studied. A ll saline treated con tro l anim als (n=6) 
had undetectable levels of m elaton in  at 1200 h whereas levels in the DM I trea ted  
group were s ig n if ic a n tly  raised (p<0.01) a t this tim e  po in t. This compared well 
w ith  the observed DM I induced changes in pineal m ela ton in  concentration at 
1200 h.
Inconsistent high serum m ela ton in  levels were measured in some o f the saline 
and DM I treated animals a t the 1800 h, 2400 h and 0600 h tim e  points. Therefore  
due to  the large in te r in d iv id u a l va ria tion , there  was no d istinguishable difference 
between the groups at any tim e  po in t o ther than 1200 h. Serum m e la ton in  levels 
d id not co rre la te  w ith  pineal m ela ton in  levels. I t  is possible th a t extrem e 
haemolysis (not ev iden t in the m idday samples) interfered w ith  binding to  the a n ti-
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m ela ton in  antiserum . However, the same samples were reassayed fo llo w in g  an 
e x tra c tio n  procedure (de ta ils  o f methods are described in Section 2.1.3.5.) and the 
results from direct and extracted methods were in close agreement.
There was no correlation, in the DM I treated animals, between percentage 
body weight d iffe re n ce  (compared to  saline contro ls) and either pineal or serum 
melatonin levels.
5.3.3. Discussion
We have studied the effect of repeated DM I treatm ent upon rat pineal and 
cortex 6-adrenergic binding, at four time-points over a 24-hour period, in 
con junction  with corresponding changes in pineal and serum m elaton in  
concentrations. The aim o f the study was to  determine whether changes in cortical 
6-adrenoceptor number reflected changes in pineal func tion  fo llo w in g  chronic 
antidepressant treatm ent.
In contrast to  previous reports, we found tha t repeated DMI administration
caused a s ig n ifica n t increase in p ineal m e la ton in  production at 2400 h and 1200 h 
compared to saline tre a te d  controls. However, th is  increase was not related to  the 
DMI-induced changes in pineal 6-adrenoceptor number. Conversely, Heydorn and 
co-workers, (1982) reported a significant DMI-induced reduction in rat pineal and 
serum m e la ton in  levels at f ive  different tim e  points in the dark phase. In a 
separate experim ent this group found th a t repeated DMI tre a tm e n t caused a 
reduction in ra t p ineal 6-adrenoceptor numbers at 0100 h and at 1300 h. These 
authors concluded tha t dim inished production  o f pineal m e la ton in  probably 
reflected 6-adrenoceptor/adenylate cyclase subsensitivity. However, in thar study 
DMI was administered fo r  a 7 day period only, compared to  22 days o f 
a dm in is tra tio n  in  the present study. Sarai et a l, (1978) have shown th a t only tw o 
days of DMI tre a tm e n t are required before a reduction in ra t cortical 6- 
adrenoceptor number is observed, a lthough a much longer period o f antidepressant 
tre a tm e n t may be necessary before the net e ffe c t o f adrenoceptor and enzyme
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system changes are rea lised. Indeed Burns and Brown, (1984) found th a t tw o weeks 
o f ch ron ic DM I tre a tm e n t s ig n if ic a n tly  reduced pineal N -ace ty lse ro ton in  levels 
whereas three weeks of treatm ent had no e ffec t compared to controls. Cowen and 
co-workers, (1983b) showed no e ffec t of 10 days DMI administration on the usual 
dark phase increase (at 2400 h) in pineal melatonin despite an observed attenuation  
of the isoprenaline-induced increase in pineal melatonin content. These authors 
suggested that a decrease in 6-adrenoceptor sensitivity may be part of an adaptive 
response to maintain normal pineal function during repeated D M I administration. 
These find ings are in agreement w ith  reports of DMI effects on plasma m ela ton in  
leve ls in  norm al volunteers (Cowen et al, 1985b; Thompson et al, 1985b).
In the present study^the amplitude and dura tion  o f noctu rna l pineal m ela ton in  
levels in saline trea ted  animals was sm alle r than would be expected in a group of 
un trea ted  anim als. S tressfu l s tim u li at n ight have been shown to  reduce ra t pineal 
m e la ton in  leve ls (R e ite r and T ro ian i, 1987), since saline in jec tions or forced  
swimming have provoked a reduction  in evening m e la ton in  synthesis. I t  is possible 
th a t adm in is tra tio n  of saline in jec tions at 1600 h or d isturbance of the animals 
before k ill in g  during the no rm a lly  undisturbed n ig h t-tim e , had a suppressive e ffe c t 
upon pineal m e la ton in  production at 2400 h and 0600 h.
The occurrence of the high in te r in d iv id u a l va ria tions in evening and n igh t- 
tim e serum melatonin levels, whilst midday levels retained good interindividual
consistency, is d if f ic u l t  to explain. Stress fac to rs  or contam ina tion  due to  the 
m ethod o f sa c rif ic e  may have in te rfe re d  w ith  m elaton in  determinations. There 
was however a clear s tim u la to ry  effect o f DMI upon midday serum m ela ton in  
leve ls. This e ffe c t has not been apparent in studies w ith  norm al vo lunteers (Cowen 
et a l, 1985b; Thompson et al, 1985b).
I t  is unlikely th a t m e la ton in  production  was in fluenced by d iffe rences in the 
in te rva ls  between the fin a l DM I in je c tion  and the tim e  of death. Heydorn and 
colleagues, (1982) have shown th a t the serum concentration of DMI measured 5 
hours a fte r a single in je c tio n  (10 mg/kg) o f the drug was not s ig n ific a n tly  d iffe re n t
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fro m  th a t measured in anim als rece iv ing  repeated in jec tions  o f DM ! and k ille d  24- 
hours a fte r  the f in a l in je c tio n . F u rthe rm ore  these authors found no d iffe re n ce  in 
the DMI-induced reduction in pineal 6-adrenoceptors whether animals were killed 3
hours or 24 hours after the  f in a l dose o f DM I.
In the present study the diurnal variation in cortex 6-adrenoceptor density 
compared remarkably well with pineal variations. Caution should be exercised in 
the interpretation of the data, since other studies of 7-8 tim e points in one 24-hour 
period have revealed no significant dally variation in the total number of 
H DHA binding sites, in rat forebrain, hippocampus and cortex tissue (Jenni-
Eierm ann et al, 1986; Lemmer et al, 1987). Detailed dissection o f the ra t co rtex
" ]  1
has indicated c ircad ian  rhythm s in H j  -D H A  binding in discrete areas only 
(review; W irz-Justice, 1987) which are analogous to reported rhythms in 
noradrenaline secretion. Stra in  differences have been shown in receptor rhythm s, 
furthermore Jenni-Eiermann and colleagues, (1987) found marked s ig n ifica n t 
differences in d iu rna l bra in receptor rhythm s in tw o ra t lines both o f W istar o rig in . 
Clearly the findings of the present study require confirmation with larger sample 
and tim e po in t numbers.
Saline treated animals displayed a nadir at 2400 h in p ineal 6-adrenoceptor 
density. This was not apparent in previous studies by Romero and colleagues, 
(1975) who described a peak of H - -DH A binding just before lights o ff and a 
continued decrease during darkness. However, Heydorn and co-workers, (1982) in 
contrast to Romero's group did not find a diurnal change in the density of pineal 
-D H A  binding sites in saline treated animals. It is not known whether timed 
saline injections alter pineal 6-adrenergic binding.
DMI adm in is tra tio n  (10 mg/kg) has been shown to reduce food intake and the 
ra te  o f body w e ight gain in the ra t (Nobrega and Coscina, 1987). In con tras t, 
depressed pa tien ts  display considerable increases in w e ight gain during TC A 
therapy. We have shown tha t anorexia nervosa patien ts  dem onstrate significantly 
e levated night-tim e plasma m ela ton in  levels (Section 3.2). Chik and colleagues.
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(1987) how ever reported  a 12% reduc tion  in ra t p ineal m e la ton in  a fte r  3 weeks o f 
food re s tr ic t io n . In add ition , H e rbe rt and R e ite r, (1981) found less pineal 
m e la ton in  in the glands o f protein-calorie m alnourished ra ts . I t  is un like ly  
therefore th a t the m e la ton in  increases due to  chronic DM I tre a tm e n t were 
provoked by changes in body weight.
This study has dem onstrated th a t the D M I-induced reduction  in co rtex  and 
p ineal 6-adrenoceptor density was not reflected by reduced m ela ton in  production. 
On the co n tra ry , p ineal m ela ton in  production  was apparently  increased. Our 
find ings support other studies (P illa y  and P o tg ie te r, 1984; Skene, 1985) showing the 
stimulatory e ffec t o f in v ivo repeated DMI in jec tions upon the unstim u la ted  release 
o f m ela ton in  fro m  ra t p ineal organ cu ltu res.
CHAPTER 6
DISCUSSION
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6 .1 . MEASUREMENT OF M ELATO NIN
The ability to measure pineal and serum melatonin concentrations using a 
variety of methods (reviewed in Section 1.6.1.) has provided researchers with basic 
information concerning pineal function. Variations in circulating melatonin have 
been shown in the rat to re flect variations in pineal melatonin content (Wilkinson 
et ai, 1977). I t  is not known however whether th is  is the case for many other 
species including man. Studies in patients following pinealectomy suggest the 
pineal is the major and possibly sole source of circulating melatonin in man 
(Neuvelt and Lewy, 1983)^therefore the measurement of melatonin in body fluids 
provides the best possible assessment of physiologically and pathologically 
important variations in man. The investigation of human melatonin secretion has 
relied almost exclus ive ly upon R IA  methodology. Recent improvements in R IA  
methods due to the production of highly specific antisera and the a v a ila b ility  o f 
pure, high specific activ ity  radiolabels (see Section 1.6.1.) has resulted in assays of 
sufficient sensitivity and specificity to measure picogram  levels o f m e la ton in .
The R IA methods described in th is  thesis have been developed and c lass ica lly  
va lida ted  fo r the measurement o f m ela ton in  and its  principal urinary m etabo lite  
aMT6s. The assays were shown to be specific, sensitive, simple and direct for both 
human plasma (melatonin and aMT6s) and urine (aMT6s) thus removing the previous 
need for time-consuming extraction procedures.
The melatonin RIA was further validated for the direct measurement of
m ela ton in  in ra t serum and pineal samples and has since been successfully adapted 
fo r  use in plasma from other species (see Section 1.6.1.). W ith very spec ific  
antibodies there was l i t t le  interference in the assay from other indoles and 
analogues tested. The presence o f p o te n tia lly  interfering compounds in tissues and 
flu ids, particularly in species not tested so fa r cannot be excluded. Thorough 
va lida tion  is necessary therefore, before using the assay for such samples. Since i t  
is not practicable to va lida te  the RIA fo r each ind iv idua l, the establishm ent o f a 
norm al range o f m ela ton in  values in a large population permits a comparison o f
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each ind iv idua ls ' p ro file  w ith  the range and the id e n tif ic a t io n  o f grossly abnorm al 
values. An international quality control scheme would aid pineal research by 
monitoring the different assay methods currently used and help with the validation  
of new methods.
Mean daytime (<10 pg/ml) and night-tim e (50 pg/ml) human plasma melatonin 
values compared well with values recently reported using d ifferent RIA methods. 
Rat serum melatonin levels were similar to those of Vakkuri et al, (1984a) and 
Webley et al, (1985); however earlier RIA methods have produced much higher 
levels (Pang et al, 1977; Geffard et al, 1982). Our inconsistent high daytime values 
in groups of rats following repeated daily saline or DM I injections (Section 5.3.) 
remain unexplained.
GC-MS is theoretically the most specific method for the measurement of 
melatonin but has lim ite d  application due to cost and time-consuming preparation 
o f samples. Reliable GC-MS methods (Lewy and Markey, 1978; Beck et al, 1981) 
serve as a valuable standard for the validation o f R lAs. The chromatographic and 
GC-MS validation o f the R lAs described in th is thesis have been published for 
melatonin (Fraser et al, 1983b) and aMT6s (Bojkowski et al, 1987b). The highly 
sensitive and specific GC-MS method of Lewy and Markey, (1978) measures 
daytime plasma melatonin levels in man of 2-5 pg/ml; consequently daytime
samples assayed using the present RIA were often below the lim it of assay
detection (5-10 pg/ml; 2.5-5 pg/tube).
Some loss o f assay sensitivity is due to rather low a c tiv ity  tritium  labels 
(relative to high activ ity  radioiodinated labels). Assay sensitivity is potentially  
increased by the in tro d u c tio n  o f radioiodinated labels o f sufficient purity. A robust 
R IA  capable of determining subpicogram levels o f melatonin would be desirable for
m ela ton in  analyses in sm a lle r volumes of plasma. The detection of possible 
daytime fluctuations in melatonin secretion would require  such sensitivity, as
would a deta iled  study o f m elaton in  concentra tions in d iffe re n t bra in areas fo r
example.
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1 25The development of a direct RIA in human plasma using I -melatonin is
decribed in Section 2.1.4. R ad io iod ina tion  o f m e la ton in  resu lted  in a tracer o f high
125purity and high incorporation of I_ however this was not reflected in assay 
sensitivity, possibly due to steric hinderance, by the bulky iodine molecule, with  
the active binding site of the antiserum. It is likely that alternative conjugation 
procedures for immunogen preparation will result in an antiserum with greater 
affin ity  for the radioiodinated melatonin molecule, i.e. sensitivity may be optimum
when the antiserum binding s ite  on the m e la ton in  m olecule is far removed from the
125position  o f attachment o f I .
The development of a direct, unextracted, validated RIA for aMT6s in plasma 
and urine (Section 2.1.5.) has provided a valuable tool for human circadian, seasonal 
and m etabo lic  studies. We have shown tha t plasma m e la ton in  correlates w e ll w ith  
plasma aMT6s and urinary aMT6s production (Arendt et al, 1985). Rhythmic 
melatonin secretion over 24 hours is reflected in rhythmic aMT6s excretion  
measured in sequentia l urine samples over 24 hours (Bojkowski e t al, 1987b). This 
RIA is more reproducib le  than that o f m ela ton in  and requires less sample volume. 
Furthermore aMT6s is particularly stable (at least 2 years at -20°C , Bojkowski et 
al, 1987b) in both plasma and urine. The measurement of urinary aMT6s is a good 
measure of total melatonin output and provides a necessary alternative to plasma 
sampling in children and the elderly. The advent o f th is  assay increases the range 
of possible investigations, in particular long term  studies of circadian changes due 
to a ffe c tiv e  disorder, travel across tim e  zones, s h if t  work and blindness. I t  is 
possible th a t m e tabo lic  changes in disease states or during drug therapy could 
change the relationship between aMT6s excretion and circulating melatonin 
concentrations and th is  therefore requires further investiga tion . The R IA  provides 
an opportunity fo r  a more deta iled  study o f drug e ffe c ts  upon m e la ton in  secretion.
Nowak and Short, (1987) reported th a t both urinary aMT6s (measured by GC- 
MS) and sa liva ry  m e la ton in  concentra tions are re liab le  indices of blood m e la ton in  
concentrations. Saliva collections provide an a lte rn a tive  method fo r the non-
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invasive study of melatonin secretion. However, the amplitude of the melatonin 
rhythm in saliva is low with levels around 30% of values found in plasma. The high 
amplitude of aMT6s excretion is likely to be of more value especially in studies of 
the elderly where melatonin production is decreased (Bojkowski, 1988).
Human studies of circulating indoles of pineal origin other than melatonin are 
scarce due to the lack of suitable methodology. The recent publication of a 
specific RIA for the measurement of 5-methoxytryptophol in different species 
(Skene et al, 1986) may prove to be adaptable for human plasma and provide the 
opportunity for such investigations.
6.2. CHARACTERISTICS OF MELATONIN SECRETION IN MAN
The physiological functions of melatonin and its relationship to a ffective  
disorder may depend upon both the timing and amplitude of its secretion. It was 
therefore important to define the characteristics of melatonin secretion in a 
sufficiently large population o f norm al subjects. Many clinical studies have 
attem pted to study m ela ton in  secretion in pathological states without provision for 
adequately sized or suitably m atched control groups. The inconvenience o f 
nocturnal sampling has most probably contributed to this situation.
A 'normal-range' of plasma melatonin levels obtained in 81 healthy adults 
(21 F, 60 M) is reported in Section 3.1. The mean acrophase (peak tim e) of the 
melatonin rhythm, determined by cosinor analysis was id e n tifie d  at 0320 h. Peak 
nocturnal levels ranged from undetectable (<10 pg/ml) to 188 pg/ml. When men 
and women were considered separa te ly a s im ila r range was evident in both groups. 
We have observed as previously reported (Arendt, 1979; Arato et al, 1984) a marked 
in tra in d iv id u a l consistency in the tim in g  and amplitude of m elaton in  secre tion . 
Ind iv idua l s ta b il ity  o f secre tion  makes m ela ton in  a p a rtic u la r ly  stable marker fo r 
de te rm in ing  pa tho log ica l rhy thm  disturbance and/or rhythm  changes fo llow ing  
pharm aco log ica l m anipu la tions.
I t  is un like ly  th a t body w e ight (unless due to  gross c lin ic a l changes) or height
210
are im p o rta n t de te rm inan ts  o f m e la ton in  levels in th is, the  la rgest reported  study 
o f 24-hour m e la ton in  secretion in norm al vo lunteers. Previous reports  o f a pos itive  
correlation with weight (Arendt et al, 1982; Ferrier et al, 1982) or a negative 
correlation with height (Beck-Friis et al, 1984) were probably exaggerated due to 
inadequate sample numbers. Furthermore we found no correlation between age 
(range 22 - 60 years) and m e la ton in . However the reported  in fluences o f puberty 
and ageing (see Section 1.3.3.) on melatonin secretion require a separate 
consideration of children and the very elderly. Urinary excretion of aMT6s has 
been studied in a large number o f norm al volunteers (Bojkowski, 1988) inc lud ing  
children and the elderly and a decline in aMT6s production is evident in subjects 
within the 60-80 years age group. Our data suggests that age effects upon 
melatonin are neglig ib le  from  young to m iddle adulthood. I t  is probably more 
important to match patients and hea lthy con tro ls  fo r sex and in p a rtic u la r female 
reproductive status. The study o f m e la ton in  secretion in women is com p lica ted  by 
possible in fluences o f the m enstrua l cyc le , menopause, pregnancy and consumption 
of oral contaceptives. Unfortunatelwreliable studies (using specific assay methods) 
have been few  in number (Fellenberg et al, 1982; Webley e t al, 1985; Webley and 
Leidenberger, 1986) and warrant further investigation. Reported ethnic 
differences in melatonin secretion may also be of importance (Das Gupta et al, 
1983).
Whether a real sex difference occurs in the timing or duration of melatonin 
secretion (Section 3.1.1) is a m atter for further investigation. It is possible that 
the observed differences between men and women were due to differences in their 
previous lig h tin g  h is to ry  and/or behaviour (e.g. - earlier waking) . B righ t lig h t o f 
around 2,500 lux is required to shift the circadian rhythm of melatonin in man, dim 
l ig h t o f o rd ina ry  indoor intensity is not successful (Broadway e t al, 1987; Lewy et 
al, 1987). It would clearly be d ifficu lt to control adequately the environmental 
photoperiod fo r a ll subjects tested, a lthough i t  has been suggested (C laus tra t e t al, 
1987) th a t in theory, pa tie n t and con tro l groups should be presynchronised
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according to  a s im ila r pho toperiod ic schedule before th e ir sampling session. Each 
subject's previous photoperiod should probably be considered in the in te rp re ta tio n  
of results. It  v/ould be of interest to compare the rhythm characteristics of 
melatonin production in subjects with rural, outdoor occupations, i.e. populations 
exposed to extended periods of bright natural light, with the urban population 
described in this thesis. Studies in Czechoslovakia (lllnerova et al, 1985), 
A ntarctica (Broadway et al, 1987) and England (Bojkowski and Arendt, 1988) have 
shown a phase advance of the melatonin rhythm in summer compared to winter 
in d ica tin g  that norm al subjects are more sensitive to  changes in the photoperiod 
than had previously been thought. Bojkowski and Arendt, (1988) have shown that 
the  aMT6s rhy thm  progressively phase advances from  winter months to  summer 
months. P atien ts  and contro ls  should p re fe rab ly  be sampled during the same m onth 
o f the year, not jus t the same season.
We have dem onstrated th a t fu l l spectrum  d im  light (300 lux) is capable o f 
suppressing noctu rna l m e la ton in  levels in healthy male subjects (Bojkowski et al, 
1987a). I t  is possible tha t o rd inary dom estic lig h tin g  w il l suppress m ela ton in  
p roduction  in some ind iv iduals since in te r in d iv id u a l differences exist in the 
in te n s ity  of l ig h t required  fo r  suppression (Bojkowski et al, 1987a). The find ing  
that man is more sensitive to low intensity light than had previously been thought 
im p lies th a t the tim in g  o f the evening rise or m orning decline in m e la ton in  may be 
masked by domestic lighting. Whether such individual differences exist in the 
in te n s ity  o f light required  fo r the en tra inm ent o f c ircad ian  rhythm s in man is not 
known.
An im p o rta n t factor in the study o f melatonin secretion in man is the 
sampling p ro toco l. Many studies have adopted a p ro toco l based on only tw o 
samples (one n ight and one day sample) or only one sample. This can produce 
m isleading resu lts since small changes in the rhy thm  characteristics of the 
melatonin p ro file  may be in te rp re ted  as changes in e ith e r amplitude, dura tion  or 
phase. By com bining m u ltip le  sampling points fo r 24-hour m ela ton in  analysis w ith
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sequentia l u rine co lle c tions  fo r long te rm  aMT6s rhy thm  studies, the 
characteristics of the melatonin rhythm may be adequately determined.
6.3. MELATONIN IN  AFFECTIVE DISORDER
An association of the pineal gland with pathological states in man is still 
obscure. Only in the inves tiga tion  o f a ffe c tiv e  d isorder have the m a jo rity  o f 
studies indicated abnormal melatonin production. Many of these studies can 
however be criticised on methodological grounds (see discussion : Section 3.3.4.). 
We have described in a c a re fu lly  con tro lled  study th a t m e la ton in  production  in 
depressed patients was not significantly different in either amplitude or timing 
from that of matched control subjects. These results do not agree with previous 
reports of either low melatonin production in depression (Mendlewicz et al, 1979; 
C la u s tra t e t al, 1984; Brown et al, 1985a) or a phase advance o f the m e la ton in  
rhy thm  in depression (Lewy, 1983b; N a ir et al, 1984).
A pa rt fro m  methodological d iffe rences, the discrepancies could be explained 
by an association of low m e la ton in  production  w ith  a subgroup o f depressed 
patien ts . Our p a tie n t group the re fo re  may not have been com parable w ith  others 
reported . U n fo rtu n a te ly  a consensus does not ex ist regarding the ch a rac te ris tics  o f 
such a subgroup. Although some investigators have found lowered amplitude of 
noctu rna l m e la ton in  in association w ith  hypercortisolaemia (W ette rberg  et al, 1984; 
Claustrat et al, 1984) others have not (Brown et al, 1985a, Boyce, 1985). Brown 
and colleagues, (1985a) found a s ig n ifican t association between decreased noctu rna l 
melatonin levels and the diagnosis o f a m elancho lic  subtype o f m ajor depressive 
disorder. Beck-Friis and Wetterberg, (1987) have further proposed that the low 
m e la ton in  syndrome is characte rised  in a subgroup o f pa tien ts  by less pronounced 
da ily  varia tions  in the depressive symptoms i.e . a dampening o f the amplitude. I t  
has been postulated th a t low  m ela ton in  in depression is an expression of a 
generalised d e fe c t in the se n s itiv ity  o f bra in 6-adrenergic receptors or o f 
sym pathe tic  transm ission (F razer e t al, 1986; Beck-Friis and W etterberg , 1987).
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Whether the human pineal reflects central noradrenergic activ ity  and whether
ce n tra l noradrenerg ic neurones are invo lved in the ae tio logy o f depression is open 
to  question (see th is  C hapter, 6.4.2). I t  is c lea r, fro m  extensive data in norm al 
volunteers (Section 3.1.) that low to undetectable levels of melatonin are found in 
around 10% o f hea lthy volunteers ind ica ting  th a t low m ela ton in  production is o f 
litt le  importance to the physiological well-being of humans.
The observed lack o f a s ig n ifica n t e ffe c t o f depression upon the rhy thm  
characteristics of melatonin production is probably of greater interest than the 
question of amplitude. We were unable to confirm (using melatonin as a marker) 
the hypothesis that there is a phase advance of circadian rhythms in depression
(Goodwin et a l, 1982). A lthough N a ir and co-workers, (1984) found the m ela ton in  
peak to  be phase advanced in depressed pa tien ts  many o ther reports  have shown no 
s ig n ific a n t differences in the m ela ton in  rhy thm  between pa tien ts  and contro ls  
(B e ck-F riis  e t al, 1985a; 1985b; C la u s tra t et al, 1984; Brown et al, 1985a). Beck- 
F riis  and W etterberg , (1987) have proposed tha t the phase Advance Theory o f 
depression be tested in acutely i l l  depressed pa tien ts  under free-running conditions 
(w ith o u t ex te rna l env ironm enta l cues).
Many theories o f c ircad ian  rhy thm  abnorm a lities  in a ffe c tiv e  disorder have 
been based upon observations in b ipo la r pa tien ts  who display d is tin c t c yc lica l 
episodes o f mania and depression. These form s o f a ffe c tiv e  disorder are uncommon 
and the app lica tion  o f rhy thm  theories to the common non-periodic depressions o f 
pa tien ts  in the present study has been questioned (Thompson et al, 1988).
I f  ce rta in  c ircad ian  rhy thm  disturbances are a d is tin c t fea tu re  o f a ffe c tiv e  
illness^then it  is possible th a t m e la ton in  is not a su itab le  m arker fo r such rhythm s. 
It has been suggested fro m  iso la tion  experim ents th a t at least tw o d is tin c t 
oscillators control c ircad ian  rhythm s in man (M oore-Ede et al, 1983). One is 
probably w ith in  the SON (Y o sc illa to r) and drives the rhythm s o f g row th  hormone, 
re s t-a c t iv ity ,  slow-wave sleep and m elaton in , w h ils t the o the r (X oscillator) is 
responsible fo r body temperature, cortisol and REM sleep rhythm s. I t  appears tha t
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the X oscillator is not located within the SCN (Reppert et al, 1981) although its 
exact loca tion  has not been determ ined. C lin ic a l studies ind ica te  tha t the phase 
positions of circadian rhythms driven by the X oscillator are abnormally early in 
depressed pa tien ts  (Goodwin et al, 1982). The SCN and the re fo re  m e la ton in  
secretion may be unaffected by such a disorder. Disturbed cortisol rhythms were 
also not apparent in any o f the severely depressed pa tien ts  described in th is  thesis. 
Thus we have no evidence for a circadian rhythm disturbance in either melatonin or 
cortisol in our patients. A carefully controlled study is required comparing acute 
and chronically ill depressed patients (unipolar) and the euthymie, manic and 
depressed phases of patients with bipolar affective disorder. This may provide a 
clearer picture of the relationship (if any) between melatonin secretion and rhythm  
disturbances in depression.
Based on hypotheses of disturbed rhythms in psychiatric disease Klein, (1983) 
suggested th a t bright l ig h t therapy be tested as a cue to reorganise and entrain the 
c ircad ian  system o f patient^ thereby providing an alternative to  conventional drug 
therapy.
B righ t lig h t therapy has proved to be dram atically successful in the 
treatm ent of populations selected specifically for winter depression (Rosenthal et 
a l, 1984; 1985; Lewy et a l, 1985b; see C hapter 1, Section 1.4.5). The mechanism o f 
action was originally thought to be due to its effects on melatonin secretion, 
thereby generating a photoperiodic message. Recent data suggest tha t the 
the rapeu tic  effec t is independent of its  influence upon melatonin (Rosenthal et al 
1987).
The f ir s t  controlled study of m ela ton in  secre tion  in SAD is described in 
Section 3.3. There was no evidence of reduced melatonin secretion in our 
popula tion of seasonally depressed patients. Indeed higher leve ls were found in the 
early morning compared to  controls ^furtherm ore^ the m e la ton in  secretion o ffse t 
was significantly delayed in the pa tien ts  w ith  SAD. Lewy and colleagues, (1985b; 
1987) have observed a phase delay in the m elaton in  onset o f pa tien ts  w ith  SAD but
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th is  was apparent in only one subject out o f seven in the present study. The mean 
dura tion  o f m e la ton in  secretion in SAD was not s ig n ific a n tly  different from  
controls although there were marked in te r in d iv id u a l d iffe rences in pa tte rns  o f 
secretion. Further investigations are required to establish whether the variability  
in profile pattern and timing of peak values is consistent from day to day in each 
individual. The long term  measurement of rhythmic urinary aMT6s excretion in 
SAD may provide a clearer picture. The observed interindividual variation may 
re flec t a disorganisation o f circadian rhythms or p hase -ins tab ility  consistent w ith  
the Oysregulation Hypothesis of A ffective Disorder (Siever and Davis, 1985). 
Perhaps a relative insensitivity to environmental lighting allows the circadian 
system o f pa tien ts  w ith  SAD to become disorganised. Normal subjects m ain ta in  
entrained (but phase delayed) rhythms even in the absence o f bright lig h t tim e  cues 
(G riffiths et al, 1986; Broadway et al, 1987) probably due to social or feeding times 
cues. Since lig h t therapy o f sufficient duration is e ffe c tiv e  in SAD at any tim e  o f 
day (Hellekson et a l, 1986; Thompson et al, 1986) its  effects are probably not due 
to zeitgeber properties. Furtherm ore dim light therapy has been shown to be as 
effective  as bright light in the alleviation of symptoms (W irz-Justice et al, 1986a). 
These findings combined with our observations in preliminary studies that dim 
light (500 lux) e ffective ly  suppresses nocturnal melatonin in SAD patients (Murphy, 
Franey, Arendt, Checkley, unpublished results, 1988) suggest that SAD patients are 
not insensitive to lig h t.
Lewy et al, (1981) have demonstrated increased se n s itiv ity  in manic 
depressive patients to the melatonin suppressive effects of light. Whether visual 
sensitivity or the reported circadian rhythm in visual sensitivity (Bassi and Powers,
1986) is altered in subgroups of the depressed population requires further
in vestiga tion .
Anorexia nervosa has been linked with affective disorder (Cantwell et al, 
1977) since alterations in mood, disturbed sleep/wake rhythms, feeding rhythms and 
weight loss are common to  both. For these reasons and also due to the incidence of
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pre-pubertal hormonal status, anorexia nervosa is of interest in pineal research. 
We have described increased m ela ton in  secretion and aMT6s excretion in groups of 
patients with anorexia nervosa compared with female controls (Section 3.2). 
Previous studies have not been adequately controlled^whereas in the present study 
aMT6s excretion was determined in young healthy female controls of low body 
weight. There was an indication in some patients of a poorly entrained melatonin 
rhythm compared to normal subjects. There was no correlation between melatonin 
secretion and percentage weight loss, body mass indices, Hamilton Rating Scale 
scores for depression or gonadoptrophin levels in the patients. Furtherm ore  
increases in gonadotrophin levels a fte r weight gain were independent of aMT6s 
levels.
In the rat, food restriction and therefore weight loss, reduces pineal
m ela ton in  levels (by 12%) but is reported to increase serum m elaton in  levels (by 
34%, Chik et al, 1987). These find ings in serum could re flect the reduced volume 
o f distribution caused by the reduction in body w e ight. Chik and colleagues, (1987) 
have cautioned th a t in underfed animals pineal m ela ton in  does not accurately 
re f le c t circulating leve ls. A reduced volume o f distribution may have contributed 
to  the high plasma m e la ton in  levels found in pa tien ts  from  the present study. The 
ability to de te rm ine  u rina ry  aMT6s excretion however has provided a useful 
measure of the total output of melatonin over a period of tim e which is 
com plem entary to m ela ton in  dete rm ina tions in plasma. The high plasma m elaton in  
leve ls were accompanied by increased urinary  aMT6s concentrations. I t  would be o f 
interest to study larger groups of 'recovered' subjects since increased melatonin 
p roduction  may provide a t r a i t  marker fo r  th is d isorder.
6.4. M ELA TO N IN  SECRETION IN  MAN: AN IN D EX OF
ADREN ER G IC  FU N C TIO N
6.4.1. Acute pharm aco log ica l manipulation
The adrenergic co n tro l o f the human pineal has been p a rtly  demonstrated
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since both plasma melatonin (Cowen et al, 1983a) and urinary aMT6s excretion  
(Arendt et al, 1985) are suppressed by the administration of atenolol-a peripherally 
active 6-adrenoceptor antagonist. We have now shown a significant acute 
stimulation of evening melatonin and aMT6s production by the specific 
noradrenaline uptake inhibitors, DMI and oxaprotiline (Section 4.1). It is most 
lik e ly  th a t th is  stimulation was due to  increased synaptic concentrations of 
noradrenaline caused by a DM I/oxaprotiline blockade of noradrenaline uptake into 
pineal sympathetic neurones. However, a possible e ffec t of DMI upon the circadian 
pacemaker cannot be ignored.
The noradrenaline precursor 1-dopa (Arendt, 1978; Moore et al, 1979) and the 
6-adrenoceptor agonists isoprenaline and orciprenaline (Vaughan e t al, 1976; Moore 
et al, 1979; Lewy, 1983a; Palazidou et al, unpublished, 1986) have, contrary to the 
findings in the rat, failed to increase daytime or evening melatonin levels in man. 
The reported e leva tion  o f plasma m ela ton in  fo llo w in g  an in fusion o f ritodrine, a 
62-agonist (Desir et al, 1983)has not been confirmed (Krautgasser-Gasperotti et al, 
1983). In view  o f these inconsistencies it is important to establish whether the 
pineal is a su itab le  model for measuring the effects of antidepressant drugs upon 
noradrenergic neurotransmission.
It has generally been assumed that the doses required for stimulation of 
melatonin production in man using 6-adrenergic agonists would be so high as to 
cause untoward cardiovascular effects (Lewy, 1984). It appears from studies in the 
Syrian hamster tha t interspecies variation occurs in the pineal response to 6- 
agonists. The sensitivity of the pineal of the Syrian hamster to isoprenaline is 
restricted to the second half of the daily dark phase only (R eiter et al, 1987). This 
find ing  im p lies tha t a period o f darkness is required for the developm ent o f 
m axim al p inea locyte  (recep to r) se n s itiv ity . Moreover, R eiter and colleagues, 
(1987) reported, contrary to  findings in the rat, th a t ch ron ic lig h t exposure (i.e. 
stim u lus depriva tion) does not produce a supersensitivity response in the pineal 
gland o f the Syrian hamster. These authors suggested tha t their findings may be
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applicab le  to the human pineal as w e ll i.e. optim um  se n s itiv ity  o f the pineal 
recep to rs  in man may only occur during the second h a lf o f the n ight.
We assumed that a single dose of DM I would have the greatest stimulatory 
e ffe c t upon m ela ton in  secre tion  at the end o f the lig h t period: at a tim e  when 
pineal 6-adrenoceptor density is greatest in the rat (Romero et al, 1975). If  pineal 
sensitivity to pharmacological stimulation is delayed in man, as in the Syrian 
hamster, the increase following DMI would have been observed later in the night 
and not in the early evening as reported. It is possible however, that increased 
availability of melatonin precursors combined with increased synaptic 
noradrenaline levels in the early evening fo llo w in g  DM I are important fa c to rs  in 
the production of melatonin whereas pineal 6-adrenoceptor density is of lesser 
importance (discussed in Section 6.4.2.).
Recent findings that a . -  and a^-^drenoceptors play a significant functional 
role in the co n tro l o f human m ela ton in  secretion have added strength to the 
hypothesis th a t m e la ton in  is a good index o f adrenergic fun c tio n  in man. Lewy and 
co-workers, (1986) reported a dose-response reduction o f nocturnal m elaton in  
levels in normal subjects fo llow ing  intravenous clon id ine administration. Melatonin 
secretion in man is also increased by the Org-3770 (Palazidou et al,
1987). However, Grasby and Cowen (1987b) using a slightly lower dose of clonidine 
than Lewy et al, (1986) were unable to confirm the findings of this group. 
Depending upon the dose o f c lon id ine  required for an e ffe c t and the magnitude o f 
reduction obtained, the measurement o f melatonin may provide a more spec ific  
a lte rn a tiv e  to  growth hormone as an index o f «^-adrenoceptor func tion . The 
reduction of noctu rna l m e la ton in  secretion fo llow ing  prazosin administration (an 
« . -antagonist) has provided evidence fo r a fun c tio na l role o f «^-adrenoceptors in 
the control o f m e la ton in  secretion in man (Palazidou e t al, 1988, in press). An 
unusual synergistic mechanism invo lv ing the p o te n tia tio n  o f B^-adrenoceptor 
a c tiva tio n  by «^-adrenoceptor activation has been described in the rat cortex 
(Skolnick et al, 1978) and in the rat pineal gland (K le in  e t al, 1983a). The find ing
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th a t p ineal - and 6 . -adrenoceptors have a s im ila r role to those o f ce n tra l brain 
«p  and B j-adrenocepto rs  (un like  adrenoceptors in the periphery) has strengthened 
the argum ent fo r using the pineal gland as a neuroendocrine model o f the central 
adrenergic system.
We have described the stimulatory e ffec t of rolipram, a phosphodiesterase 
inhibitor, on the urinary excretion of aMT6s in normal volunteers. These results 
provide the first evidence that c y c lic  AMP may influence the secretion of 
melatonin in man. Since Bn-adrenoceptors are coupled to adenylate cyclase (Zatz  
et al, 1976) and cyclic AMP is the second messenger (Klein, 1979) in the rat pinea^ 
it is possible that in man cyclic AMP is the second messenger through which 
noradrenaline ac tiva tes  the synthesis o f m e la ton in .
Due to the circadian rhythm in pineal sympathetic a c tiv ity  the pineal gland 
provides other approaches for the evaluation of adrenergic function (Lewy, 1984).
The sym pathe tic  nerves are quiescent during the day and therefore the m elaton in  
response to daytim e pharmacological manipulation could indicate postsynaptic 
fun c tio n  whereas measurement o f night-tim e m ela ton in  levels m ight provide an 
assessment o f both pre- and postsynaptic fun c tio n . By comparing daytim e and 
night-tim e studies presynaptic function can be estimated. A daytime pineal 
stimulation test in man would be of use both pharmacologically and clinically. 
N ig h t- t im e  sam pling is a m ajor m ethodolog ica l problem  in pineal research whereas 
the s tim u la tio n  o f daytim e m ela ton in  production would permit acute investiga tions 
o f pineal func tion  in physio log ica l and pa tho log ica l states. Such a pineal func tion  
te s t may be o f particular use in the de tec tion  o f some human pinealomas before 
and a fte r  treatm ent. A number o f miscellaneous drugs reportedly increase daytim e 
melatonin (see Section 1.3.2.2.). However, in most of the studie^ the mechanism of 
ac tion  is unknown and the results have ye t to be replicated. We showed, for the 
firs t tim e , th a t the DMl-induced increase in early  evening m elaton in  (2100 h and 
2200 h) was proportional to the subject's endogenous night-time production of 
m e la ton in . Therefore^ the measurement o f plasma m elaton in  at 2100 h fo llow ing
220
DM I administration may provide a suitable pineal function test. DM I had no 
s ig n ifica n t effec t however upon daytim e  plasma melatonin or urinary aMT6s levels. 
The monoamine oxidase type A inhibitor, clorgyline and the nonselective inhibitor, 
tranylcypromine have been shown to increase plasma melatonin levels in the 
morning probably by a combination of increased pineal serotonin and noradrenaline 
concentrations (Oxenkrug et al, 1986; Murphy et al, 1986). The finding that 
fluvoxamine (a serotonin uptake inhibitor) increases night-tim e and morning 
melatonin production (Demisch et al, 1987b) suggests that pineal serotonin 
availability is more important in the control o f human m elaton in  secretion than had 
previously been thought and deserves further investigation. R eports o f psoralen 
stimulation of daytime melatonin levels are in agreement (Birau, 1981; Grota et al, 
1985; Souetre et al, 1987) although the mechanism of these effects is not known.
The human pineal has been o f p a rtic u la r in te res t as a marker for central 
adrenerg ic fun c tio n  since i t  does not appear to  p a rtic ip a te  in the stress response. 
Vaughan, (1984) demonstrated that stressful stimuli (pneumoencephalography, 
hypoglycaem ia, sprinting, lumbar puncture) calculated to  e levate  circulating 
cortisol, grow th  hormone and catecholamines had no e ffe c t on m ela ton in  secre tion . 
However, R eiter and Troiani, (1987) have shown in ra ts  tha t p ineal responses to 
stress vary w ith  the severity o f adverse stim u lus as w e ll as w ith  the tim e  o f day or 
n igh t the stressor is applied. During the day ra t p ineal m ela ton in  levels are 
increased by adverse stimuli while at night melatonin levels are decreased. A 
thorough investiga tion  o f the e ffe c ts  o f stress upon noctu rna l m ela ton in  in man is 
required since Vaughan, (1984) found s ig n ific a n tly  low er nocturnal m elaton in  in 
burns pa tien ts  (w ith  raised sym pathe tic  activ ity) than contro ls . The find ing  o f 
raised daytime m elaton in  levels in women fo llo w in g  heavy exercise (Carr e t al, 
1981) has not been confirmed (Vaughan, 1984).
6.4.2. E ffe c ts  o f chronic antidepressant adm in is tra tion  on pineal func tion
Reduced responsiveness o f the B-adrenoceptor/adenylate cyclase system
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following chronic antidepressant administration in the rat has been proposed as the 
common mechanism of antidepressant action (Sulser et al, 1978). Whilst the 
antidepressant-induced effects of uptake blockade and down-regulation at 
presynaptic «-adrenoceptors are to increase neurotransmission (Charney et al, 
1981) it is s till unclear whether the net e ffec t of chronic antidepressant treatm ent 
is to reduce or increase brain noradrenergic transmission (see Section 1.5.1.). The 
pineal provides a convenient model for the study of antidepressant effects upon 
adrenergic function and circadian rhythms.
A stimulatory e ffe c t o f ch ron ic (3 weeks) DMI treatm ent on noctu rna l 
m e la ton in  secretion was found in depressed patients whereas noctu rna l m ela ton in  
secre tion  in normal volunteers rem ained unchanged after 1 and 3 weeks o f DMI 
treatm ent (Section 5.1.). In addition repeated DMI injections (22 days) caused a 
s ig n ifica n t increase in ra t p ineal m e la ton in  levels (a t 2400 h and 1200 h) and in 
serum melatonin levels (at 1200 h) whereas pineal and cortical B-adrenoceptor 
density was s ig n ific a n tly  decreased at the fou r tim e  points studied. In none o f the 
studies was m ela ton in  decreased.
Since acute DMI treatm ent increases nocturnal m elaton in  production in 
norm al volunteers (Section 4.1.) we have proposed tha t in norm al subjects, longer 
term  DM I tre a tm e n t (1-3 weeks) may induce a decrease in p ineal B-adrenoceptor 
fun c tio n  as p a rt o f an adaptive response to maintain norm al p ineal func tion . In 
depressed patien ts  however, the process o f B-adrenoceptor down-regulation may be 
im pa ired . This theory has been supported by the findings th a t 4 but not 2 weeks o f 
im ip ram ine  treatm ent s ig n ific a n tly  e levates 24-hour plasma melatonin in depressed 
patients (Hariharasubramanian et al, 1985) and th a t urinary 6-hydroxy melatonin 
e xc re tion  is elevated over a 3 week period o f DM I treatm ent in depressed patients 
(Sack and Lew y, 1986) whereas 3 weeks o f DM I adm in is tra tion  in norm al vo lunteers 
has no s ig n ific a n t e ffe c t on noctu rna l m e la ton in  secre tion  (Cowen et al, 1985b). A 
recent study has challenged th is  theory since norm al subjects have been found to 
respond to  chronic (3 weeks) (+ )-oxap ro tiline  administration by elevated nocturna l
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melatonin production (Checkley et al, unpublished data, 1988). Our data obtained 
in experimental animals supports these findings.
In the present study, DM I treatm ent caused a decrease in rat cortical and 
pineal B-adrenoceptor density comparable with previous findings (see Section
1.5.2.1. and 1.5.4.1.), whereas the accompanying increase in pineal melatonin 
suggests that the net e ffec t of DM I treatm ent was to increase neurotransmission. 
Studies of the rat pineal gland in vitro following repeated DM I administration in 
vivo have provided similar data (Skene, 1985; Pillay and Potgeiter, 1984). Skene,
(1985) observed an accompanying reduction in pineal cyclic AMP responsiveness to 
isoprenaline when pineal melatonin production  was increased.
One explanation for these, and our findings is that elevated synaptic 
noradrenaline levels produced by in h ib itio n  o f uptake combined w ith  « -
adrenoceptor subsensitivity (Section 1.5.2.2.) was s u ff ic ie n t to  overcome the
reduction in B.-adrenoceptor fun c tio n . I t  is un like ly  th a t DM I has a direct 
stimulatory e ffect on pineal SNAT a c t iv ity  since in v it ro  DM I fa ils  to increase 
SNAT a c t iv ity  in denervated rat pineal glands (P a rfitt and K le in , 1976). DM I may 
a ffec t SNAT a c tiv ity  through mechanisms other than via the B^-
adrenoceptor/adenyla te  cyclase system since a variety o f receptors and binding 
sites other than adrenergic have been characterised in the m am m alian pineal 
(Section 1.2). A m ajor recent development in the control o f p ineal m ela ton in  
production is the discovery th a t m u ltip le  receptor mechanisms regulate pineal 
cyclic AM P and cyc lic  GMP production  (review Klein e t al, 1987). Two synergistic 
receptor regula ted systems have been c le a rly  defined in the pineal. A c tiv a tio n  by 
«^-adrenocep to rs  a m p lifie s  the stimulatory e ffe c t which B^-adrenergic or VIP 
agonists have on the pineal cyc lic  nucleotides (Y uw ile r, 1987). VIP occurs in the 
p ineal gland and can induce SNAT activity by acting  on peptidergic sites distinct 
fro m  the Bi-adrenergic recep to r (Kaku et al, 1983). I t  appears tha t both the VIP 
and Bi-adrenergic systems are linked in th e ir  a b ility  to  interact w ith  the «n - 
adrenerg ic system. W hether the s tim u la to ry  e ffe c t o f DM I upon melatonin
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production occurred partly via VIP or other neuropeptides is not known. It has been 
reported that chronic DM I treatm ent does not result in a decrease in the density of 
rat brain -adrenoceptors. On the contrary -adrenoceptor supersensitivity has 
been indicated from behavioural studies in animals (Section 1.5.2.). It is possible 
therefore that increased melatonin production occurred as a result of increased - 
potentiation of the B.-adrenergic or VlP-ergic systems. Ebadi and Govitrapong
(1986) have proposed that the pinealocyte contains numerous and cascading groups 
of receptor sites one of which is a B.-adrenergic receptor site. Possibly the 
m am m alian pineal is less a model o f adrenergic function but more a model o f 
m ulti-receptor mediated functions.
The importance of B .-receptor down-regulation as a mechanism of 
antidepressant action  must be questioned. This study clearly demonstrates the
re levance o f measuring an "end p o in t" o f antidepressant-induced changes ra the r 
than single receptor populations. The increase in melatonin suggests tha t increased 
neurotransmission is associated w ith  the antidepressant e ffe c ts .
These studies have also provided an oppo rtun ity  to investiga te  the e ffe c t o f 
DM I upon the c ircad ian  rhy thm  o f m elaton in  secretion. In experim en ta l animals 
chron ic antidepressant tre a tm e n t has been shown to slow a v a rie ty  o f c ircad ian  
rhythm s. Under entra ined conditions th is appears as a delay in the phase position 
of the rhythm (W irz-Justice and Campbell, 1982). No such phase delay of the 
m e la ton in  rhy thm  was evident in e ithe r the c lin ic a l or anim al studies described. 
On the contrary there was a trend towards higher evening levels during DM I 
tre a tm e n t. I t  seems unlikely fro m  these studies tha t the mechanism o f ac tion  o f 
antidepressants is via an e ffe c t upon c ircad ian  rhythm s.
6.5. CONCLUSIONS
Plasma m ela ton in  and u rinary aMT6s provide m arkers in p sych ia tric  studies 
fo r  d isturbances o f the pineal's endogenous circad ian pacemaker (SCN) and the 
e ffe c ts  o f lig h t.
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In tra in d iv id u a l rep roduction  of the m e la ton in  rhy thm  in norm al subjects has 
been dem onstrated w ith  no m a jo r sex, w e ight, height or age d iffe rences  w ith in  our 
group o f vo lunteers (age range 23-63 years).
There was no d isturbance o f m e la ton in  p roduction  in endogenous depression 
however g rea te r in te r in d iv id u a l va ria tion  in the m e la ton in  rhy thm  was observed in 
SAD. Only in anorexia nervosa were m inor am plitude  changes found.
The noradrenergic co n tro l o f the human pineal is c le a rly  re in fo rced  by th is  
w ork and although m e la ton in  production does not re f le c t  pineal B-adrenoceptor 
se ns itiv ity ^  i t  is probably a good m arker o f the fun c tio na l status o f the 
noradrenergic synapse at least w ith in  the pineal its e lf .
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